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This thesis focuses on the use of evidence-informed deliberative processes (EDPs) to support 
legitimate health benefit package design in the context of universal health coverage (UHC). 
UNIVERSAL HEALTH COVERAGE
Many citizens around the globe, including those in high-income countries, do not have access 
to high quality and affordable essential health services. This has led governments to put UHC 
high on the health agenda. Sustainable development goal (SDG) 3.8 seeks to achieve UHC, 
including financial risk protection, access to quality essential healthcare services and access to 
safe, effective, quality and affordable essential medicines and vaccines for all.1 To achieve UHC, 
countries can advance in at least three dimensions as reflected in the so-called UHC cube: 
include more priority services in the essential benefit package, expand coverage of existing 
priority services to non-covered populations or reduce out-of-pocket payments for existing 
priority services (Figure 1).2 For example, countries can decide to increase the coverage of 
skilled birth attendance by making it available to all rural populations, or to reduce co-payments 
for antibiotic treatment of children with pneumonia. 
Progressive realisation is invoked as the guiding principle for countries on their own path to 
UHC and achievement of the SDG health targets. It refers to the governmental obligations 
to immediately and progressively move towards the full realisation of UHC, recognising the 
constraints imposed by limited available resources.2,3 The principle is to be understood in two 
different ways. First, as the progression towards UHC over time. Second, with ‘progressive’ 
being interpreted in the social sense as ensuring that equity concerns are fully considered in 
decision making. 
Countries around the world are increasingly rethinking the design of their health benefit package 
as a means to support the progressive realisation of UHC. Which decisions they make may have 
far-reaching consequences for the level and distribution of health in the country, and of financial 
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Figure 1. The UHC c be1
HEALTH TECHNOLOGY ASSESSMENT
Health technology assessment (HTA) guides governments in their choices on the public funding 
of health technologies and is as an important policy tool on the path towards achieving UHC. 
HTA has recently been redefined and is to be understood as: 
“A multidisciplinary process that uses explicit methods to determine the value of a health 
technology at different points in its lifecycle. The purpose is to inform decision-making in 
order to promote an equitable, efficient, and high-quality health system.” 4
Health technologies can be a test, device, medicine, vaccine, procedure, program or 
system developed to prevent, diagnose or treat medical conditions; promote health; provide 
rehabilitation; or organize healthcare delivery.4
The dimensions of value for a health technology may be assessed by examining the intended 
and unintended consequences of using a health technology compared to existing alternatives. 
These dimensions often include clinical effectiveness, safety, costs and economic implications, 
ethical, social, cultural and legal issues, organizational and environmental aspects, as well as 
wider implications for the patient, relatives, caregivers, and the population. The overall value may 
vary depending on the perspective taken, the stakeholders involved, and the decision context.4





The purpose of undertaking HTA often is broader than just informing policy makers on the 
reimbursement of health technologies or health benefit package design (Figure 2).5 In this 
thesis we limited our scope to the use of EDPs to support HTA bodies in making legitimate 
reimbursement and health benefit package design choices. 
Figure 2. Purposes of undertaking HTA, proportion of countries by (a) region and (b) country income.2
AFR: WHO African Region; AMR: WHO America Region; EMR: WHO Eastern Mediterranean Region; EUR: 
WHO European Region; SEAR: WHO South-East Asian Region; WPR: WHO Western Pacific Region.
DEFINING THE HEALTH BENEFIT PACKAGE
Benefit package design is an intrinsically complex and value-laden political process that takes 
place in an environment of diverging social values and interests.6-10 Society, including relevant 
stakeholders, such as patients, the public, providers, payers, industry, and policy makers, reflect 
a wide range of social values and interests that result in different perceptions of what makes 
health technologies valuable.11 In such pluralist societies, stakeholders may reasonably disagree 
on what values can be used to guide benefit package design and their importance.12
Health authorities make priority setting decisions on behalf of society, e.g. when deciding on the 
public reimbursement of new health interventions. The power that health authorities possess to 
make priority setting decisions on behalf of societies is justified only in so far decision-making is 
carried out in legitimate ways.
2  WHO. 2015 Global Survey on Health Technology Assessment by National Authorities. Main findings. 
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However, value frameworks commonly employed by HTA bodies or units around the world 
to design benefit packages do not sufficiently account for this complex reality.6-8,13 These 
frameworks are typically based on the use of a limited set of predefined criteria, also labelled 
‘substantive’ criteria, which are believed to reflect the most important social values. This has led 
HTA bodies to use, for example, ‘clinical benefit’, ‘safety’ and ‘cost-effectiveness’ as important 
decision criteria.3
There is broad recognition that such frameworks are ill fitted to take into account the wide range 
and diversity of stakeholder values and lead to insufficient sets of relevant information. This 
compromises the fairness of the decision-making process, and eventually the legitimacy of 
forthcoming decisions.13 
Legitimacy here refers to the reasonableness, or fairness, of recommendations as perceived 
by stakeholders, which is an important prerequisite for broad societal support for these 
recommendations. For example, the decision whether or not to publicly fund expensive drugs for 
third-line antiretroviral therapy (ART) should take into account the values and reasons of those 
affected by the decision, e.g. HIV patients (wanting to receive the best treatment), other patients 
(whose treatment may be displaced in case ART is funded), or tax payers (wanting to minimize 
public health expenditure).
LEGITIMATE DECISION-MAKING
Legitimate decision-making requires that processes reflect efforts of authorities to treat all 
stakeholders as moral equals.14 Fair, legitimate processes have to reflect efforts of authorities 
to treat all stakeholders as moral equals and thus provide people with well-justified, reasonable 
reasons to endorse the process and thus the decision – even if it is the case that they would have 
preferred another outcome.14,15 
Independently of what kind of normative theory one endorses, it can be seen as a fundamental 
ethical requirement, that those who are carrying the burdens of the decisions are (i) explicitly 
recognized as being stakeholders; and (ii) entitled to being provided with good reasons to 
appreciate the decision-making process as fair. If these concerns are not taken seriously by 
decision-makers, they lose their moral authority for making priority setting decisions in health. 
Subsequently, they may undermine the legitimacy of their own decision-making process.16
3   Contemporary HTA is mainly focused on assessing the properties of health technologies. The criteria traditionally 
include: level of clinical benefit, safety, quality of the evidence, and in some cases a measure of the incremental cost-
effectiveness. Recently, also indirect or unintended outcomes (e.g. potential benefits and harms for patients and their 




Increasingly, there is attention for organizing ‘fair, legitimate decision-making processes’ and 
facilitating ‘stakeholder deliberation.’ In line with this trend, health authorities often organize 
some form of stakeholder participation, embedded in their processes. However, in practice, 
health authorities lack easy-to-use tools that can support them in carefully organizing meaningful 
stakeholder participation. As such, there is a risk that participation of stakeholders, if organized 
at all, merely reflects tokenism rather than justified and adequately integrated participation.
THE NEED FOR EVIDENCE-INFORMED DELIBERATIVE PROCESSES
Several guides already exist on benefit package design, such as the publication ‘What’s in, 
what’s out’ by the Center for Global Development17, the WHO ‘Making Fair Choices’ report2 and 
its handbook on ‘Strategizing national health in the 21st century’.18 Specific guidance on the use 
of HTA for benefit package design is provided in the recently published HTA Toolkit by iDSI19 
and the HTA roadmap specifically focusing on institutionalizing HTA.20 All guides cover critical 
aspects of benefit package design, including institutional set-up, required decision-making 
processes, the need for stakeholder involvement, collection of evidence, and monitoring and 
evaluation aspects. 
Important academic work on the conditions of fair processes is the accountability for 
reasonableness (A4R) framework.9 This framework identifies four key conditions for organizing 
fair processes: (i) all relevant values should be taking into account; (ii) ensuring transparency of 
the decisions; (iii) organization of appeal opportunities; and (iv) regulation of conditions i-iii.9 A4R 
has been criticized for being largely theoretical and not providing guidance on the identification 
and operationalization of values.14,21,22 Multicriteria decision analysis (MCDA) is a structured 
method that can be used to evaluate the overall value of interventions by reference to a set of 
multiple explicit criteria23; although MCDA is generally praised for its rational pursuit, it is criticized 
for being technocratic and lacking a deliberative component that involves stakeholders.14,21,24 
“Evidence-informed deliberative processes” (EDPs) combine the virtues of both A4R and MCDA. 
They incorporate the element of structured decision-making from MCDA but not the mathematical 
elements, as we consider the latter to be only of limited relevance for priority setting. 
EDPs provide an alternative framework to support HTA bodies in their aim to achieve this type 
of legitimate benefit package design, based on deliberation between stakeholders to identify, 
reflect and learn about the meaning and importance of values, informed by evidence on these 
values.25,26 EDPs are developed as a practical stepwise approach for HTA bodies to organize 
their processes to achieve legitimate benefit package design in the context of this thesis and 
guidance on their operationalization is subject to continued development and updating. 
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An EDP integrates four core elements. First, the element of stakeholder deliberation which refers 
to the critical examination of an issue involving the weighing of reasons for and against a course 
of action. A deliberative process is generally defined as “a series of coordinated activities allowing 
a group of people (or relevant stakeholders) to receive and exchange information, to critically 
examine an issue, and to come to an overall group judgement. Second, the element of evidence-
informed evaluation which allows for the use of scientific evidence but also for contributions 
from stakeholders in terms of their experiences and judgments when (stronger) evidence is 
unavailable.27 Third, the element of transparency which ensures that the deliberative processes, 
including the objectives, modes of stakeholder involvement, the decision reached and its related 
argumentation is explicitly described and made publicly available. Fourth, the element of appeal 
which ensures that a decision can be challenged and revised if new information or insights become 
available. As such, EDPs provide the best way to combine evidence, information, perspectives, 
and values, while also allowing these aspects to be identified and openly discussed.
These elements have been translated into a set of practical steps to support HTA bodies as 
much as possible in the development of their processes (Figure 3).25 Step A-C, include advise 
on how to install an advisory committee, including the organisation of stakeholder participation; 
on how to define decision criteria, and on how to set up a process for identifying and selecting 
health technologies for hta. In steps D1-D3, we advise on how to scope, assess and appraise 
a specific health technology. Step E-F, provide guidance on communication & appeal, and 
monitoring & evaluation, respectively. The use of EDPs is strongly dependent on its embedding 
in the context of an HTA body, including the linkage between HTA and policymaking, the level of 
institutionalisation, and its capacity. While the steps are presented as separate activities and in 
a linear fashion, in practice there is often iteration between them. Moreover, ‘HTA’ refers to steps 




A  Installing an advisory committee
B Defining decision criteria
C Selecting health technologies for hta
D 1  Scoping
 2  Assessment
 3  Appraisal
E  Communication and appeal
F  Monitoring and evaluation
for every health
technology
Figure 3. The EDP framework.4 
 
RATIONALE FOR THIS THESIS
Some HTA agencies already have several good practices on these steps in place (e.g., the 
Canadian Agency for Drugs and Technologies in Health (CADTH), Scottish Medicines Consortium, 
National Institute for Health and Care Excellence (NICE) in the United Kingdom, and the National 
Committee for Health Technology Incorporation (CONITEC) in Brazil). These agencies rely on 
deliberative processes, for example regarding identifying topics for HTA and how to appraise 
health technologies. These agencies may serve as inspiration for others, especially those who 
have recently formally setup their HTA practice (e.g., the Ministry of Public Health in Uruguay, and 
the Centre of Standardization of the Republican Centre for Health Development in Kazakhstan), 
but they can also improve regarding certain components.
At the time of writing the methodological development of EDPs is in an advanced state, and 
EDPs are being implemented in a range of countries such as Kazakhstan, Iran, Pakistan and 
Indonesia. Furthermore, deliberative processes and stakeholder involvement have become hot 
topics in the HTA community. This thesis reflects the methodological development of EDPs, their 
ongoing implementation and evaluation, as published in a series of papers in recent years.
4   Adjusted from: Oortwijn W, Jansen M, Baltussen R. Evidence-informed deliberative processes. A practical guide for HTA 
agencies to enhance legitimate decision-making. Version 1.0. Nijmegen: Radboud University Medical Centre, Radboud 




The main research question of this thesis is: 
How can legitimate health benefit package design be improved using evidence-informed 
deliberative processes in the context of UHC?  
The sub-questions of this thesis are:
1.   What guidance do HTA agencies need to implement evidence-informed deliberative 
processes to support health benefit package design?
2.  How can HTA agencies implement evidence-informed deliberative processes to support health 
benefit package design?
3  What is the added value of using evidence-informed deliberative processes to support health 
benefit package design?
THESIS OUTLINE 





What guidance do HTA agencies 
need to implement evidence-
informed deliberative processes 
to support health benefit package 
design?
Chapters 2 - 4
Sub-question 2
How can HTA agencies implement 
evidence-informed deliberative 




What is the added value of using 
evidence-informed deliberative 
processes to support health 
benefit package design?
Chapters 8 - 10
General discussion
Chapter 11
What guidance do HTA agencies need to implement evidence-informed deliberative 
processes to support health benefit package design?
In chapters 2 and 3 we argue that embedding HTA in a fair process has great potential to capture 
societal values relevant to public reimbursement decisions on health technologies. We propose 
the use of EDPs as an approach that explicitly recognises benefit package design as a political 
process and an intrinsically complex task and argue that with EDPs in place, HTA (or priority 




In chapter 4 we identify the level of application of EDPs by HTA bodies, identify their needs for 
guidance, and learn about best practices. A questionnaire for an online survey was developed 
based on the EDP framework, consisting of elements that reflect each part of the framework. 
The survey was sent to members of the International Network of Agencies for Health Technology 
Assessment (INAHTA), a network of 51 HTA agencies that support health system decision 
making that affects over 1 billion people in 32 countries around the globe.
How can HTA agencies implement evidence-informed deliberative processes to 
support health benefit package design?
In chapter 5 we spell-out the implications of using EDPs with regards to how HTA agencies should 
ideally organize their processes. In chapter 6 we provide procedural guidance for countries in 
the context of progressive realization of UHC, that is, how they can best organise their processes 
and evidence collection to make decisions on what services to provide first under progressive 
realisation of UHC. 
In chapter 7 we stress the point that fair, legitimate processes should reflect efforts of authorities 
to treat all stakeholders as moral equals in terms of providing all people with well-justified, 
reasonable reasons to endorse the decisions. Health authorities need to operationalize this 
requirement into real world action. To support health authorities, we operationalized five key 
steps in doing so and developed a checklist in the form of 29 reflective questions to assist them 
in the practical organization of legitimate priority setting in healthcare.
What is the added value of using evidence-informed deliberative processes to support 
health benefit package design?
In chapter 8 we report on an evidence-informed deliberative Citizen Forum ‘Choices in healthcare’ 
which was held in the Netherlands to obtain insight into the criteria informed citizens would 
propose for the public reimbursement of healthcare (or health benefit package design). The 
government of the Netherlands, like its counterparts in most other countries that have some 
form of universal health insurance, faces challenges in obtaining public support for its choices 
regarding the composition of the benefits package. In the context of increasing pressure on a 
limited healthcare budget, decisions to not or no longer fund certain treatments regularly meet 
with opposition from healthcare providers, private-sector parties, politicians, patient interest 
groups, and the public in general. During 3 weekends, 24 citizens participated in evidence-
informed deliberation on the basis of 8 case studies. In chapter 9 we report on semi-structured 
interviews which were held with 8 participants before and after their participation in the Citizen 
Forum. Opinions about the public reimbursement of healthcare were reconstructed using the 
method of reconstructing interpretive frames. The aim of this study was to assess how the 
opinions of 8 participants in the deliberative Citizens Forum changed and if so, why participants 
themselves believe their opinions have changed, whether participation influenced their perceived 
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reasonableness of other participants in the forum and whether it influenced their opinions about 
involvement of citizens in decision-making. 
In chapter 10 we report on the use of EDPs to support health authorities in Pakistan in the 
design of the health benefit package. Pakistan recognizes health benefit package design as an 
important element in its strive for UHC and achievement of SDG 3, Good health and well-being. 
As described in the country’s long–term development strategy ‘Vision 2025’, a revision of the 
package would improve the type of services that individuals and communities receive and offer 
protection against financial hardship when accessing health services. The application of EDPs 
in the context of Pakistan was embedded in a broader institutional effort around health benefit 
packages in Pakistan, initiated by a joint WHO-EMRO and Disease Control Priorities 3 (DCP3) 
secretariat mission visit to Pakistan and took place from late 2019 to late 2020. DCP3 responds 
to the increasing need of low- and lower middle-income countries (LMICs) for technical guidance 
and support in benefit package design and in accelerating progress towards UHC. Pakistan is 
one of the first countries globally to implement the project, labelled ‘DCP UHC Pakistan’ explicitly 
using EDPs. The application of EDPs in the context of DCP UHC Pakistan was organized over the 
course of two workshops in Nijmegen, the Netherlands (Oct 2019; Feb 2020) with participants 
from all project partners. All procedures, customized templates and instructions were pilot tested 
and trainings for facilitators were organised prior to each UHC benefit package design workshop 
in Islamabad, Pakistan (Nov 2019 and Feb 2020). We used a semi-structured online survey to 
collect the views of participants about the used EDP process, based on a broader Theory of 
Change framework produced for the project.
General discussion 
Last, in chapter 11 we discuss the findings for each sub-question and respond to the main 
research question on how legitimate health benefit package design can be improved using 
evidence-informed deliberative processes in the context of UHC. Furthermore, the limitations of 
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What guidance do HTA agencies need  
to implement evidence-informed 
deliberative processes to support  
health benefit package design? 

CHAPTER 2
Priority setting for universal health coverage: 
we need evidence-informed deliberative processes, 
not just more evidence on cost-effectiveness
Published as:
Baltussen R, Jansen MP, Mikkelsen E, Tromp N, Hontelez J, Bijlmakers L, Van der Wilt GJ.
Priority setting for universal health coverage: we need evidence-informed deliberative 
processes, not just more evidence on cost-effectiveness.




Priority setting of health interventions is generally considered as a valuable approach to support 
low- and middle-income countries (LMICs) in their strive for universal health coverage (UHC). 
However, present initiatives on priority setting are mainly geared towards the development of 
more cost-effectiveness information, and this evidence does not sufficiently support countries 
to make optimal choices. The reason is that priority setting is in reality a value-laden political 
process in which multiple criteria beyond cost-effectiveness are important, and stakeholders 
often justifiably disagree about the relative importance of these criteria. Here, we propose the 
use of ‘evidence-informed deliberative processes’ as an approach that does explicitly recognise 
priority setting as a political process and an intrinsically complex task. In these processes, 
deliberation between stakeholders is crucial to identify, reflect and learn about the meaning and 
importance of values, informed by evidence on these values. Such processes then result in the 
use of a broader range of explicit criteria that can be seen as the product of both international 
learning (‘core’ criteria, which include eg, cost-effectiveness, priority to the worse off, and 
financial protection) and learning among local stakeholders (‘contextual’ criteria). We believe 
that, with these evidence-informed deliberative processes in place, priority setting can provide a 
more meaningful contribution to achieving UHC.




In January 2016, the Prince Mahidol Award Conference (PMAC) in Thailand brought together 
more than 900 delegates from 60 different countries, to discuss priority setting of health 
interventions to achieve universal health coverage (UHC).1 The goal of UHC is to ensure that 
all people obtain the health services they need, without suffering financial hardship when 
paying for them.2 At the conference, the World Health Organization (WHO) and the Disease 
Control Priority (DCP) project presented their impressive work to expand the evidence base 
on the cost-effectiveness of interventions, concentrated on low- and middle-income countries 
(LMICs).3,4 The underlying implicit assumption to these analyses is that priority setting should 
be geared towards maximisation of population health, and that the provision of more evidence 
on cost-effectiveness will improve decision-making and lead to better health. This rationale also 
underpins the development of many international disease control guidelines. For example, the 
most recent WHO guidelines on when to start antiretroviral therapy for HIV are largely based on 
the expected epidemiological impact and cost-effectiveness.5
In this editorial, we argue that the mere provision of cost-effectiveness information does not 
adequately support countries to make optimal choices. The reason is that priority setting is in 
reality a value-laden political process, in which multiple criteria beyond cost-effectiveness are 
important and stakeholders often justifiably disagree about their relative importance. Instead, 
we propose the use of ‘evidence-informed deliberative processes’ as an approach that does 
explicitly recognise priority setting as a political process and an intrinsically complex task. In 
these processes, deliberation between stakeholder is crucial to identify, reflect and learn about 
the importance of relevant values, informed by evidence on these values.
We first outline the need for evidence-informed deliberative processes, illustrate this with 
examples from Indonesia, Thailand, and the Netherlands, discuss how to preserve the use of 
social core values in these processes, and then elaborate on their use to achieve UHC.
THE NEED FOR EVIDENCE-INFORMED DELIBERATIVE PROCESSES
It has been recognised since long that priority setting is in reality a value-based political process 
which takes place in an environment of social values and diverging interests.6-10 It involves 
“pluralistic bargaining between different lobbies, by shifting political judgements made in the 
light of changing pressures”11 and is described as “a complex interaction of various decisions 
at diverse levels in the organization. There is no self-obvious set of ethical principles or scientific 
tools to determine what decisions we should take at various levels.”12 
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If we agree that priority setting is a value-based political process, this then requires a paradigm 
shift in how research should approach the challenge of priority setting, addressing two important 
issues. Firstly, society – including relevant stakeholders such as patients, providers, insurers, 
and citizens – has a wide range of social values to judge decisions. These go beyond only health 
maximization as reflected in the criterion ‘cost-effectiveness,’ for example caring for the worse off 
in society or responsibility for own health.13-18 We argue that the whole of these values should be 
considered when setting priorities. Second, stakeholders often disagree about the importance of 
these values, and may have good reasons to do so when it comes to setting priorities. In the light 
of this, Daniels and Sabin have proposed the use of fair processes as an alternative approach 
to priority setting. In their seminal work on ‘accountability for reasonableness’ (A4R), they argue 
that it is more likely that stakeholders will agree on a fair process to set priorities than on the 
use of specific social values – and if they do so, stakeholders are then also more likely to confer 
legitimacy to the decisions that are made through this process.10 
Following this logic, and in acceptance of these two issues, the central question in priority 
setting becomes: ‘How can priority setting processes be organised such that stakeholders 
confer legitimacy to the decisions that will eventually be taken’? Or in other words: ‘so that they 
accept these decisions as reasonable?’ Daniels and Sabin propose conditions for transparency, 
relevance, appeal, and enforcement that processes should meet to achieve legitimacy.10 The 
aim of such processes is to develop a mutual basis for decisions among stakeholders, through 
the identification, interpretation and deliberation on a range of values that they find important, 
and informed by evidence where possible. 
Where Daniels and Sabin speak of ‘fair processes,’ we preferably name these ‘evidence-
informed deliberative processes’ to better position the approach in the present public health 
debate. On the one hand, these processes are based on deliberation between stakeholders to 
identify, reflect and learn about the meaning and importance of relevant social values. On the 
other hand, they are based on rational decision-making – through evidence-informed evaluation 
of the identified values where possible. We speak of evidence-informed rather than evidence-
based evaluation as the former concept leaves ample room for clinical experience as well as the 
constructive judgements of stakeholders such as practitioners and patients who are in constant 
interaction and dialogue with one another.19 We see ‘evidence-informed’ and ‘deliberation’ as 
the two essential elements to achieve legitimacy in priority setting. To date, the work on fair 
processes (or how we name it: evidence-informed deliberative processes), has mainly been 
theoretical, and we see large potential for their practical application to support countries in their 
strive for UHC.
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DEVELOPMENT OF EVIDENCE-INFORMED DELIBERATIVE PROCESSES 
We distinguish six steps in the use of evidence-informed deliberative processes (Figure 1), and 
these are described in detail elsewhere.20 The dotted lines reflect that the process is iterative.
1. Situational 
analysis










3. Identification of 
relevant criteria
Figure 1. Six Steps of Evidence-Informed Deliberative Processes*
*The EDP framework has been revised over the course of this PhD. For the most up-to-date version see Chapter 1, Figure 3.
The way these steps can be applied in a decision-making context to foster the legitimacy of the 
eventual decisions, depend on the already existing priority setting process. To illustrate this, we 
provide two examples: (i) a case study to support HIV control in Indonesia, where priority setting 
has historically been implicit and entire processes need to be established; (ii) reimbursement 
decisions in the Netherlands and Thailand where HTA agencies are firmly established, and 
processes are relatively well-developed. It is obvious that in the former example, there is a 




Supporting HIV Control in Indonesia 
We recently supported West Java provincial authorities in Indonesia in the development of 
their strategic plan on HIV/AIDS.20-23 The process included a situational analysis on the current 
response to the HIV epidemic (step 1); the formation of a multi-stakeholder consultation panel 
(step 2); the identification of stakeholder values for the most important goals in HIV control, 
resulting in a set of criteria for priority setting that were considered reasonable by all panel 
members (step 3); a listing of HIV/AIDS intervention options by the consultation panel, including 
the collection of evidence to assess their performance (step 4); a deliberative discussion among 
the consultation panel members on this evidence, in view of their values and interests, to reach 
agreement on the final rank order of interventions (step 5); and a listing of institutions that would 
be suitable and/or fund high priority interventions (step 6). The overall aim of the process was to 
organise priority setting as an interactive learning process, in which the consultation panel refined 
the participatory steps of identifying, elaborating and deciding on the inclusion of further relevant 
stakeholders, criteria and evidence. A recent evaluation indicated that panel members were 
overall positive about the process, as it had improved the quality of decision-making – especially 
in terms of use of multiple criteria and concrete evidence, active participation of stakeholders, 
and transparency of decision-making.22,23 
Yet, we also recognize that, for logistic and budgetary reasons, it is not feasible to develop such 
processes from scratch in all decision-making contexts where no priority setting process is in 
place. Ideally, countries should work towards the development of more generic centrally-led 
institutionalized processes, which would then be used at decentralised level as guidance for 
priority setting.24,25 We see our work as a stepping stone towards such institutionalized processes, 
by spelling out important principles, documenting the initial experiences, and thereby creating 
awareness about its potential and limitations. In this context, we applaud the pioneering work of 
the International Decision Support Initiative (iDSI), which provides policy-makers at sub-national, 
national, regional, and international levels with technical support in coordinating priority setting 
as a means towards achieving UHC.25
Reimbursement Decisions by Health Technology Assessment Agencies 
A number of national health technology assessment (HTA) agencies have already important 
components of evidence-based deliberative processes in place. For example, the Netherlands 
Health Care Institute (ZINL) employs an appraisal committee that represents the Dutch society 
and advises the Minister of Health. The committee deliberates on the social value of health 
technologies on the basis of the available evidence on four generic criteria (effectiveness, cost-
effectiveness, necessity, and feasibility), along with other contextual criteria that are considered 
relevant to the interventions under scrutiny.26 In Thailand, the National Health Security Office 
employs a consultation panel which works with a large group of stakeholders to select interventions 
for assessment. The panel appraises the interventions on several criteria and deliberates to 
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reach consensus on which interventions should be adopted in the benefit package.27 While 
these agencies employ various elements of evidence-based deliberative processes, they can 
still improve on other elements eg, stakeholder involvement in the Netherlands. This in order to 
further foster the legitimacy of their decisions. 
From a more methodologically point of view: various approaches to priority setting contain 
important elements of evidence-informed deliberative processes, including A4R,10 multi-criteria 
decision analysis (MCDA)28 and programme budgeting and marginal analysis (PBMA).29,30 The 
frameworks have been applied in various settings.27,31-36 The added value of our framework is that 
it combines these elements in an integrated approach. 
THE USE OF SOCIAL ‘CORE’ VALUES TO ACHIEVE UNIVERSAL HEALTH 
COVERAGE 
An important issue in the use of evidence-informed deliberative processes is how important 
social values can be preserved in the process. Stakeholder consultation, especially in the 
presence of vested interests, does not necessarily capture such public interests. 
In its report ‘Making fair choices on the path to UHC,’ the WHO recently proposed the use 
of ‘cost-effectiveness,’ ‘priority to the worse off,’ and ‘financial protection’ as the three most 
essential criteria for countries to consider when setting priorities.18 We consider these as ‘core’ 
criteria, representing social values for which there is broad consensus on their importance and 
which are of generic relevance across countries, disease areas and health interventions. Their 
identification can be seen as the product of international learning, particularly in academic 
circles, on priority setting.37 One way to preserve these ‘core’ values in evidence-informed 
deliberative processes is to consider them as mandatory criteria for healthcare priority setting. 
Another, less stringent option is to use them as ‘opt-out’ criteria, for which a decision-maker 
should provide compelling arguments when declining them. We argue that the use of evidence-
informed deliberative processes would then be instrumental to consider additional criteria for 
priority setting for which there is no broad consensus or which are only relevant for a particular 
decision – we call these ‘contextual criteria.’ These can include many criteria, eg, ‘responsibility 
for own health’ or ‘size of the population affected.’37
 
Above we criticize WHO and the DCP project for its use of cost-effectiveness analysis as the sole 
criterion. Yet, how we see it, ‘cost-effectiveness’ can very well be a ‘core’ criterion in priority setting 
but should be interpreted in the context of other stakeholder values. In other words, our critique 
concerns the dominant use of cost-effectiveness analysis, not cost-effectiveness analysis as 
such. In fact, the DCP project is now conducting extended cost-effectiveness analysis (ECEA), to 
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also capture the financial protection which interventions offer to target populations.38 We applaud 
this effort as it provides valuable evidence on what we see as one of the core criteria in priority 
setting to achieve UHC. Yet, we recommend that this DCP work should be coupled with the 
development of evidence-informed deliberative processes at the country level, to also identify 
other contextual criteria.22
OUR CONTRIBUTION 
As a research group, we carry out various activities under the heading of the REVISE (REthinking 
the Value of Interventions to improve priority SEtting) project to further develop evidence-informed 
deliberative processes.39 We are: 
•   developing best practices on the various elements of these processes, eg, on whose values to 
consider, how to best guide the identification of criteria, and how to deal with vested interests. 
Our first findings are published in a companion paper;40 
•   collaborating with other disciplines such as public administration and political sciences, to 
learn from similar processes in other fields;41,42 
•   experimenting with the implementation of processes in various contexts and evaluate these; 
and 
•   stimulating the debate between researchers, policy-makers, and society on the need to set 
legitimate priorities in healthcare.39 
CONCLUSION 
It is time to focus on the development of evidence-informed deliberative processes to set 
legitimate priorities, and we call for more research in this area. We believe that with such 
processes in place, priority setting can provide an important contribution to achieving UHC.
We need EDPs, Not just more evidence on cost-effectiveness
35
2
1.  Teerawattananon Y, Luz A, Kanchanachitra C, 
Tantivess S, Prince Mahidol Award Conference 
s. Role of priority setting in implementing 
universal health coverage. BMJ. 2016;532:i244. 
doi:10.1136/bmj.i244 
2.  World Health Organization (WHO). Universal 
health coverage: Global coalition calls for 
acceleration of access to universal health 
coverage. http://www.who.int/universal_
health_coverage/en/. Accessed June 10, 2016. 
Published 2016. 
3.  Jamison DT. Disease Control Priorities Project, 
3rd edition: Improving health and reducing 
poverty. Lancet. 2015. doi:10.1016/ S0140-
6736(15)60097-6 
4.  World Health Organisation (WHO). WHO-
CHOICE database on cost-effectiveness. 
http://www.who.int/choice/en/. Accessed 
March 30, 2016. 
5.  World Health Organisation (WHO). Guidelines 
on when to start antiretroviral therapy and on 
pre-exposure prophylaxis for HIV. Geneva: 
WHO; 2015. 
6.  Holm S. The second phase of priority setting. 
Goodbye to the simple solutions: the second 
phase of priority setting in health care. BMJ. 
1998;317(7164):1000-1002. 
7.  Mitton C, Donaldson C. Health care priority 
setting: principles, practice and challenges. 
Cost Eff Resour Alloc. 2004;2(1):3. 
doi:10.1186/1478-7547-2-3 
8.  Daniels N. Accountability for reasonableness. 
BMJ. 2000;321(7272):1300-1301. 
9.  Kapiriri L, Martin DK. A strategy to improve 
priority setting in developing countries. Health 
Care Anal. 2007;15(3):159-167. doi:10.1007/
s10728-006-0037-1 
10.  Daniels N, Sabin JE. Accountability 
for reasonableness: an update. BMJ. 
2008;337:a1850. doi:10.1136/bmj.a1850 
11.  Martin DK, Hollenberg D, MacRae S, Madden 
S, Singer P. Priority setting in a hospital drug 
formulary: a qualitative case study and 
evaluation. Health Policy. 2003;66(3):295-303. 
12.  Holmstrom S. Sweden and priority setting. In: 
Foundation SAHC, ed. 1997. 
13.  Golan O, Hansen P, Kaplan G, Tal O. Health 
technology prioritization: which criteria for 
prioritizing new technologies and what 
are their relative weights? Health Policy. 
2011;102(2-3):126- 135. doi:10.1016/j.
healthpol.2010.10.012 
14.  Guindo LA, Wagner M, Baltussen R, et al. From 
efficacy to equity: Literature review of decision 
criteria for resource allocation and healthcare 
decisionmaking. Cost Eff Resour Alloc. 
2012;10(1):9. doi:10.1186/1478-7547-10-9 
15.  Johri M, Norheim OF. Can cost-effectiveness 
analysis integrate concerns for equity? 
Systematic review. Int J Technol Assess Health 
Care. 2012;28(2):125-132. doi:10.1017/
S0266462312000050 
16.  Norheim OF, Baltussen R, Johri M, et 
al. Guidance on priority setting in health 
care (GPS-Health): the inclusion of equity 
criteria not captured by cost-effectiveness 
analysis. Cost Eff Resour Alloc. 2014;12:18. 
doi:10.1186/1478-7547-12-18 
17.  Tromp N, Baltussen R. Mapping of multiple 
criteria for priority setting of health interventions: 






18.  World Health Organisation (WHO). WHO 
Consultative Group on Equity and Universal 
Health Coverage. Making fair choices on the 
path to UHC. Geneva: Who; 2016. 
19.  Nevo I, Slonim-Nevo V. The Myth of Evidence-
Based Practice: Towards Evidence-Informed 
Practice. British Journal of Social Work. 2011. 
doi:10.1093/bjsw/bcq149 
20.  Baltussen R, Mikkelsen E, Tromp N, et al. 
Balancing efficiency, equity and feasibility of 
HIV treatment in South Africa - development of 
programmatic guidance. Cost Eff Resour Alloc. 
2013;11(1):26. doi:10.1186/1478-7547-11-26 
21.  Tromp N, Prawiranegara R, Subhan Riparev 
H, Siregar A, Sunjaya D, Baltussen R. 
Priority setting in HIV/AIDS control in West 
Java Indonesia: an evaluation based on the 
accountability for reasonableness framework. 
Health Policy Plan. 2015;30(3):345- 355. 
doi:10.1093/heapol/czu020
22.  Tromp N, Prawiranegara R, Siregar A, Jansen 
MP, Baltussen R. Time to recognise countries’ 
preferences in HIV control. Lancet. 2016:1053-
1054. doi:10.1016/S0140-6736(16)00659-0 
23.  Tromp N, Prawiranega, R, Siregar A, Jansen 
MP, Baltussen R. Towards participatory and 
evidence-based resource allocation decisions 
for AIDS funding in Indonesia. Nijmegen; 2016. 
24.  Ottersen T, Norheim OF. Making fair choices 
on the path to universal health coverage. 
Bull World Health Organ. 2014;92(6):389. 
doi:10.2471/BLT.14.139139 
25.  International Decision Support Initiative (iDSI). 
http://www. idsihealth.org/. Accessed March 
30, 2016. 
26.  Zorginstituut Nederland (National Health Care 
Institute). Kosteneffectiviteit in de praktijk 
(Cost-effectiveness analysis in practice). 
Diemen; 2015. 
27.  Youngkong S, Baltussen R, Tantivess S, Mohara 
A, Teerawattananon Y. Multicriteria decision 
analysis for including health interventions in 
the universal health coverage benefit package 
in Thailand. Value Health. 2012;15(6):961-970. 
doi:10.1016/j.jval.2012.06.006 
28.  Thokala P, Devlin N, Marsh K, et al. Multiple 
Criteria Decision Analysis for Health Care 
Decision Making-An Introduction: Report 1 of 
the ISPOR MCDA Emerging Good Practices 
Task Force. Value Health. 2016;19(1):1-13. 
doi:10.1016/j.jval.2015.12.003 
29.  Mitton C, Peacock S, Donaldson C, Bate A. 
Using PBMA in health care priority setting: 
description, challenges and experience. Appl 
Health Econ Health Policy. 2003;2(3):121-127. 
30.  Gibson J, Mitton C, Martin D, Donaldson 
C, Singer P. Ethics and economics: does 
programme budgeting and marginal 
analysis contribute to fair priority setting? J 
Health Serv Res Policy. 2006;11(1):32-37. 
doi:10.1258/135581906775094280 
31.  Byskov J, Marchal B, Maluka S, et al. The 
accountability for reasonableness approach 
to guide priority setting in health systems 
within limited resources--findings from action 
research at district level in Kenya, Tanzania, and 
Zambia. Health Res Policy Syst. 2014;12:49. 
doi:10.1186/1478-4505-12-49 
32.  Youngkong S, Kapiriri L, Baltussen R. Setting 
priorities for health interventions in developing 
countries: a review of empirical studies. 
Trop Med Int Health. 2009;14(8):930-939. 
doi:10.1111/j.1365- 3156.2009.02311.x 
33.  Miot J, Wagner M, Khoury H, Rindress D, 
Goetghebeur MM. Field testing of a multicriteria 
decision analysis (MCDA) framework for 
coverage of a screening test for cervical 
We need EDPs, Not just more evidence on cost-effectiveness
37
2
cancer in South Africa. Cost Eff Resour Alloc. 
2012;10(1):2. doi:10.1186/1478-7547-10-2 
34.  Adunlin G, Diaby V, Xiao H. Application of 
multicriteria decision analysis in health care: 
a systematic review and bibliometric analysis. 
Health Expect. 2015;18(6):1894-1905. 
doi:10.1111/ hex.12287 
35.  Marsh K, Lanitis T, Neasham D, Orfanos P, 
Caro J. Assessing the value of healthcare 
interventions using multi-criteria decision 
analysis: a review of the literature. 
Pharmacoeconomics. 2014;32(4):345-365. 
doi:10.1007/s40273-014-0135-0 
36.  Tsourapas A, Frew E. Evaluating ‘success’ 
in programme budgeting and marginal 
analysis: a literature review. J Health Serv 
Res Policy. 2011;16(3):177-183. doi:10.1258/
jhsrp.2010.009053 
37.  Norheim OF. Ethical priority setting for universal 
health coverage: challenges in deciding upon 
fair distribution of health services. BMC Med. 
2016;14(1):75. 
38.  Pecenka CJ, Johansson KA, Memirie ST, 
Jamison DT, Verguet S. Health gains and 
financial risk protection: an extended cost-
effectiveness analysis of treatment and 
prevention of diarrhoea in Ethiopia. BMJ Open. 
2015;5(4):e006402. 
39.  Nijmegen International Center for Health 
Systems Research and Education (NICHE). 
http://www.niche1.nl/. Published March 30, 
2016. 
40.  Jansen MP, Helderman JK, Boer B, Baltussen 
R. Fair processes for priority setting: putting 
theory into practice. Int J Health Policy Manag. 
2016; forthcoming. 
41.  MacCoun R. Voice, control and belonging: The 
double-edged sword of procedural fairness. 
Annual Review of Law and Social Science. 
2005;1:171-201. 
42.  Esaiasson P, Gilljam M, Persson M. Which 
decision-making arrangements generate the 




Evidence-informed deliberative processes – 
early dialogue, broad focus and relevance: 
a response to recent commentaries
Published as:
Jansen MP, Baltussen R, Mikkelsen E, Tromp N, Hontelez J, Bijlmakers L, Van der Wilt GJ.
Evidence-informed deliberative processes – early dialogue, broad focus and relevance: 
a response to recent commentaries.
Int J Health Policy Manag 2018, 7(1), 96–97
Chapter 2.1
40
EDPs – early dialogue, broad focus and relevance
41
2.1
The recent Health Technology Assessment international (HTAi) conference in Rome discussed 
how we can move ‘towards an integrated HTA framework for a more sustainable healthcare 
ecosystem’ and improve ‘the role of multi-stakeholder involvement in HTA to face ethical 
dilemmas for health system’s economic, social and environmental sustainability.’1 
Evidence-informed deliberative processes (EDPs) to support priority setting for universal 
health coverage (UHC), as described in our editorial,2 are well-aligned with HTAi’s call for a 
more integrated HTA (or priority setting) framework. EDPs specifically achieve this by promoting 
early deliberation among a wide variety of stakeholders to identify, reflect and learn about the 
meaning and importance of values, informed by evidence on these values.2,3 Being a generic 
value-assessment framework, it may be applied to prioritization exercises with either broad or 
narrow scopes and should be contextualized to its local setting. 
We agree with Gopinathan and Ottersen that the “focus of such processes [to support priority 
setting for UHC] should go beyond clinical services to accommodate also public health 
interventions.”4 We also concur with Lauer et al that priority setting should take into account higher 
level, systemic activities that can strengthen progression towards UHC such as ‘improving health-
system governance,’ ‘ensuring equitable access to quality services,’ ‘separating prescribing 
from dispensing,’ or ‘setting up a pooled funding mechanism to purchase services.’5 Moreover, 
EDPs “should adapt to a diverse set of factors shaping the relationship between evidence and 
policy.”4 Ideally, EDPs are initiated at an early stage, as policy-relevant evidence can still be 
commissioned or searched for during this stage, and there is still time to reflect on input or ideas 
put forward by stakeholders. As Gopinathan and Ottersen point out, this requires involvement 
of the right stakeholders, including non-health stakeholders where relevant.4 At the same time, 
Lauer et al raise the question “who should be invited to the deliberative dialogue?”5 We argue 
that those affected by decisions should at least be provided the opportunity to participate and 
provide relevant reasons or evidence3 – and we acknowledge that it is hard to determine who the 
relevant stakeholders are, and that standardized approaches are required to identify and engage 
relevant stakeholders. The description by Gopinathan and Ottersen of the complex relationship 
between evidence and policy further demonstrates the challenge of knowledge translation and 
how evidence can eventually be presented so as to facilitate its uptake and inclusion in policy 
formulation or revision.6 More broadly speaking, these comments highlight the challenge of 
institutionalization: how to work towards a situation that priority setting for UHC gets integrated in 
the routine decision making processes at both national and sub-national levels. 
With regard to whether stakeholder deliberation as part of EDPs departs from a ‘blank slate,’ 
we agree with Lauer et al that countries should not ignore global level policy as formulated and 
endorsed by the World Health Organization (WHO) member states.5 Universal goals do need 
to be aligned with local context and priorities. We also recognize the point made by Lauer et al 
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that EDPs, generic as they are, are already in place to a certain degree at the country level and 
are supported by the WHO Secretariat,5 in the form of consultative groups, and part of health-
sector reviews and strategic planning and budgeting. Likewise, as Chalkidou et al point out, 
the International Decision Support Initiative (http://www.idsihealth.org/) has been established 
to strengthen in-country institutional and technical capacity together with open participative 
processes for evidence-informed policy-making.7 We hope that such initiatives will benefit from 
the further development of EDPs.
That said, it is not our intention to devalue cost-effectiveness evidence in itself – or to criticize 
agencies specialized in producing this particular type of evidence.5,7 On the contrary, evidence on 
the cost-effectiveness of a clinical or public health intervention provides relevant information on 
the opportunity costs of alternative investments that are foregone. Hence we do not oppose, but 
instead welcome efforts to integrate evidence on multiple criteria as is the case in the extended 
cost-effectiveness analysis approach.5,8,9
Nevertheless, we agree with Chalkidou et al and would like to highlight again that “global 
approaches to CEA can hardly be too context-sensitive” for the very reason that “studies done 
by global players that ignore local contexts but nonetheless presume to advise may undermine 
local priorities and distort local spending decisions.”7 We furthermore applaud WHO for providing 
broader support and guidance to countries.5 Yet, we observe in practice that cost-effectiveness 
is often considered the dominant criterion when used in priority setting. This effectively makes 
the generation of other evidence and deliberation on additional criteria secondary to cost-
effectiveness, which may undermine the legitimacy of decisions at the country level. 
We thank all authors who commented on our editorial, and we look forward to working together 
in the coming years to help harmonize EDPs with like-minded initiatives and align them with 
sustainable country-led decision-making processes.
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Embedding health technology assessment (HTA) in a fair process has great potential to capture 
societal values relevant to public reimbursement decisions on health technologies. However, the 
development of such processes for priority setting has largely been theoretical. In this paper, we 
provide further practical lead ways on how these processes can be implemented. We first present 
the misconception about the relation between facts and values that is since long misleading the 
conduct of HTA and underlies the current assessment-appraisal split. We then argue that HTA 
should instead be explicitly organized as an ongoing evidence-informed deliberative process, 
that facilitates learning among stakeholders. This has important consequences for whose values 
to consider, how to deal with vested interests, how to consider all values in the decision-making 
process, and how to communicate decisions. This is in stark contrast to how HTA processes are 
implemented now. It is time to set the stage for HTA as learning.
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Daniels and colleagues have recently called for an expansion of the practice of health technology 
assessment (HTA), in order to capture societal values relevant to public reimbursement decisions 
of health technologies.1 We agree with their suggestion that embedding HTA in a fair process 
has great potential in achieving this, in the sense that this allows for the inclusion of stakeholder 
values. We see this an important development in the revision of theory and tools for priority 
setting – by moving away from rather technocratic approaches that merely aim to maximize 
health gains, to, instead, interpreting priority setting as a value laden political process, in which 
the use of evidence-informed deliberative processes contributes to setting legitimate priorities 
in health.1-3 
Yet, as we see it, the development of such processes for priority setting has largely been 
theoretical. A companion article stresses the need for development and implementation of 
evidence-informed deliberative processes.3 In this paper, we propose further practical lead 
ways on how these processes can be implemented. We argue that this requires the inclusion of 
stakeholder’s values and expertise, and this can only be realized if HTA is explicitly organized 
as an ongoing learning process among stakeholders – to acquire shared knowledge on what 
is valuable about a specific health technology4 and help negotiate between vested interests of 
stakeholders. This is in stark contrast to how HTA processes are implemented now. We present 
this misfit, and then proceed by providing practical lead ways on how HTA as learning can be 
implemented. We argue that these processes of learning about the facts and values of priority 
setting need to be proactively coordinated.5,6 This is how we believe that HTA can best contribute 
to setting fair and legitimate priorities in health.
THE MISCONCEPTION ABOUT FACTS AND VALUES
It is widely acknowledged that present HTA processes fall short to provide decision-makers with 
a comprehensive set of information to base their decisions on.1,7-9 Especially, HTA processes do 
not provide decision-makers with proper guidance on how they should judge ethical issues. With 
others, we argue that an important reason is the conduct of HTA in two separate phases: (i) the 
generation of evidence itself, or the assessment phase and (ii) the interpretation of the evidence 
collected, or the appraisal phase.10 The mistaken underlying belief is that the assessment phase 
is a value-free kind of scientific research – which produces objective data for the appraisal 
phase, during which then values are brought to bear on the available evidence. This distinction 
is utterly misconceived, since it assumes we can collect facts in a value-free and completely 
objective way.10 In reality, value-based choices are already made at the point of choosing what 
evidence needs to be collected.
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HTA agencies that have institutionalized this separation often choose to use a standard set 
of criteria during the assessment phase, pushing the consideration of other criteria into the 
appraisal phase. The consequence is that the evaluation of further concerns – which are not 
automatically covered by the standard criteria – becomes a post-assessment assessment 
exercise. Evidence on these aspects will not be collected or it will not be in time for use in the 
decision-making process. 
A demonstration of the misconception about the relation between facts and values is the 
prominent use of cost-effectiveness analysis (CEA) as a method of evaluation in HTA. There is 
little explicit recognition that the choice to conduct a CEA is already dependent on valuing health 
maximization in the first place and that it does not adequately reflect all relevant societal values. 
Worse yet, many of the ‘objective’ criteria that HTA relies on in its assessment phase, depend to 
a large extent on the way they work out in operational practice.11 
ORGANIZING HEALTH TECHNOLOGY ASSESSMENT AS A LEARNING 
PROCESS 
Organizing ‘HTA as learning’4,10-13 instead requires that well-organized deliberative processes 
and procedures are established that induce and help stakeholders spell-out what they find 
relevant values at the very start of the decision-making process. Also, it is key that stakeholders 
reflect upon evidence whenever it is, or becomes, available – they need to ask themselves what 
the evidence means to them in their current practices and what new questions are relevant to 
answer. This includes a deliberation on initial constraints and conditions that may hinder the 
approval of the technology, and whether and how these can be overcome so that a positive or 
provisional decision comes within the realm of politically legitimated conditions.6,14 This appraisal 
among all public and private stakeholders must continue throughout the process, until the end, 
when politically authorized decision-makers have to reach a final (or provisional) decision. As 
such, the process must not be organized as a two-phase process – separating assessment and 
appraisal. Instead, it should be organized as a continuous interactive and dialectical exploration 
of what is valuable (or what gives stakeholders reason for concern) about the health technology 
at stake. 
The underlying assumption is that stakeholders’ understanding of the technology, the disease 
or its further context may change, or evolve, when stakeholders participate in a learning process 
among stakeholders. This requires from stakeholders that they are both able and willing to learn, 
and experimental and anecdotal evidence supports this.15-18 Also, it is assumed that such new 
understanding is an improvement, compared to the initial understanding of stakeholders, and 
that decision-making based on this new understanding is better able to provide both stakeholders 
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and citizens outside the process with well-justified reasons to confer legitimacy to the decision-
making process and its final decision. 
WHOSE VALUES ARE IMPORTANT? 
In order to identify all relevant values, knowledge and questions, all stakeholders who are 
somehow affected by the to-be-made decision should be able to participate in the process – 
either indirectly represented via appraisal committees, interest groups, organizations, or directly 
as patients, healthcare workers or citizens (taxpayers). If not all stakeholders are involved, 
potentially valuable insights are easily missed out on – hindering the learning process. 
In particular, there is a strong normative demand to provide people who are adversely affected 
by priority setting decisions with well-justified reasons for conferring legitimacy to the decision.19 
This implies that HTA processes that aim to optimize priority setting decisions – with the aim of 
increasing the fairness and legitimacy of these processes – should be organized in such a way 
that special attention is given to consult those who are adversely affected by decisions each time 
a tentative decision is reached. This specific (conflict) interaction can at the same time be an 
important driver for learning and produce relevant questions for further assessment. 
ARE PUBLIC VALUES THE SUM OF PRIVATE VALUES? 
Stakeholders often have strong vested interests and it should not come as a surprise that 
they initially push in favour of these interests. This has two consequences. Firstly, in practice, 
unregulated discussions and unorganized deliberative processes easily end up in unending 
disputes. Especially so, when stakeholders are only involved at the end of the decision-making 
process, during the appraisal phase – giving stakeholders the impression there are only limited 
opportunities left to have an impact on decision-making and offering them little time to learn 
from other perspectives and arguments. This again indicates the need to regulate deliberative 
processes, and involve all stakeholders right from the start. Such regulation should clarify 
how stakeholders can contribute to the process, rules of argumentation, weighing, trading-off 
arguments and should make explicit how the final decision is to be taken. 
Second, stakeholder consultation in the presence of vested interests likely captures private 
values, but it is less able to capture specific public interests that we have good reasons to 
care about, such as safeguarding equal access to good quality healthcare, efficiency and cost 
containment. Such public interests are not per se endorsed or defended as important by (private) 
stakeholders. Therefore, if we agree on the importance of specific public interests, that are the 
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product of (inter)national learning about what should count as legitimate public interests, their 
consideration and inclusion into the learning process must be organized – in a legitimate way. 
This may translate eg, into a mandatory consideration of criteria that reflect broad societal interest 
and consensus, like effectiveness, cost-effectiveness or severity of disease. Or, in countries 
where mandatory consideration of criteria is not pursued (or where they lack consensus on 
criteria that reflect broad societal interest) there is potential to learn from internationally endorsed 
societal values, that are the result of international and academic learning. 
HOW TO CONSIDER ALL VALUES IN THE DECISION-MAKING PROCESS? 
When relevant values or key questions are identified throughout the process, they likely require 
further assessment. This may take the shape of (systematically) reviewing the literature, or 
creating an evidence-base for values that are quantifiable – eg, if health maximization is valued, 
then the technology’s performance can be assessed quantitatively by means of CEA, or for 
severity of disease by calculating the associated proportional shortfall.20 Values that are more 
difficult to quantify may be subjected to qualitative analysis, ie, ethical analysis or (expert) 
stakeholder opinions, to the extent possible. In the decision-making process, these pieces of 
quantitative and qualitative evidence – in conjunction with other values – should be deliberated 
on. The focus should be on finding out how these different pieces of information relate to each 
other and includes the making of value judgments about the available information. Again, this 
implies that appraisal and assessment go hand in hand throughout the process – constantly 
building and progressing towards a coherent and legitimate decision – and are not organized 
as separate phases. In a democratic society, political accountable decision-maker(s) hold the 
final authorizing decision-making power and therefore, stay accountable, not only for taking the 
final (or provisional) decision, but also for the deliberative procedures and actions that have been 
undertaken to come to this decision. However, this then warrants clarification on how responsible 
public decision-makers proceed from being one of the stakeholders – representing their own 
(public) interests – to taking the final decision in a fair way. How to best achieve this is yet unclear. 
HOW TO COMMUNICATE THE ARGUMENTATION – AND LEARNING – THAT 
LED TO THE FINAL DECISION? 
It is important that all argumentation – on the use (or rejection) of criteria and their importance – 
is documented and made explicit in documents that serve to explain the decision to those who 
did not participate themselves. It is essential that not only the final result and its main rationales 
are spelled-out, but explanations why other identified concerns were not included should also 
be made explicit. Doing so in accountable ways will increase the likelihood that citizens who did 
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not participate – and did not go through a learning process – can follow the complete reasoning 
underlying to the final decision. This allows for vicarious learning,4 and makes it more likely that 
they confer legitimacy to the process – and consider the decision as fair and legitimate – for 
well-justified reasons. Also, it may prevent that involved stakeholders shy away from making well-
justified compromises that they would otherwise feel burdened to communicate in a convincing 
way to the ones they represent. 
CURRENT DELIBERATIVE APPROACHES 
A number of approaches for priority setting concentrate on evidence-informed deliberative 
processes, including the accountability for reasonableness (A4R),2,21 multi-criteria decision 
analysis (MCDA)22 and programme budgeting and marginal analysis (PBMA) frameworks.23,24 
All consider deliberative processes important to develop and interpret the evidence-base for 
decision-making on the basis of stakeholder values and interests and to a certain extent foster 
learning among stakeholders. Interactive technology assessment (iTA)12,13 is specifically tailored 
to the concept of ‘HTA as learning’ and deliberative decision-making and is currently only in 
its experimental stage. Other approaches include citizen juries25 or round table conferences 
where stakeholders (eg, medical professionals, healthcare providers, health purchasers) are 
induced to reflect upon the technology at stake.18 We see large potential in the integration of 
such approaches to support evidence-informed deliberation and learning among stakeholders. 
As an example, we have recently operationalized, implemented and evaluated a new process to 
guide priority setting in HIV/ AIDS26 in West Java, Indonesia that integrates the A4R and MCDA 
frameworks.27-29 The overall aim of the process was to organise priority setting as an interactive 
learning process. A recent evaluation indicated that involved stakeholders were overall positive 
about the process, as it had improved the quality of decision-making – especially in terms of 
use of multiple criteria and concrete evidence, the active participation of stakeholders, and 
transparency of decision-making.27,29 
Also, the Dutch National Health Care Institute is now introducing a scoping exercise in their 
decision-making process. During this scoping exercise stakeholders are consulted to help 
determine relevant outcome measures for the effectiveness of an intervention, which is a first 
step towards overcoming the assessment – appraisal split.14,20 Furthermore, a recent exploration 
of the potential role for MCDA in the Dutch decision-making process, showed that more 




We see the following research agenda as key for progressing towards evidence-informed 
deliberative processes in priority setting: 
•   The use of a deliberative fair process is based on the assumption that stakeholders learn 
throughout the process and adjust their perspectives on the importance of criteria. Research 
– in the form of case studies – is needed that qualifies this assumption and evaluates learning 
by stakeholders and its impact on the final decision. 
•   Further research is needed on the translation of the practical lead ways as identified in this 
paper into organizational processes of HTA agencies. This relates to questions as: how can 
the concept of learning be best integrated into already existing deliberative approaches? 
How can processes be organized such that they can properly involve stakeholders?30 What 
kind of skills and expertise are needed throughout the process to make it a success, eg, 
interviewing skills to elicit stakeholder’ values? And how can this be organized within the 
time limits for decision-making? How can responsible decision-makers best guarantee that 
the final decision is taken fairly, considering they themselves are first actively participating in 
deliberation? How can decisions be best documented, reported and communicated to the 
general public, eg, with empathy, and in an understandable way? To answer these questions, 
it may be instrumental to review institutionalized deliberative processes in other sectors in 
society, eg, law.6 
•   Research has produced several lists of ‘relevant’ criteria that decision-makers can use 
when making a decision.31-33 Each list claims to capture a basic, generic, core set of criteria. 
Research is needed that identifies whether such a default list is useful to decision-makers as 
a starting point for deliberation, and if so, what should be on the list and in what form it can 
be provided to decision-makers. Eg, do stakeholders need in depth explanations of these 
criteria, or do they only require a short overview? Should the list of criteria be accompanied by 
an overview of arguments in favor or against trading-off specific criteria, to help stakeholders 
deliberate and form their judgements on the relative importance of criteria? Do the information 
needs differ per stakeholder group? 
•   Research is needed on how the use of evidence-informed deliberative processes relates to 
the currently dominant theoretical welfare framework on priority setting. Eg, does the use of 
such processes lead to welfare maximization in the same sense? 
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THE BIGGER PICTURE: HEALTH TECHNOLOGY ASSESSMENT AS SOCIAL 
LEARNING 
Presently, HTA is focused on providing a solution to the temporary task in front of us, namely, 
the priority setting exercise for which a decision has to be made. However, if efforts are made 
to organize HTA processes such that they truly enable learning among stakeholders and help 
shape understanding, then the impact of HTA will reach beyond the specific decision at hand – 
helping us to refine our societal understanding of what is valuable about health technologies and 
health. As such, it can actually stimulate social debate – which is valuable in itself. Learning from 
stakeholders (including citizens) is also instrumental in the sense that their expertise may help 
decision-makers to alter the limiting conditions and constraints in such ways that (provisional) 
approval becomes in the realm of possibilities.6 Then, HTA will be instrumental to discovering 
means to push out the boundaries of the possible, creating access to health technologies that 
are judged valuable but would otherwise have remained unavailable. 
In conclusion, if we truly want to establish fair processes for priority setting that take into account 
all relevant social values, then we must re-organize the HTA process as an ongoing learning 
process – by soliciting stakeholders’ values and expertise right from the start, organize evidence 
collection on the basis of these values, and allow an organized interactive dialogue between 
stakeholders on the need for additional evidence and its meaning throughout the process. It is 
time to set the stage for HTA as learning.
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Evidence-informed deliberative processes (EDPs) were recently introduced to guide health 
technology assessment (HTA) agencies to improve their processes towards more legitimate 
decision-making. The EDP framework provides guidance that covers the HTA process, ie, 
contextual factors, installation of an appraisal committee, selecting health technologies and 
criteria, assessment, appraisal, and communication and appeal. The aims of this study were to 
identify the level of use of EDPs by HTA agencies, identify their needs for guidance, and to learn 
about best practices.
Methods
A questionnaire for an online survey was developed based on the EDP framework, consisting 
of elements that reflect each part of the framework. The survey was sent to members of the 
International Network of Agencies for Health Technology Assessment (INAHTA). Two weeks 
following the invitation, a reminder was sent. The data collection took place between September-
December 2018. 
Results
Contact persons from 27 member agencies filled out the survey (response rate: 54%), of which 25 
completed all questions. We found that contextual factors to support HTA development and the 
critical elements regarding conducting and reporting on HTA are overall in place. Respondents 
indicated that guidance was needed for specific elements related to selecting technologies and 
criteria, appraisal, and communication and appeal. With regard to best practices, the Canadian 
Agency for Drugs and Technologies and the National Institute for Health and Care Excellence 
(NICE, UK) were most often mentioned. 
Conclusion
This is the first survey among HTA agencies regarding the use of EDPs and provides useful 
information for further developing a practical guide for HTA agencies around the globe. The 
results could support HTA agencies in improving their processes towards more legitimate 
decision-making, as they could serve as a baseline measurement for future monitoring and 
evaluation.




Implications for policy makers
• The evidence-informed deliberative processes (EDPs) framework can support the decision-
making process of health technology assessment (HTA)-agencies but is also relevant for 
countries that have not (yet) established such an agency. It takes the current decision-
making context as the starting point, and offers specific advice depending on the level of 
HTA development. 
• Using EDPs can contribute to the legitimacy of recommendations and/or decisions, eg, by 
improving the quality, consistency and transparency of the HTA process.
• The results provide an overview of the level of use of EDPs by HTA agencies around the 
globe. It includes best practices for the different parts of the EDP framework, and as such 
the results are practice-oriented and meant to be inspirational to improve HTA practices. 
Implications for the public
Health technology assessment (HTA) is intended to inform decision-making, including decisions 
regarding which health technologies (eg, drugs, medical devices, surgical procedures, 
vaccination programs) should be reimbursed or not (anymore). There is a need for structured, 
explicit and transparent approaches with regard to how such decisions are made to facilitate 
legitimate decision-making. Current HTA methodologies and decision-making informed by HTA 
only partly respond to these requirements. Using evidence-informed deliberative processes 
(EDPs) can support this; by enhancing stakeholder deliberation throughout the HTA process it 
contributes to the legitimacy of recommendations and/or decisions. This manuscript provides 
insight in (a) how HTA agencies ideally should organise their processes in line with EDPs, which 
could include the involvement of citizens and their views; and (b) to what extent this is currently 





Health technology assessment (HTA) is used to inform decision-making, such as coverage-
decision making, and is described as a process that includes governance and structure, 
scoping, assessment, appraisal and implementation and monitoring.1 There is broad recognition 
that current HTA processes are ill fitted to take into account the wide range and diversity of 
stakeholder values and lead to insufficient sets of information. Ethical issues in particular are left 
unaddressed, thereby compromising the legitimacy of eventual decisions. The call for a more 
integrative perspective on HTA aligns with evidence-informed deliberative processes (EDPs) 
that were recently introduced to support HTA agencies in organizing legitimate processes.2,3 
Although the use of EDPs is relatively new, deliberative methods have been developed and used 
to some extent in the field of HTA since the 2000s.4-9 
EDPs draw on this earlier work and provide a structured process in which stakeholders 
participate throughout the HTA process to identify criteria for the selection of health technologies 
and assessment, to interpret forthcoming evidence, and to deliberate on recommendations 
and decisions.10,11 EDPs are based on rational decision-making through evidence-informed 
evaluation of identified relevant values (reflected as criteria used in multi-criteria decision analyses 
[MCDAs]) as well as fair decision-making (as reflected in the accountability for reasonableness 
approach – A4R). The underlying premises of the EDP framework are: (1) that involvement of 
relevant stakeholders to identify, reflect, and learn about the meaning and importance of relevant 
values and questions, and (2) an evidence-informed evaluation of the identified values (criteria), 
can contribute to the legitimacy of recommendations and/or decisions by improving the quality, 
consistency and transparency of the HTA process. 
Some HTA agencies already have several of these components in place (eg, the Canadian 
Agency for Drugs and Technologies in Health [CADTH], Scottish Medicines Consortium, 
National Institute for Health and Care Excellence [NICE] in the United Kingdom, and the National 
Committee for Health Technology Incorporation [CONITEC] in Brazil).11 Several approaches 
undertaken by these agencies rely on deliberative processes, for example regarding identifying 
topics for HTA and how to appraise health technologies. These agencies may serve as inspiration 
for others, especially those who have recently formally set-up their HTA practice (eg, the Ministry 
of Public Health in Uruguay, and the Centre of Standardization of the Republican Centre for 
Health Development in Kazakhstan), but they can also improve regarding certain components.3 
In order to support HTA agencies in the use of EDPs, we recently developed a first version of 
a guide.12 In this practical guide, we describe the EDP framework that consists of 5 steps and 
contextual factors for HTA development (Figure 1). 
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We defined the core elements of each step on the basis of our previous work in this field,3,10 
and existing checklists such as the checklist for HTA reports from the International Network of 
Agencies for Health Technology Assessment (INAHTA).13 The way in which these steps can be 
applied in a specific country or region depends on the context, and therefore is not meant as a 
blueprint. 
To identify the level of use of EDPs by HTA agencies, and to further develop the guide to support 
HTA agencies, we felt it was important to collect views and experiences from HTA agencies 
around the globe. We therefore conducted a survey among INAHTA member agencies to 
identify the current level of use of EDPs, identify the need for guidance regarding elements of the 
framework, and to learn about best practices. In this article, we present the main findings from 
the survey.
METHODS
A questionnaire for a semi-structured online survey was developed based on the EDP framework, 
consisting of elements that reflect each step of the framework and the contextual factors for 
HTA development. We also asked respondents to list any element that they felt was missing 
and for best practices regarding each part of the framework. The questionnaire is provided as 
Supplementary file 1. 
We contacted the INAHTA secretariat for supporting us in contacting their members. INAHTA 
is a network of 50 HTA agencies that support health system decision-making in 31 countries 
around the globe (2018 figures). The INAHTA secretariat provided consent and agreed to send 
an invitation to participate in the survey to their members through email. Two weeks following 
the initial invitation, a reminder was sent by the research team, targeting the contact persons 
as listed on the INAHTA website, which is publicly available. A second reminder was sent 2 
weeks after the first reminder. The data collection took place, using the online tool CheckMarket, 
between September-December 2018. 
In the introduction to the survey, we made clear that all answers were treated confidential, ie, 
no attribution would be made to specific persons. Two survey respondents explicitly wished not 
to disclose their affiliation. Therefore, we provide the results anonymously, presenting the main 
results and highlighting specific areas that were felt to be in need of guidance. We used basic 
descriptive statistics (frequencies, presented as percentage), derived from the CheckMarket 




1 - Installation of an appraisal committee
2 - Selecting technologies and criteria
3 - Assessment
4 - Appraisal
5 - Communication and appeal
Figure 1. The Steps of EDPs. Abbreviation: EDPs, evidence-informed deliberative processes.*
*The EDP framework has been revised over the course of this PhD. For the most up-to-date version see Chapter 1, Figure 3.
RESULTS 
Response Rate 
Twenty-five completed survey forms were received from 15 European HTA agencies, 4 HTA 
agencies were located in the Asia-Pacific region (15%), 3 HTA agencies in Latin- America (11%), 2 
came from North-America (7%) and 1 was situated in South-Africa (4%). We received incomplete 
survey responses from 5 other HTA agencies, of which we included the survey responses from 
2 European HTA agencies that provided meaningful responses to some of the questions (63%). 
As the number of member agencies was 50 in 2018, the overall response rate was 54%. This is 
comparable with other studies that surveyed INAHTA members.14,15 In addition, the distribution of 
HTA agencies providing responses, per region can be considered a representative reflection of 
the INAHTA membership. From the 50 member agencies, 64% is located in Europe, 14% in the 
Asia-Pacific region, 10% in Latin-America as well as in North-America, and 2% in South-Africa; 
http:// www.inahta.org. 
Contextual Factors 
All agencies were asked about the presence of factors that are supportive of HTA development 
and whether these were in need of guidance in their specific context, ie, factors reflecting the 
linkage between HTA practice and policy; the level of institutionalization of HTA and the ability 
to networking and capacity building. Overall, the respondents mentioned that the contextual 
factors were present in their contexts, and up to 30% of the respondents felt that guidance was 
needed for specific factors (Table 1). There was no clear distinction between member agencies 
with a longer (well-established agencies; 93%) or shorter tradition (agencies that are new, in 
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the process of being established, and/or are not yet producing HTA reports; and a member of 
INAHTA for less than 2 years) of HTA development (7%). 
Nineteen respondents (70%) answered the question about which HTA practice serves as best 
practice. Of these respondents, 21% mentioned CADTH, followed by NICE (16%). 
Table 1. Views regarding the presence of contextual factors and the need for guidance (n=27)
Contextual factor Present Present to 
some extent























A (formal) mechanism or process to link HTA 
to policy making  (e.g. legislation) 52% 48% 0% 30%
Allocation of public funding to HTA on an 
annual basis 74% 15% 11% 26%
A policy statement on the willingness to use 












An independent organizational structure and/or 
institutional set-up for HTA (HTA organization 
or HTA focal point) 
78% 22% 0% 22%
HTA process guidelines (is a systematic 
process in place eg, assessment and 
appraisal)
67% 30% 4% 26%
HTA method guidelines (e.g. for conducting 













An (inter)national networking strategy for 
collaboration between HTA organization(s)  
and relevant stakeholders 
52% 33% 15% 30%
Sufficient capacity to carry out HTA 52% 41% 7% 30%
Ability to review international literature  
(i.e. access to databases), including expertise 
in searching the internet
93% 7% 0% 4%
(Domestic) HTA training opportunities  
(short courses, workshops, Master programs 
and PhD training)  
59% 33% 8% 22%
Abbreviation: HTA, health technology assessment.
Step 1 – Installation of an Appraisal Committee/Stakeholder Panel 
With regard to the existence of an appraisal committee/ stakeholder panel and related guidance it 
became clear that 62% of the respondents mentioned to have such a committee installed in their 
country. Two respondents questioned the need for one central committee, and mentioned that it 
could be beneficial to have several specialised committees (eg, for drugs and medical devices) 
with overlapping functions and responsibilities. A publicly available guideline or document that 
describes the roles and responsibilities of the committee/ panel (remit and scope), and the 
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procedures followed was present according to slightly more than half of the respondents (54% 
and 58%, respectively). A document that describes the composition, terms, and selection of 
members, as well as the roles and responsibilities of stakeholders involved in the process was 
felt to be less often present (46%). The respondents expressed the need for guidance with 
respect to various elements of an appraisal committee/stakeholder panel, ranging from 38%–
46% for the different elements (Table 2). Two respondents also explicitly mentioned that training 
of stakeholders about how to contribute to an appraisal committee/panel could be beneficial. 
We also asked the respondents if they were aware of any HTA practice that could serve as best 
practice. Of the 19 respondents that answered this question (73%), both CADTH and NICE were 
mentioned each by 21%.
Table 2. Views regarding the presence of elements related to an appraisal committee/stakeholder panel, 
and the need for guidance (n=26)






Existence of a committee for appraisal/HTA 
decision-making or a stakeholder panel
































The composition, terms, and selection of 
members
46% 35% 19% 38%
The roles and responsibilities of the committee 
/ panel (remit and scope)
58% 27% 15% 38%
The roles and responsibilities of stakeholders 
involved in the process
46% 31% 23% 46%
The (formal) approach(es) followed by the 
committee/panel
54% 31% 15% 46%
Step 2 – Selecting Technologies and Criteria 
The elements in relation to selecting technologies and criteria (ie, existence of an early warning 
system/horizon scanning, and existence of a scoping procedure) were most often not present 
or present to some extent, according to the majority of the respondents. Also, more than half of 
the respondents felt that guidance was needed for almost all specific elements; with regard to 
the methods used for horizon scanning 46% of the respondents had the opinion that guidance 
was needed (Table 3). 
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Fourteen respondents (54%) answered the question regarding best practices for horizon 
scanning. Of these respondents, 14% mentioned the UK National Institute for Health Research 
Innovation Observatory, CADTH was also mentioned by 14%, as well as the Spanish cross-
regional collaboration between HTA agencies in the field of non-pharmaceuticals,16 and 
EuroScan, a non-for-profit network and scientific association of public HTA agencies, scientific 
organizations and individuals for sharing and collecting information and development of methods 
for the early identification, appropriate use and awareness of health technologies.17 CADTH was 
specifically mentioned as a best practice in relation to scoping by several respondents.
Table 3. Views regarding the presence of elements related to selecting technologies and criteria, and the 
need for guidance (n=26)






Existence of an early warning system / 
horizon scanning system 































The process of identification and selection 
of health technologies  
(i.e. procedures, criteria)
35% 50% 15% 58%
The roles and responsibilities  
of stakeholders involved in  
the process
23% 31% 46% 58%
The methods used 35% 38% 27% 46%































The process of scoping  
(i.e. procedures, criteria)
31% 35% 34% 54%
The roles and responsibilities of 
stakeholders involved
8% 58% 34% 65%
The methods used 27% 38% 35% 62%
Abbreviation: HTA, health technology assessment.
Step 3 - Assessment 
The findings show that 2 out of the 3 elements related to conducting and reporting assessments 
are present in most of the HTA practices surveyed. The element that was mainly present to 
some extent concerns stakeholder consultation to review the plausibility of the evidence reports. 
However, the respondents overall felt that there was less need for guidance regarding the 
elements linked to the assessment phase, ranging from 12%–32% for the different elements 
(Table 4). By those who answered the question on best practices (63%), European Network for 
Health Technology Assessment (EUnetHTA) (HTA Core Model18 and methodological guidelines) 
was mentioned as a best practice example by 35%, followed by the Cochrane Handbook for 
Systematic Reviews of Interventions (12%).19
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Table 4. Views regarding the presence of elements related to conducting and reporting assessments, and 
the need for guidance (n=25)
Element Present Present to 
some extent
Not present Guidance 
needed
Publicly available guidelines / documents on how to 
undertake the HTA in terms of data collection and 
analysis
72% 24% 4% 12%
Existence of a tool/template for reporting and 
summarising the (quality of the) evidence per 
relevant aspect as part of HTA (assessment)
76% 20% 4% 24%
Existence of approach for stakeholder consultation 
to review the plausibility of the evidence reports
32% 56% 12% 32%
Abbreviation: HTA, health technology assessment.
Step 4 – Appraisal 
With regard to the appraisal phase it became clear that all the surveyed elements (existence of 
a formal framework/ approach and a publicly available document/guideline for conducting the 
appraisal) are present in less than half of the responding HTA agencies. More than half of the 
respondents mentioned that there was a need for guidance; only with regard to the process less 
than half (44%) of the respondents felt that guidance was needed (Table 5). Three respondents 
explicitly mentioned the need to receive guidance on how to involve stakeholders in the appraisal 
process. Sixty percent of the respondents answered the question on best practices. Of these, 
20% mentioned NICE as best practice for undertaking appraisal, followed by CADTH (13%).
Table 5. Views regarding the presence of elements related to the appraisal phase, and the need for guidance 
(n=25)
Element Present Present to 
some extent
Not present Guidance 
needed
Existence of formal framework / 
approach for appraisal/HTA decision 
making



























The process of appraisal (i.e. 
procedures, deliberation)
48% 28% 24% 44%
The roles and responsibilities of 
stakeholders involved in the process
24% 52% 24% 56%
The methods used 28% 36% 36% 64%
Abbreviation: HTA, health technology assessment.
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Step 5 – Communication and Appeal 
Almost all respondents (92%) indicated that decisions and the underlying reasons are made 
public or made public to some extent, and 60% indicated that there is no need for guidance in 
this respect. However, guidelines or documents describing the mechanism(s) for appeal, how to 
propose revisions, and to receive a reasoned response, as well as addressing monitoring and 
evaluation of the process were less present. Not surprisingly, more than half of the respondents 
felt that there is a need for guidance (52% and 56%, respectively) (Table 6). With regard to best 
practices, NICE was mentioned by 14% of the respondents (56%) to this sub-question.
Table 6. Views regarding the presence of elements related to communication and appeal, and the need for 
guidance (n=25)
Element Present Present to  
some extent
Not present Guidance 
needed
The decisions and the underlying 
reasons are made public
































The mechanism(s) for appeal, how to 
propose revisions, and to receive a 
reasoned response
24% 40% 36% 52%
The process of monitoring and 
evaluation of the HTA process and 
the recommendations / guidance or 
decisions made
20% 36% 44% 56%
Abbreviation: HTA, health technology assessment.
DISCUSSION 
This semi-structured survey intended to collect views and experiences from HTA agencies 
around the globe in order to identify the level of use of EDPs by HTA agencies, and to further 
develop the EDP guide to support HTA agencies. The level of use of EDPs was measured by 
asking respondents about the extent to which elements of the EDP framework were present and 
whether there was a need for further guidance. We found that contextual factors to support HTA 
development and the critical elements regarding conducting and reporting on HTA are in place. 
This is reflecting current HTA practice of the respondents, as most INAHTA members are already 
well-established HTA agencies. However, respondents indicated that guidance was needed for 
specific elements related to selecting technologies and criteria, appraisal, and communication 
and appeal. Guidance was especially felt in terms of the practical organization of meaningful 
stakeholder participation and the methods to include deliberation during the appraisal step. 
As a result, we have updated the practical guide12 using these insights. Specifically, we have 
added guidance on stakeholder participation20 as well as guidance on how to use MCDA for HTA 




It is important to highlight the limitations of this study. First, the response rate (54%) might suggest 
that some selection bias might be present. However, the survey respondents reflect the INAHTA 
membership (in 2018) in terms of geographical representation. As such we feel confident that 
some conclusions can be drawn from this study, even though we acknowledge that reports by 
single persons from an INAHTA member agency are not representing the overall HTA practice in 
a particular jurisdiction. In addition, bias might be that the responses came from HTA agencies 
that are already doing quite well, while the survey might not have captured responses from less 
well-established HTA agencies. This might have led to an underestimation of the percentage of 
HTA agencies that actually are in need of guidance. We are aiming to broadening the survey 
towards HTA organizations from low- and middle-income countries. Second, reporting on any 
set of elements implies that they are equally important, but this is not true. Depending on the 
contextual factors, certain steps and/or elements can be more important than others. Therefore 
the findings should be mainly viewed as indicative for the level of EDP use by HTA agencies.
Alignment With Other Study Findings 
The findings suggest that contextual factors to support HTA development and the critical elements 
regarding conducting and reporting on HTA are currently overall present, mainly in countries with 
well-established HTA practices. Furthermore, respondents indicated that specific guidance was 
needed for elements related to selecting technologies and criteria, including scoping, appraisal, 
and communication and appeal. These results are in line with the findings of the ISPOR HTA 
Council that recently presented a report on good practices in HTA.1 From this report it becomes 
clear that many good practices have been developed in the areas of assessment (Step 3), 
and several with regard to priority setting, scoping (Step 2), only a few with regard to structure, 
governance, organizational aspects (Step 1), deliberative processes (Step 4), and measuring 
the impact (Step 5). The findings are also in line with previous work on priority setting22,23 and 
reported needs of HTA agencies in specific regions. For example, in Latin America, the need 
for transparency in the production of HTA, involvement of relevant stakeholders in the process, 
mechanisms to appeal decisions, clear priority-setting processes, and a clear link between 
HTA and decision-making have recently been emphasized.24,25 In addition, HTA agencies in 
Asia recently expressed their need to improve transparency and accountability throughout the 
process. For example, it was recommended by the HTAi Asia Policy Forum members that a 
standardized, transparent methodology for priority-setting regarding coverage decision-making 
needs to be developed.26 Furthermore, some respondents explicitly mentioned particular best 
practices per step, such as the CADTH for scoping, and NICE for having clear procedures in 
place for appeal. Also, Brazil was mentioned as best practice for the Latin American region. 
These findings are in line with previous studies in this area.3,27 As such, we feel empowered to 
further optimize the guide on EDPs to support HTA agencies.




This is the first survey among HTA agencies regarding the use of EDPs and provides useful 
information for further developing a practical guide for HTA agencies around the globe. Based on 
the results from the survey, we conclude that – as expected – several HTA agencies have already 
certain (elements of) EDPs in place and can serve as inspiration for others. The results could also 
serve as a baseline measurement for HTA agencies for future monitoring and evaluation of the 
level of EDP use and to study the effectiveness of EDPs in practice. This could support them in 
improving their processes and enhancing legitimate decision-making.
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SUPPLEMENTARY FILE 1: SURVEY
Welcome to the survey on the potential use of ‘evidence-informed deliberative processes’ (EDPs) 
by HTA organizations. EDPs provide guidance to HTA organizations to improve their processes 
towards more legitimate decision-making. 
Completing this survey will take approximately 20 minutes as most of the questions only require 
you to tick a box. 
Please note that all your answers will be treated confidential: no attribution will be made to 
specific persons. 
General information
What is your name and title?
What is your email address?
What is the name of your organization/department?
What country or region are you representing?
Introduction to EDPs
EDPs provide guidance to HTA organizations to improve their processes towards more 
legitimate decision-making. The framework is not entirely new, and integrates two increasingly 
popular and complementary approaches to HTA informed decision-making. EDPs are based 
on rational decision-making through evidence-informed evaluation of identified values (as 
reflected in multi-criteria decision analyses) as well as fair decision-making (as reflected in the 
accountability for reasonableness approach – A4R). In other words, EDPs focus on stakeholder 
deliberation throughout the HTA process to learn about the importance of relevant values. 
We distinguish several steps in the use of EDPs (Figure 1), and define its elements on the basis 
of literature5, and existing checklists such as the INAHTA checklist for HTA reports6. The way in 
which these steps can be applied depends on the context. 
We are aware that some HTA organizations already have (some of) the processes in place, and 
they may serve as inspiration for others. There may be other organizations that can substantially 
improve their processes. In order to increase our understanding of the potential use of EDPs in 
HTA organizations, to identify topics that are in need of more guidance, and to learn about best 
practices in relation to each step, we would like to collect your views and experiences. 




1 - Installation of an appraisal committee
2 - Selecting technologies and criteria
3 - Assessment
4 - Appraisal
5 - Communication and appeal
Figure 1. The steps of EDPs. 
Context
It is important to understand the context of a HTA practice, as this influences the implementation 
of EDPs.
QUESTION:
Please could you indicate a) if any of the following factors are Present, Present to some extent 
or Not present in your country/region and b) whether particular factors are in need of guidance 
in your country/region (Yes/No):
 
Linkage between HTA and policy/practice
 •  A (formal) mechanism or process to link HTA to policy making  (e.g. legislation) 
 •  Allocation of public funding to HTA on an annual basis
 •  A policy statement on the willingness to use HTA in policy and/or practice
Institutional environment
 •  An independent organizational structure and/or institutional set-up for HTA (HTA 
organization or HTA focal point) 
 •  HTA process guidelines (is a systematic process in place for e.g. assessment and 
appraisal)
 •  HTA method guidelines (is methodological guidance available for e.g. conducting 




 •  An (inter)national networking strategy for collaboration between HTA organization(s) and 
relevant stakeholders 
 •  Sufficient capacity to carry out HTA, including medical disciplines, public health specialists, 
epidemiologists, statisticians, psychologists, biomedical engineers and/or economists 
 •  Ability to review international literature (i.e. access to databases), including expertise in 
searching the internet
 •  (Domestic) HTA training opportunities (short courses, workshops, Master programmes 
and PhD training)  
QUESTION:
Please could you indicate below a) if any important contextual factor has not been listed and b) 
whether these areas are in need of guidance in your country/region:
QUESTION:
With regard to all contextual factors listed in the questions above, are you aware of any HTA 
practice that can serve as best practice? If so, please can you provide more information?
Step  1. Installation of an appraisal committee / stakeholder panel
Most HTA practices have an appraisal committee or stakeholder panel in place. Such committee 
or stakeholder panel can be involved throughout the entire HTA process, including scoping (step 
2), assessment (step 3), and appraisal (step 4). In some HTA practices, the committee or panel 
develops recommendations or guidance, in other contexts it is responsible for taking decisions.
 
It is increasingly acknowledged that the members of such a committee or panel should represent 
societal perspectives. For this purpose, it is advised to set-up an (independent) committee or 
stakeholder panel including relevant stakeholders (e.g. clinicians, patients, citizens, payers, 
providers, decision-makers). For reasons of legitimacy, it is important that at least the composition, 
selection of members, the terms, its independence (e.g. COI statement), remit and scope are 
explicit and transparent.
QUESTION:
Please could you indicate a) if any of the following elements are Present, Present to some 
extent or Not present in your country/region and b) whether particular elements are in need of 
guidance in your country/region (Yes/No):
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Existence of a committee for appraisal/HTA decision making or a stakeholder panel
 •  Guidelines / document – that is publicly available - describing:
  •  The composition, terms, and selection of members;
  •  The roles and responsibilities of the committee / panel (remit and scope);
  •  The roles and responsibilities of stakeholders involved in the process;
  •  The (formal) approach(es) followed by the committee/panel.
 •  Please could you indicate below a) if any important element has not been listed and b) 
whether these areas are in need of guidance in your country/region:
 •  With regard to all elements related to an appraisal committee or stakeholder panel listed in 
the questions above, are you aware of any HTA practice that can serve as best practice? If 
so, please can you provide more information?
Step 2. Selection of technologies and criteria
The selection of health technologies in need for HTA is an important step in the HTA process. This 
requires standardised systems for the identification of health technologies through e.g. horizon 
scanning or an early warning system, and the prioritization of these health technologies on the 
basis of agreed criteria or guidelines. 
Subsequently, for selected health technologies, HTA organizations should define the scope of the 
assessment. This includes a clearly defined policy question(s) of direct significance to decision-
makers and the identification of criteria for which evidence needs to be collected. Scoping is 
ideally done in consultation with relevant stakeholders, e.g. patients, informal carers, and health 
professionals. Often HTA organizations are responsible for the scoping procedure, but this can 
also be done by policy makers, Ministry of Health, external committees, in consultation with 
relevant stakeholders and/or experts. 
QUESTION:
Please could you indicate a) if any of the following elements are Present, Present to some 
extent or Not present in your country/region and b) whether particular elements are in need of 
guidance in your country/region (Yes/No):
 •  Existence of an early warning system / horizon scanning system 
 •  Guidelines / document – that is publicly available - describing:
  •  The process of identification and selection of health technologies (i.e. procedures, 
criteria);
  •  TThe roles and responsibilities of stakeholders involved in the process;
  •  TThe methods used.
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 •  TExistence of a scoping procedure for HTA 
 •  Guidelines / document – that is publicly available - describing:
  •  TThe process of scoping (i.e. procedures, criteria);
  •  TThe roles and responsibilities of stakeholders involved;
  •  TThe methods used.
 •  Please could you indicate below a) if any important element has not been listed and b) 
whether these areas are in need of guidance in your country/region:
 •  With regard to all elements related to the identification and selection of health technologies 
listed in the questions above, are you aware of any HTA practice that can serve as best 
practice? If so, please can you provide more information?
Step 3. Assessment
The assessment process consists of evidence collection, analysis of the quality of the evidence, 
synthesising the evidence, and reporting the findings and implications. HTA organizations should 
ideally develop an elaborated HTA protocol to plan this process, based on the policy question(s) 
defined during scoping (step 2). Several guidelines exist for data collection and analysis (e.g. 
methodological guidance such as the EUnetHTA core model, INTEGRATE-HTA, as well as country/
agency-specific guidelines on how to conduct the assessment – e.g. NICE, CADTH, PBAC; and 
GRADE for assessing the quality of the evidence). Ideally, HTA organizations should present the 
collected evidence in evidence reports and standardised evidence summaries for each relevant 
assessment aspect (defined during scoping). The reports should ideally be subjected to an 
independent review and discussed by relevant stakeholders. 
QUESTION:
Please could you indicate a) if any of the following elements are Present, Present to some 
extent or Not present in your country/region and b) whether particular elements are in need of 
guidance in your country/region (Yes/No):
 •  Publicly available guidelines / documents on how to undertake the HTA in terms of data 
collection and analysis
 •  Existence of a tool/template for reporting and summarising the (quality of the) evidence per 
relevant aspect as part of HTA (assessment)
 •  Existence of approach for stakeholder consultation to review the plausibility of the evidence 
reports
 • P lease could you indicate below a) if any important element has not been listed and b) 
whether these areas are in need of guidance in your country/region:
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 •  With regard to all elements related to the assessment of health technologies listed in the 
questions above, are you aware of any HTA practice that can serve as best practice? If so, 
please can you provide more information?
Step 4. Appraisal
In the appraisal step, the HTA organization interprets the results of the assessment and formulates 
a recommendation or guidance to inform decision makers. In several HTA organizations, this 
task is carried out by a specific committee (step 2). Ideally, such a committee follows an explicit 
approach which guarantees the quality, consistency and transparency of the recommendations, 
guidance or decisions. The approach should preferably include a deliberative component for the 
interpretation of the assessment results, and involvement of relevant stakeholders to allow the 
inclusion of their perspectives in the development of recommendations, guidance or decisions. 
Several methods are available to support HTA organizations in this process, such as multi-criteria 
decision analysis or qualitative decision tools. 
QUESTION:
Please could you indicate a) if any of the following elements are Present, Present to some 
extent or Not present in your country/region and b) whether particular elements are in need of 
guidance in your country/region (Yes/No):
 •  Existence of formal framework/approach for appraisal/HTA decision making 
 •  Publicly available guidelines / documents describing:
  •  The process of appraisal (i.e. procedures, deliberation);
  •  The roles and responsibilities of stakeholders involved in the process;
  •  The methods used.
 •  Please could you indicate below a) if any important element has not been listed and b) 
whether these areas are in need of guidance in your country/region:
 •  With regard to all elements related to the appraisal of health technologies listed in the 
questions above, are you aware of any HTA practice that can serve as best practice? If so, 
please can you provide more information?
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Step 5. Communication and appeal
Communication and appeal are important features that enhance the legitimacy of decision 
making. These concepts are part of the A4R framework, which states that the decisions should 
be made public as well as the argumentation and evidence on which decisions are based. In 
addition, there must be a mechanism in place that gives stakeholders the possibility to appeal 
against decisions, propose revisions, and receive a reasoned response. This should give decision 
makers the chance to reconsider their decisions using extra (new) arguments or (new) evidence.
QUESTION:
Please could you indicate a) if any of the following elements are Present, Present to some 
extent or Not present in your country/region and b) whether particular elements are in need of 
guidance in your country/region (Yes/No):
 •  The decisions and the underlying reasons are made public
 •  Guidelines / document – that is publicly available – describing the mechanism(s) for 
appeal, how to propose revisions, and to receive a reasoned response 
 •  Guidelines / document – that is publicly available – describing the process of monitoring 
and evaluation of the HTA process and the recommendations/guidance or decisions made
 •  Please could you indicate below a) if any important element has not been listed and b) 
whether these areas are in need of guidance in your country/region:
 •  With regard to all elements related to communication and appeal listed in the questions 
above, are you aware of any HTA practice that can serve as best practice? If so, please can 
you provide more information?
Further comments
QUESTION:
If you wish to make any further comments about your experiences with EDPs in your country and/
or this survey, please use the space provided below
May we contact you if we have additional questions? (Yes/No)
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Priority setting in health care has been long recognized as an intrinsically complex and value-laden 
process. Yet, health technology assessment agencies (HTAs) presently employ value assessment 
frameworks that are ill fitted to capture the range and diversity of stakeholder values and thereby 
risk compromising the legitimacy of their recommendations. We propose “evidence-informed 
deliberative processes” as an alternative framework with the aim to enhance this legitimacy. 
This framework integrates two increasingly popular and complementary frameworks for priority 
setting: multicriteria decision analysis and accountability for reasonableness. Evidence-informed 
deliberative processes are, on one hand, based on early, continued stakeholder deliberation to 
learn about the importance of relevant social values. On the other hand, they are based on rational 
decision-making through evidence-informed evaluation of the identified values. The framework 
has important implications for how HTA agencies should ideally organize their processes. First, 
HTA agencies should take the responsibility of organizing stakeholder involvement. Second, 
agencies are advised to integrate their assessment and appraisal phases, allowing for the 
timely collection of evidence on values that are considered relevant. Third, HTA agencies should 
subject their decision-making criteria to public scrutiny. Fourth, agencies are advised to use 
a checklist of potentially relevant criteria and to provide argumentation for how each criterion 
affected the recommendation. Fifth, HTA agencies must publish their argumentation and install 
options for appeal. The framework should not be considered a blueprint for HTA agencies but 
rather an aspirational goal—agencies can take incremental steps toward achieving this goal.




Priority setting in health care has long been recognized as an intrinsically complex and value-
laden political process that takes place in an environment of diverging social values and 
interests.1-5 The role of politics in health policy is described as “central in determining how citizens 
and policy makers recognize and define problems with existing social conditions and policies, in 
facilitating certain kinds of public health interventions but not others, and in generating a variety 
of challenges in policy implementation.”6 Indeed, society, including relevant stakeholders, such 
as patients, providers, insurers, and citizens, has a wide range of social values and interests 
that result in different perceptions of what makes health interventions valuable.7 In such pluralist 
societies, stakeholders may reasonably disagree on what values can be used to guide priority 
setting.4 
However, present value assessment frameworks currently employed by health technology 
assessment (HTA) agencies around the world do not sufficiently account for this complex reality. 
These frameworks are typically based on the use of predefined key principles, also labeled 
“substantive” criteria, which are believed to reflect the most important social values. This has 
led HTA agencies to use, for example, “cost-effectiveness” as an important decision criterion.8
There is broad recognition that such frameworks are ill fitted to take into account the wide range 
and diversity of stakeholder values and lead to insufficient sets of information.1-3,9 Ethical issues 
in particular are left unaddressed, thereby compromising the legitimacy of eventual decisions as 
perceived by stakeholders. This is illustrated in countries like Brazil, Mexico, and Thailand, where 
patients frequently launch court challenges against decisions taken by health authorities.10-12
We propose an alternative, hybrid value assessment framework for HTA agencies to explicitly 
address this issue of legitimacy. Legitimacy here refers to the reasonableness, or fairness, of 
recommendations as perceived by stakeholders, which is an important prerequisite for broad 
societal support for these recommendations.4 The framework is based on an integration of two 
increasingly popular and complementary frameworks: multicriteria decision analysis (MCDA) 
and accountability for reasonableness (A4R). MCDA evaluates the overall value of interventions 
by reference to a set of multiple explicit criteria13; although MCDA is generally praised for its 
rational pursuit, it is criticized for being technocratic and lacking a deliberative component that 
involves stakeholders.14-16 A4R recognizes that stakeholders often justifiably disagree about the 
importance of specific social values in setting priorities and argues that stakeholders are more 
likely to accept priorities that are the outcome of a fair process.4,17,18 The aim of such a process is 
to develop a shared basis for decision-making among stakeholders. A4R has been criticized for 




“Evidence-informed deliberative processes,” as we name them, combine the virtues of both 
A4R and MCDA. They incorporate the element of structured decision-making from MCDA but 
not the mathematical elements, as we consider the latter to be only of limited relevance for 
priority setting. Evidence-informed deliberative processes are, on the one hand, based on early, 
continued deliberation among stakeholders to identify, reflect, and learn about the meaning 
and importance of relevant social values. On the other hand, they are based on structured and 
rational decision-making—through evidence-informed evaluation of the identified values where 
possible. Evidence-informed evaluation allows contributions from stakeholders in terms of their 
(clinical) experience and their judgments when stronger evidence is unavailable.21
The framework aims to support HTA agencies, at a centralized or decentralized level, in making 
reimbursement recommendations. The framework reflects our vision of how HTA agencies 
should ideally organize their processes, that is, in such a way that all stakeholders can confer 
legitimacy to the recommendations. This ideal should not be interpreted as a blueprint for HTA 
agencies but rather as an aspirational goal—HTA agencies are advised to take incremental 
steps toward this goal.
This article first describes the key elements of the framework—stakeholder deliberation to 
facilitate learning—and then presents the implications for the conduct of HTA. We use the term 
“values” to refer to the preferences of stakeholders and “criteria” to refer to their more formal 
operationalization.
STAKEHOLDER DELIBERATION TO FACILITATE LEARNING
The aim of stakeholder involvement in HTA processes is threefold. First, it serves to identify 
the full range of relevant values that society holds in relation to a particular recommendation 
and to ensure relevant evidence collection on these values. Second, it intends to improve the 
understanding among stakeholders of each other’s values. Third, it seeks to achieve maximum 
coherence among stakeholders in their argumentation regarding a recommendation.22 Together, 
this may lead to an enhanced sense of legitimacy, in the sense that the recommendation is 
considered to be more reasonable. Importantly, the objective of stakeholder involvement is not 
necessarily to reach mutual consensus on a recommendation or to come to a joint decision. In 
a democratic society, policymakers hold the final authority and should be held accountable for 
their final decisions.
Value assessment through stakeholder involvement is an intrinsically complex task. It requires 
that stakeholders gain, as much as possible, an in-depth understanding of the health intervention 
under scrutiny, including the consequences of its implementation. In addition, stakeholders need 
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to interpret these consequences in the context of their own values, other stakeholders’ values, 
and widely endorsed public health values, such as respect for autonomy and nonmaleficence.23 
Stakeholders are thus required to engage in intellectually demanding moral reasoning.
Learning among stakeholders is considered essential in this process and is most likely to occur 
when stakeholders with different backgrounds deliberate on a specific issue.24-26 Deliberation 
among stakeholders can facilitate learning by clarifying the different ways in which stakeholders 
frame policy problems. By making their underlying assumptions and preferences explicit, 
participants may learn from one another and gain a better understanding of their own position. 
If confronted with interpretive frames that are different from their own, stakeholders may be 
triggered to reflect on their own frames, to verify their own assumptions, and to partially revise 
them.25,27
In this process, evidence is key to inform stakeholders’ understanding, and evidence collection 
should be focused on providing answers to key questions raised by stakeholders during their 
deliberation.7,24,28 There is anecdotal evidence that deliberation leads to significant learning 
effects in HTA.27,29,30 However, knowledge of how best to foster learning among stakeholders is 
still limited in the field of HTA.
IMPLICATIONS FOR THE HTA PROCESS
The use of evidence-informed deliberative processes as value assessment framework has five 
important implications for how HTA agencies can best organize their processes.
Stakeholders’ Involvement
Relatively little is known about optimal stakeholders involvement in HTA.31-36 The A4R framework 
specifies a number of key conditions for fair processes, including the nature of stakeholders’ 
argumentation,4,17,18 but does not provide specific guidance. In practice, active stakeholder 
involvement in HTA can take different shapes.37,38 First, stakeholder involvement can be organized 
as an exercise independent of HTA agencies through, for example, round table conferences,29 
deliberative dialogues,39 or interactive technology assessment.7,40 A disadvantage of organizing 
stakeholder involvement independent of HTA agencies is that it could hamper the uptake of its 
findings by these agencies, and we do not recommend this approach.
Second, HTA agencies can initiate stakeholder involvement under their own responsibility. They 
can commission studies involving stakeholders deliberation on specific topics, such as cochlear 
implants in The Netherlands.27 More formally, they can integrate stakeholder involvement in 
the various phases of the HTA process. For example, stakeholders, including the public, can 
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nominate topics for assessment in Sweden.41 In the appraisal phase, stakeholder involvement 
can be organized through, for example, granting speaking time during appraisal committee 
meetings, as in The Netherlands42; organizing a citizen council, as in the United Kingdom43; or 
soliciting input and feedback from patients, as in Canada44 and Scotland.45
We recommend that HTA agencies take responsibility for organizing stakeholder involvement, 
as the agency’s commitment is essential to the political leverage of eventual findings. As an 
important component, we argue that, ideally, an appraisal committee should include both 
permanent and temporary stakeholders. Permanent members should be installed to endorse 
the broad public interest and take the responsibility of developing recommendations on the 
basis of the deliberative process. Temporary members should be included to represent specific 
stakeholders, including their interests and expertise, with their appointment dependent on the 
recommendation under scrutiny. HTA agencies are advised to take incremental steps toward 
this ideal.
Integration of Assessment and Appraisal Phases
HTA agencies typically separate the assessment from the appraisal phase in the HTA process. 
The assessment phase involves the collection of evidence of a standard set of criteria, pushing 
the consideration of further criteria into the appraisal phase. However, this often leaves an 
appraisal committee with incomplete evidence upon which to base their recommendation. 
We argue that the assessment and appraisal phases should be integrated, in the sense that 
the relevant considerations should be explored from the outset—this would then allow the 
timely collection of evidence on these aspects and their inclusion in the appraisal of the health 
intervention. The Netherlands is now introducing an early scoping exercise in its HTA process, in 
which stakeholders are consulted to determine relevant outcome measures for the effectiveness 
of an intervention.46
Ideally, HTA should be organized as an iterative learning process, which allows the ongoing 
identification of values and collection of evidence on associated criteria throughout the process. 
This may require an expansion of the present, strict time frames that HTA agencies have for the 
development of recommendations. If such an expansion is not possible, we instead recommend 
HTA agencies to intensify their decision-making process.
Specification of Criteria
Priority setting may involve a wide range of criteria, as repeatedly demonstrated in international 
surveys,47 decision frameworks,48-50 and guidelines.49 Among this wide range, many HTA agencies 
consistently use a number of explicit criteria for the evaluation of every intervention. For example, 
“safety,” “effectiveness,” “cost-effectiveness,” “severity of disease,” and “budget impact” are 
often considered as such by HTA agencies.51-53 We label these criteria as “generic criteria.” 
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At the same time, more “contextual” criteria appear to be used for specific interventions only, 
and these include many considerations (e.g., “responsibility for own health” for interventions 
targeting behavior-related diseases, such as smoking, or “size of the population affected” for 
interventions targeting orphan diseases).
The use of “generic” criteria in particular give the impression of being politically sanctioned 
and therefore justified. In reality, however, they are often the manifestation of how HTA 
agencies (attempt to) specify the more abstract and fundamental politically ratified values in a 
country.22 This specification by HTA agencies, typically lacking proper stakeholder participation, 
risks compromising the legitimacy of this use of standard criteria and any forthcoming 
recommendations. HTA agencies should subject their decision-making criteria to public scrutiny 
by means of a democratic process.54 In doing so, HTA agencies may learn from other countries 
in terms of how to organize this democratic process and/or specify their criteria.
Development of Recommendations
The criteria that are identified throughout the process likely require further assessment. This may 
take the shape of generating an evidence base for criteria that are quantifiable—for example, an 
intervention’s performance on the criterion “cost-effectiveness” can be assessed quantitatively 
by means of cost-effectiveness analysis.55-57 Criteria that are nonquantifiable may be subjected 
to qualitative analysis (e.g., ethical analysis or [expert] stakeholder opinions). These pieces of 
quantitative and qualitative information are inputs into the deliberative process. HTA agencies 
are advised to develop a checklist, including their range of identified and specified criteria. They 
can use this checklist to verify whether these criteria are relevant to particular recommendations 
in order not to overlook criteria.
For every criterion, the appraisal committee should argue whether and how it affects the 
recommendation (in a positive or negative way). The committee must eventually come to a 
final recommendation, thereby providing argumentation for which criteria are considered to be 
of overriding importance. We stress that this process should not be considered as a one-time 
exercise but, ideally, as an iterative learning process in the committee—of course, within the time 
frame of the HTA agencies. Also, we stress the importance of deliberation in dealing with the full 
range of criteria and wish to emphasize that, in our view, quantitative decision aids can never fully 
replace the force of argumentation.58
An important issue in stakeholder involvement in formal HTA processes is that of vested 
interests, wherein stakeholders (initially) plead in favor of their own interests. As such, 
stakeholder involvement in the presence of vested interests likely captures private values, but it 
is less able to capture public interests that countries may rightfully choose to endorse, such as 
safeguarding equal access to good quality health care, efficiency, and cost containment. These 
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public interests are not typically acknowledged as important by individual stakeholders. As 
noted earlier, we advise HTA agencies to install permanent members in the appraisal committee, 
being stakeholders representing public interests. In the appraisal process, all argumentation that 
is tabled must be subjected to deliberation and, in the end, balanced against each other. The 
permanent members have the responsibility to develop recommendations on the basis of this 
process, and the final decision rests with the accountable policymaker.
The task of HTA agencies is not restricted to development of strictly positive or negative 
recommendations. The above process may lead to recommendations for price negotiation 
or the collection of further evidence. Together with stakeholders, agencies may also identify 
alternative ways of implementing interventions, which may optimize their value.
Communication and Appeal
In a democratic society, policymakers hold the authority to make decisions and are accountable 
for the decision-making process. It is, therefore, important that HTA agencies communicate 
all argumentation to justify the recommendation on the use (or rejection) of criteria. Doing so 
in accountable ways will increase the likelihood that stakeholders, including citizens who did 
not participate4,7—and did not go through a learning process—can understand and accept the 
reasoning underlying the final decision.
In addition, societal perceptions of what should count as legitimate arguments for 
recommendations are subject to change over time or as new evidence becomes available. 
Health authorities should, therefore, organize an appeal mechanism—or at least be receptive to 
new input and arguments that were initially not taken into account.1,4
DISCUSSION
This article presents evidence-informed deliberative processes as a hybrid value assessment 
framework that integrates the virtues of A4R (i.e., the deliberation among stakeholders to 
incorporate relevant social values) and MCDA (i.e., structured and rational decision-making 
informed by evidence on multiple criteria). The framework includes various elements that 
are frequently mentioned in the HTA literature (e.g., involving stakeholders), ensuring that all 
potentially relevant criteria are considered and explaining the reasoning for recommendations.
These are now, for the first time, being presented in a unifying framework and translated into 
practical guidance for HTA agencies. Adopting evidence-informed deliberative processes as a 
value assessment framework could be an important step forward for HTA agencies in optimizing 
the legitimacy of their priority-setting decisions.
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To achieve this, HTA agencies can probably best incorporate elements of the framework 
incrementally, adjusting them to local needs and affordances. For example, HTA agencies may 
decide to include scoping exercises with stakeholders on the relevant contextual criteria for 
a specific decision, organize deliberative dialogues, or decide to publish their argumentation 
vis-à-vis their recommendations. Again, evidence-informed, deliberative processes should by 
no means be considered a blueprint for HTA agencies—they should, rather, be considered an 
aspirational goal, and HTA agencies can implement components to progress toward that goal. 
We are now undertaking research activities under the heading of the REVISE2020 project to 
develop practical guidance for HTA agencies. This will take the shape of a menu of options that 
HTA agencies can consider to improve the legitimacy of their decision-making process.59
Evidence-informed deliberative processes require the collection and/or development of 
evidence on all identified values where possible, supplemented with experiences and judgments 
where relevant. The interpretation of this information may be challenging in terms of the great 
uncertainties involved. Yet, we see this challenge as merely reinforcing the need to deliberate on 
these values as informed by available evidence, rather than ignoring it altogether.
We recommend that HTA agencies use a comprehensive checklist of criteria that may be 
relevant in particular contexts, including their range of identified and specified criteria. Yet, one 
may question whether a good deliberative process would not lead to the consideration of the 
same values and to the same recommendation. We believe that, as the development of such 
processes is in its infancy, the use of a checklist may still be useful to avoid overlooking certain 
criteria.
On a more methodological note, evidence-informed deliberative processes can also be 
considered a general heading for various HTA approaches that are based on the same principles 
of stakeholder deliberation and evidence gathering, for example, program budgeting and 
marginal analysis60 and choosing health plans all together.61 These approaches share the same 
challenges in their processes, such as avoidance of stakeholder dominance. Shared research 
activities can inform the optimal form and implementation of evidence-informed deliberative 
processes, per decision context. The fields of general policy and technology assessment,24 
political sciences, and governance studies62,63 can provide important lessons.
Ideally, evidence-informed deliberative processes are also applied in the early phase of 
the development of interventions, to take into account stakeholder values vis-à-vis medical 
innovations. In the early phase, this inclusion offers great opportunity to better steer the practice 
of medical innovation toward high-value interventions, to more efficiently collect relevant 
evidence, and to avoid the implementation of low-value interventions.64 Yet, to our knowledge, 
this has rarely been applied.
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Finally, as countries around the world face challenges regarding the sustainability of their health 
systems, driven by medical innovations, growing needs of aging populations, and higher public 
expectations,65 they will be increasingly confronted with the need to make difficult choices. We 
see the development of evidence-informed deliberative processes as a suitable response and a 
necessary condition to safeguard societal support for the choices that are made.
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Progressive realisation is invoked as the guiding principle for countries on their own path to 
universal health coverage (UHC). It refers to the governmental obligations to immediately and 
progressively move towards the full realisation of UHC. This paper provides procedural guidance 
for countries, that is, how they can best organise their processes and evidence collection to 
make decisions on what services to provide first under progressive realisation. We thereby use 
‘evidence-informed deliberative processes’, a generic value assessment framework to guide 
decision making on the choice of health services. We apply this to the concept of progressive 
realisation of UHC.
We reason that countries face two important choices to achieve UHC. First, they need to define 
which services they consider as high priority, on the basis of their social values, including cost-
effectiveness, priority to the worse off and financial risk protection. Second, they need to make 
tough choices whether they should first include more priority services, first expand coverage 
of existing priority services or first reduce co-payments of existing priority services. Evidence 
informed deliberative processes can facilitate these choices for UHC, and are also essential to 
the progressive realisation of the right to health. The framework informs health authorities on 
how they can best organise their processes in terms of composition of an appraisal committee 
including stakeholders, of decision-making criteria, collection of evidence and development of 
recommendations, including their communication. In conclusion, this paper fills in an important 
gap in the literature by providing procedural guidance for countries to progressively realise UHC.
Key questions
What is already known about this topic?
 •  Countries are recommended to progressively realise universal health coverage, and to 
make explicit choices regarding the expansion of priority services, the inclusion of more 
people and reduction of out-of-pocket payments.
 •  Countries should use fair processes to be accountable to their populations.
What are the new findings?
 •  This paper provides practical procedural guidance to countries on how they can best 
organise their decision-making process to make these choices in a well reasoned and 
publicly accountable manner.
Recommendations for policy
 •  Countries are recommended to establish evidence-informed deliberative processes.
 •  The use of these processes has consequences for the composition of an appraisal 
committee including stakeholders, choice of decision-making criteria, collection of 
evidence and development of recommendations, including their communication and 
options for appeal.




Sustainable development goal (SDG) 3.8 seeks to achieve universal health coverage (UHC), 
including financial risk protection, access to quality essential healthcare services and access 
to safe, effective, quality and affordable essential medicines and vaccines for all.1 Progressive 
realisation is invoked as the guiding principle for countries on their own path to UHC and 
achievement of the SDG health targets. It refers to the governmental obligations to immediately 
and progressively move towards the full realisation of UHC, recognising the constraints imposed 
by limited available resources.2,3
The WHO report ‘Making fair choices on the path to universal health coverage’ provides strategic 
advice to countries committed to achieving UHC.2 This paper follows up on the report, and 
provides procedural guidance to countries, that is, on how they can best organise their decision-
making process to make well reasoned and publicly accountable choices on their path to UHC. 
It thereby fills an important gap in the literature. The paper is especially relevant for governmental 
health authorities, at national or subnational levels, in charge of overseeing and guiding the 
progress towards UHC.
To achieve UHC, countries must make important choices at two levels. First, they need to 
classify their services in priority classes. Prioritising services is not straightforward, and often 
involves difficult trade-offs between various values that a country finds important. Countries may, 
for example, attach extra value to services that are cost-effective, target severe diseases or 
disadvantaged populations, and provide financial risk protection from the impoverishing impact 
of ill-health.2 Countries need to establish such a list of high priority services, and periodically 
update it, for example, every 4 years. Many countries may already have established their priority 
services in the context of their essential package of health services, as part of their strategy to 
achieve UHC. Examples are Chile, Ghana, Mexico, Nigeria, Rwanda, Thailand and Vietnam.4
Second, countries need to make difficult choices regarding the implementation of high priority 
services, in terms on what they do first (and next) on their path to UHC. Progressive realisation of 
UHC is specifically related to these types of incremental decisions. Countries can advance in at 
least three dimensions: include more priority services in the essential package, expand coverage 
of existing priority services to non-covered populations or reduce out-of-pocket payments 
for existing priority services (Figure 1).2 We call these implementation options. For example, 
implementation options may be to increase the coverage of skilled birth attendance by making 
it available to all rural populations, or to reduce co-payments for antibiotic treatment of children 
with pneumonia. Which implementation option they choose to do first may have far-reaching 
consequences for the level and distribution of health in the country, and of financial risk protection. 
Countries should therefore recognise that these choices should preferably be made among 
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implementation options on all three dimensions simultaneously. We consider this interpretation 
of progressive realisation, in terms of making choices among a set of implementation options, as 
a further operationalisation of the mentioned WHO report.2 Countries should make these choices 
on a recurrent, ongoing basis, always within the envelope of available resources in current and 
future fiscal years.
Figure adapted from the World Health Report 20104
Direct costs: 
proportion of the 
costs covered
Include      
other                  
services
Reduced 
cost sharing  
and fees
Services:       




Population: who is covered?
Current pooled funds
Figure 1. Three dimensions to consider when moving to universal health coverage. 
This paper is organised as follows. The next section spells out the core principles of public 
accountability, and required processes for progressive realisation of UHC. Following sections 
provide guidance on the classification of services in priority classes, and on how to choose 
between implementation options in terms of what to do first. The final section puts these issues 
in a broader perspective.
PUBLIC ACCOUNTABILITY
In making choices between services and implementation options on the path to UHC, health 
authorities should be accountable to the populations they serve. Information about their decisions 
and actions should be transparently available in accessible formats, which requires freedom 
of information laws; authorities should be required to justify their criteria and decisions when 
questioned; and remedies should be available when agreed-upon services are not available in 
practice, or when such decisions have been shown to be arbitrary or discriminatory. The public’s 
role is to actively hold the health authorities accountable, but institutions such as Ombuds offices, 
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courts and other independent review mechanisms are required to ensure effective enjoyment of 
health rights in practice.5
Meaningful public accountability can facilitate progressive realisation of UHC in various ways. 
It forces decision makers to be more systematic, explicit and transparent, by making decisions 
sensitive to a wider range of needs and values, and by promoting consistency across decisions. 
It can also make the implementation of decisions more efficient by addressing disagreement 
at an earlier stage and by facilitating ownership, by discouraging fraud and waste, and by 
promoting collaboration within the community. Accountability is central to health systems and 
health reforms, including the post-2015 development agenda.2
‘Evidence-informed deliberative processes’ is a value assessment framework that explicitly 
addresses this issue of public accountability, and builds on existing tools for health technology 
assessment such as ‘Accountability for Reasonableness’6 and ‘Multi-criteria decision analysis’.7 
The framework spells out how policy makers can best organise their processes.8,9 On the one 
hand, it is based on early, continued stakeholder deliberation to identify relevant values and 
to foster a shared understanding among stakeholders of these values. Stakeholders may be 
members of the public, but may also involve actors such as patient groups, health workers, 
hospitals, insurers or manufacturers, at the national or international level. These stakeholders 
each bring in important interests, values and considerations, and the framework aims to balance 
these interests, and foster decisions that are justifiable and considered reasonable by all 
involved stakeholders. On the other hand, evidence-informed deliberative processes are based 
on reasoned decision making—through evaluation of the identified values.
Health authorities in many countries already have a process in place which often involves 
stakeholders and uses evidence. But the way this is organised is often not ideal in terms of 
accountability—stakeholder involvement is not meaningful or it comes late, and relevant values 
are not always identified in time or not at all. Also, the collection of evidence on only a limited set 
of values is often incomplete. ‘Evidence-informed deliberative processes’ proposes a vision for 
how health authorities should ideally organise their process. This ideal should not be interpreted 
as a blueprint for authorities but rather as an aspirational goal; countries are advised to take 
incremental steps towards this goal.
First choice: The use of evidence-informed deliberative processes to identify high-
priority services
Health authorities first need to classify services in low-priority, medium-priority and high-priority 
classes, and they should periodically review this, for example, every 4 years. The use of evidence-
informed deliberative processes has implications for the organisation of processes to support 
















Figure 2. The organisation of evidence-informed deliberative processes. M&E, monitoring and evaluation.* 
*The EDP framework has been revised over the course of this PhD. For the most up-to-date version see Chapter 1, Figure 3.
Step 1: Situational analysis
The situational analysis serves to map out disease prevalence, severity, level of service coverage 
and of financial risk protection. The situational analysis should also identify relevant stakeholders.
Step 2: Establishment of an appraisal committee
Authorities are advised to establish an appraisal committee that steers the various activities in 
the decision-making process, and finally develops recommendations to the health authorities 
on which services should be classified as high priority. This committee should ideally comprise a 
variety of stakeholders as their members. Permanent members should be installed to advocate 
for the broad public interest. Temporary members can be included to represent specific 
stakeholders including their interests and expertise—making their appointment dependent on 
the recommendation under scrutiny. Temporary members do not have mandate to develop 
recommendations.
In certain countries, stakeholder participation in appraisal committees may not be possible. 
Alternatively, stakeholders can be involved through a citizen council as in the UK, or soliciting 
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input and feedback from patients as in Canada and Scotland. Yet, meaningful stakeholder 
participation involves interaction and deliberation.9
Step 3: Identification of interventions and criteria
Health authorities, in consultation with stakeholders, are advised to establish a list of services for 
appraisal. Health authorities are advised to identify explicit decision-making criteria for selecting 
high-priority services, with criteria referring to the formal operationalisation of stakeholders’ 
values. The WHO report ‘Fair choices on the path to UHC’ has proposed three such criteria2:
 •  Cost-effectiveness: Priority should be given to the most cost-effective policies. This is 
typically motivated by the goal of health maximisation, that is, to obtain as much benefit as 
possible from the available resources.
 •  Priority to the worse off: Priority should be given to the policies benefiting the worse off 
groups in terms of health and socioeconomic status. As to the latter, many countries face 
significant coverage gaps, especially among rural populations, the poor and marginalised 
groups due to gender, race or social status. This implies that an expansion of such services 
to an underserved poor and rural population should take priority over an expansion to a 
well off, urban population, at least where other things are roughly equal. Reasons for this 
can be framed in terms of the importance of health and health services to individuals and 
society, respect for the right to health and social solidarity relating to equal and affordable 
access.
 •  Financial risk protection: Out-of-pocket medical payments can lead to impoverishment 
within households. Protection from financial risks associated with healthcare expenses has 
emerged as a critical component of national health strategies in many countries.
Other generic criteria (ie, criteria that are relevant across a broad selection of services) include 
‘safety’ and ‘effectiveness’ of services. In addition, ‘contextual’ criteria are relevant to further 
help classify high-priority services. These may relate to various considerations, for example, 
‘individual responsibility for health’ for services targeting behaviour-related diseases such as 
smoking.10
In order not to overlook criteria, health authorities are advised to develop a checklist including 
their range of generic and contextual criteria. Several classifications of decision criteria can be 
used as starting points for this.10–12 The specification of criteria in such a checklist is important, 
as it may have far-reaching consequences for the choice of services—this should take place 
through a robust public deliberation and participatory procedure.13
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Step 4: Collection of evidence
Health authorities are advised to generate an evidence base on criteria. The evidence collection on 
safety and effectiveness of services is relatively well developed.14 Also, methodological guidance 
for evidence collection on cost-effectiveness of services,15,16 and databases of evidence are 
available.17–19 Yet, health authorities may be required to make substantial investments to obtain 
timely and context-specific data on this. The collection of evidence on the criterion ‘priority to the 
worse off’ can, for example, be estimated by considering healthy life years lost.2,12,20 Methods 
for the evidence collection on the criterion ‘financial risk protection’ are now being developed 
through the growing application of extended cost-effectiveness analysis.21
In the event that the abovementioned refined evidence on criteria cannot be generated, authorities 
are advised to use aggregated data or expert opinion. In addition, the use of evidence-informed 
deliberative processes will likely lead to the identification of further criteria, and these may also 
require further qualitative or quantitative assessment.
Step 5: Development of recommendations
In order to develop recommendations on the ranking of services into priority classes, the appraisal 
committee should make balanced judgements regarding the ranking of the various criteria, and 
the performance of services on these criteria. The committee can use different strategies to 
arrive at these judgements.
One useful strategy is to start with the safety and effectiveness considerations, as they are 
fundamental to approval of services in any health system, and to consider these as knockout 
criteria. Next, since health maximisation is a prime objective of many health systems, the 
committee can choose to initially classify services in priority classes on the basis of their cost-
effectiveness (with ‘highly cost-effective’ services classified in the high-priority class, etc). The 
committee should define cost-effectiveness thresholds regarding these classes.22,23 All other 
criteria can affect this initial classification. The appraisal committee should make an overview 
of the performance of the various services on these criteria. Such an overview likely combines 
evidence of a quantitative or qualitative nature—depending on the nature of the criteria. For 
every criterion, the appraisal committee should argue whether and how it affects the priority 
class in which a service was initially classified (on the basis of its cost-effectiveness). Arguments 
brought to table should be subjected to deliberation, and in the end balanced against each 
other. The committee will eventually need to come to a final recommendation, thereby providing 
argumentation on which criteria are considered of overriding importance.9 The importance of 
deliberation regarding the full range of criteria cannot be underestimated; quantitative decision 
aids such as weights can never fully replace reasoned judgements.24 The evidence to decision 
framework provides practical guidance including tools on how to organise this deliberative 
process.25
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Interest groups in reality have different capacities to influence the prioritisation process, for 
example, in some countries there may be a more effective political lobby promoting cancer 
services over other services. Moreover, disadvantaged groups in society may face challenges 
that hinder their effective participation in deliberative processes.26 The challenge for the appraisal 
committee is to mitigate such differences, if present. Importantly, stakeholder involvement 
in the appraisal committee does not necessarily need to lead to mutual consensus on a 
recommendation, or to a joint decision. Thus, any particular stakeholder dominance or pressure 
from strong interest groups is only relevant to the extent the accountable health authority allows 
this.9 The final decision, and accountability, rests with the accountable health authority.
Step 6: Communication, appeal, regulation and enforcement, monitoring and 
evaluation
In a democratic society, policy makers hold the authority to make decisions and are accountable 
for the decision-making process. It is therefore important that health authorities communicate 
their decisions, including all reasons that have been put forward by the appraisal committee, to 
justify these decisions. Doing so in transparent and accessible ways will increase the likelihood 
that stakeholders including citizens who did not participate—and did not go through a learning 
process—can understand and accept the reasoning underlying the final decision.6
In addition, societal perceptions of what should count as legitimate arguments for recommendations 
are subject to change over time or with new evidence becoming available. Health authorities 
should therefore organise a revision and appeal or review mechanism.6 Additionally, the decisions 
taken must be implemented effectively through regulation, and be subject to enforcement.
Health authorities need a strong system for monitoring and evaluation, to promote accountability 
and to effectively pursue UHC in general. Authorities should carefully select a set of indicators 
tailoring SDG indicators to national priorities, invest in health information systems and properly 
integrate the information in policy making.2
Second choice: The use of evidence-informed deliberative processes to evaluate high 
priority service implementation options
Whereas health authorities first need to select high priority services (as discussed above), they 
subsequently need to decide on what to do first regarding different implementation options to 
make high priority services available. For these choices, the same kind of evidence-informed 
deliberative processes including the same appraisal committee can be employed, yet with the 
following specific characteristics.
First, choices on implementation options need to be made on an ongoing, recurrent basis. 
Second, the appraisal committee should identify implementation options in terms of including 
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more services in the essential package, expanding the coverage of specific services and/or 
reducing co-payments for specific services. For example, at a certain point in time, an appraisal 
committee may define the following implementation options: (1) expanding coverage of measles 
vaccine to rural populations without co-payments; (2) introducing malaria prophylaxis in urban 
areas with co-payments; and (3) eliminating co-payments for assisted deliveries at current 
coverage levels. The appraisal committee may also wish to define disinvestment options, to free 
up resources for investment in the progressive realisation of UHC. Third, the task of an appraisal 
committee is not restricted to develop strictly positive or negative recommendations. The above 
process may also lead to recommendations for price negotiation, or the collection of further 
evidence. Together with stakeholders, health authorities may also identify alternative ways of 
implementation of services, which may optimise their value.9
BROADER CONSIDERATIONS
This paper presents practical guidance for health authorities to make two important choices in 
the context of progressive realisation of UHC. The first type of choice relates to the classification 
of services in priority classes. In case where countries lack the analytical capacity to make 
these choices, they may also base their classification on international recommendations in this 
context, for example, on the essential services for reproductive, maternal, newborn and child 
health.27 The second type of choice pertains to what health authorities should do, at a certain 
point in time, to implement these priorities. It is preferable for health authorities to explicitly 
define implementation options, defined in terms of a service, its coverage level and related co-
payment, and use evidence-informed deliberative process to make these important choices. 
Health authorities are advised to make institutional arrangements that facilitate processes for 
making both types of choices.
Many health authorities often already have some sort of evidence-informed deliberative process 
in place,4,28 and we advise them to incrementally improve on these, according to local needs 
and affordances. For example, authorities may decide to organise deliberation, or publish their 
argumentation vis-à-vis their recommendations. Various other proposed approaches to priority 
setting are based on the same principles of stakeholder deliberation and evidence gathering29,30—
these may also provide important lessons for authorities. In general, these approaches comprise 
the same steps described in this paper.
The guidance provided here is centred around the concept of ‘progressive realization’ and is to 
be understood in two different ways. First, as the progression towards UHC over time. Second, 
with ‘progressive’ being interpreted in the social sense as ensuring that equity concerns are fully 
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considered in decision making, such as reducing coverage gaps of essential services for those 
currently left behind.31
To be truly robust, accountability and participation mechanisms should be institutionalised. Many 
countries that have succeeded in moving towards UHC—such as Mexico, Rwanda, Thailand, 
and Turkey—have created innovative institutions that promote accountability and participation.4 
These can surely be strengthened. Nevertheless, when robust participation and accountability 
are included, and protections against legal and de facto discrimination accompany it, such 
an evidence-informed deliberative process is consistent with priority setting for the progressive 
realisation of the right to health. The latter is recognised by virtually every country in the world 
through the international treaties states have ratified, and is increasingly enshrined and enforced 
in national legal systems.5,32
This paper provides technical guidance to countries on how to make service choices on their 
path to UHC, and addresses various political aspects, such as stakeholder involvement and 
development of recommendations in the context of stakeholder dominance. Yet, it does not 
address broader political issues such as the role of pressure groups on determining the total 
budget envelop for healthcare and therefore UHC. These issues are nevertheless important for 
countries to consider in their efforts to achieve UHC, and further integration of political sciences 
in the development of methods for healthcare priority setting is critical.33
Finally, achieving UHC also requires broad health financing changes, such as increasing 
mandatory, progressive prepayment with pooling of funds.34
CONCLUSION
The use of evidence-informed deliberative processes fills in an important gap in the literature 
on UHC. It responds to key questions that countries have, that is, how they can best organise 
their processes and evidence collection to make decisions on what services to provide first 
under progressive realisation. In this way, the framework contributes to the quest of countries to 
progressively realize UHC as an important SDG.
Box: Identifying high priority services in HIV/AIDS control in West Java province, 
Indonesia
In Indonesia, West Java is among the provinces with the highest HIV prevalence, and its provincial 
AIDS commission is responsible for coordination of HIV/AIDS activities. Here we describe the 
use of an evidence-informed deliberative process to select high-priority services for the 5 years 
(2014–2018) HIV/AIDS strategic plan of the AIDS commission.
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The implementation followed similar steps as described in the main text to identify priority 
services, and was carried out by the West Java provincial AIDS commission (named health 
authorities hereafter), supported by Padjadjaran University in Bandung, and Radboud university 
medical centre in the Netherlands. In step 1, the health authorities analysed the HIV prevalence 
among key populations, its future spread and coverage of services, and conducted a stakeholder 
analysis to identify relevant stakeholders in West Java. In step 2, on the basis of this analysis, 
an appraisal committee was established including government staff from the health office, 
labour office, education office and the coordinating body for family planning (n=6); staff from 
community organisations working on family planning and representing people living with HIV/
AIDS and high-risk groups (n=4); programme managers from the West Java AIDS commission 
(n=7); and researchers with backgrounds in economics and epidemiology working on HIV/AIDS 
at Padjadjaran University (n=6). In step 3, this committee discussed criteria to prioritise services, 
with, as inputs, the results of a local survey on the importance of criteria for priority setting, WHO 
treatment guidelines, and implicit criteria used during the development of former National and 
West Java strategic plans. Each committee member first identified his/her own top five criteria, 
and these were subsequently discussed together, resulting in the following criteria: ‘impact on 
the epidemic’, ‘stigma reduction’, ‘cost-effectiveness’ and ‘universal coverage’. In addition, 
a larger group of 70 stakeholders proposed a total of 50 services for potential prioritisation 
in the strategic plan. In step 4, the health authorities collected evidence on the performance 
of these services on all criteria, on the basis of international literature, a locally adapted HIV 
disease model, and, if necessary, expert opinion. All evidence, including a grading of its quality, 
was presented as scores in a performance matrix. In step 5, on the basis of this matrix, and 
in a deliberative process, the appraisal committee agreed on high-priority services. In step 6, 
the appraisal committee developed an implementation plan, in terms of task division and the 
identification of funders per service. The results of the priority setting process were included in 
West Java’s 5-year (2014–2018) strategic document for HIV/AIDS control, which was presented 
to the governor for approval in 2016.
This example illustrates the use of an evidence-informed deliberative process to select high-
priority services (as spelled out in section 3 of the main text), with the exception of organising 
activities related to communication, appeal, or monitoring and evaluation mechanisms.
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Accountable decision-makers are required to legitimize their priority setting decisions in health 
to members of society. In this perspective we stress the point that fair, legitimate processes 
should reflect efforts of authorities to treat all stakeholders as moral equals in terms of providing 
all people with well-justified, reasonable reasons to endorse the decisions. We argue there is a 
special moral concern for being accountable to those who are potentially adversely affected by 
decisions. Health authorities need to operationalize this requirement into real world action. In this 
perspective, we operationalize five key steps in doing so, in terms of (i) proactively identifying 
potentially adversely affected stakeholders; (ii) comprehensively including them in the decision-
making process; (iii) ensuring meaningful participation; (iv) communication of recommendations 
or decisions; and (v) the organization of evaluation and appeal mechanisms. Health authorities 
are advised to use a checklist in the form of 29 reflective questions, aligned with these five key 
steps, to assist them in the practical organization of legitimate priority setting in healthcare.




Health authorities make priority setting decisions on behalf of society. Their decisions are 
bound to be controversial as stakeholders likely disagree over which priorities should be set 
and over who should benefit and who should not. Increasingly, there is attention for organizing 
‘fair, legitimate decision-making processes’ and organizing ‘public deliberation.’ In line with this 
trend, health authorities often organize some form of stakeholder participation, embedded in 
their decision-making processes.1 In doing so they may use different deliberative methods, 
identified and described elsewhere.1,2 Reasons for organizing stakeholder participation can be 
multiple, eg, gaining an understanding of the stakeholders’ values and how a specific decision 
affects these values, enhancing the epistemic outcome of deliberation, educating the public, or 
promoting democracy by making citizens co-decision-makers.1-4 
Whatever the health authorities’ specific reason for organizing stakeholder participation, fair, 
legitimate processes have to reflect efforts of authorities to treat all stakeholders as moral equals 
and thus provide people with well-justified, reasonable reasons to endorse the process and thus 
the decision – even if it is the case that they would have preferred another outcome.5,6 This is 
especially relevant for stakeholders who carry the negative consequences of a decision, the so-
called adversely affected stakeholders. 
In practice, health authorities lack easy-to-use tools that can support them in carefully organizing 
meaningful stakeholder participation. As such, there is a risk that participation of stakeholders, 
if organized at all, merely reflects tokenism rather than justified and adequately integrated 
participation. In response to this, we here present a checklist for carefully organizing stakeholder 
participation. This can help health authorities in being accountable for their priority setting 
decisions, especially towards adversely affected stakeholders.
WHY ARE HEALTH AUTHORITIES ACCOUNTABLE TO (ADVERSELY 
AFFECTED) STAKEHOLDERS?
Priority setting in health is recognized as a value-laden political process, which takes place 
in an environment of diverging social values and interests.7-13 Indeed, members of society, 
or stakeholders, may carry a wide range and diversity of social values, such as maximizing 
population health, doing no harm, avoiding catastrophic expenditure, or giving priority to the 
worse off.14-16 According to liberal theory, stakeholders may reasonably disagree on the relative 
importance of such values and as well on how some of them are specified during priority setting.17 
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Health authorities make priority setting decisions on behalf of society, eg, when deciding on the 
public reimbursement of new health interventions. The power that health authorities possess to 
make priority setting decisions on behalf of societies, characterized by representing this value 
pluralism, is justified only in so far decision-making is carried out in legitimate ways.
Legitimate decision-making requires that processes reflect efforts of authorities to treat all 
stakeholders as moral equals.5 Ideally, this means all stakeholders would have good reasons 
to endorse the decision-making process as fair - even those who would have preferred another 
outcome than the resulting decision.5,6 In order to enjoy the moral authority to make priority setting 
decisions in health (as opposed to some contingent social power), there is an ethical demand on 
health authorities to be accountable to adversely affected stakeholders.5 Independently of what 
kind of normative theory one endorses, it can be seen as a fundamental ethical requirement, 
that those who are carrying the burdens of the decisions are (i) explicitly recognized as being 
stakeholders; and (ii) entitled to being provided with good reasons to appreciate the decision-
making process as fair. If these concerns are not taken seriously by decision-makers they lose 
their moral authority for making priority setting decisions in health. Subsequently, they may 
undermine the legitimacy of their own decision-making process.18
WHO ARE THE ADVERSELY AFFECTED STAKEHOLDERS? 
We distinguish between four reasons why stakeholders can be considered adversely affected by 
decisions: (i) stakeholders experience a health loss as a direct result of a priority setting decision 
(the health loss reason); (ii) stakeholders experience a health loss as an indirect result of a priority 
decision, which is the case when a newly approved health intervention displaces their personally 
needed intervention (the indirect health loss reason); (iii) stakeholders need to communicate 
decisions which may adversely affect the patient-clinician relationship (the communication 
reason)19; (iv) stakeholders are responsible for implementing a decision they strongly disagree 
with (the integrity reason). This list is not necessarily exhaustive: further categories may be added 
according to a specific burden inflicted by a decision. 
DEVELOPMENT OF THE CHECKLIST 
Important academic work on the conditions of fair processes is the accountability for 
reasonableness (A4R) framework.10,20 This framework identifies four key conditions for organizing 
fair processes: (i) organizing deliberation among stakeholders to identify relevant rationales; 
(ii) ensuring transparency of the decisions; (iii) organization of appeal opportunities; and (iv) 
regulation of conditions i-iii.10,20 However, there is a gap in the literature on how to comprehensively 
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translate these requirements into practice in general,21 and more specifically when it comes to 
ensuring accountability towards the adversely affected identified above.5 
We developed a checklist by operationalizing the A4R framework and reflecting on the ethical 
notions it invokes, supported by broader literature on stakeholder participation and public 
deliberation, paying special concern for the ethical demand to be accountable to adversely 
affected stakeholders.2-5,20,22-27 Based on this reflection we defined five key actionable steps 
in being accountable to adversely affected stakeholders: (i) proactively identifying potentially 
adversely affected stakeholders; (ii) comprehensively including stakeholders; (iii) ensuring 
meaningful participation; (iv) communication of recommendations and/or decisions; and (v) 
the organization of evaluation and appeal mechanisms – further explained below. In doing 
so, we did not assume a generic model of decision-making, as real-world decision-making 
processes are unlikely to take place in a chronological and tidy manner. Further reflection on 
what it would entail to actually operationalize these five steps was carried out in accordance 
with the underlying imperative of treating people as moral equals. A simple test of whether the 
inclusion of stakeholders meets this imperative or not, is to imagine whether we would have felt 
respectfully recognized and properly involved on the suggested terms ourselves. By following this 
methodology we could spell out questions that health authorities should think about when they 
organize stakeholder participation. This reflection process resulted in a shortlist of questions for 
use by health authorities. The five steps and their respective questions are together presented as 
a reflective checklist (Box 1). The checklist is not meant to be all-encompassing or exhaustive, 
rather, it is meant to cover key concerns and invoke reflection by health authorities on the most 
relevant and actionable choices they make. Therefore, the checklist should be taken as a starting 
point for discussion and future adjustment. 
Step 1: Identifying Potentially Adversely Affected Stakeholders 
Authorities must make efforts to systematically identify potentially adversely affected stakeholders 
before making a decision, as to ensure that stakeholders’ perspectives, suggestions and 
arguments will enter into the decision-making process, preferably as early as possible during 
the deliberative process.5 The first step is to identify real world persons as representatives of 
the potentially adversely affected stakeholders according to the categories we identified above. 
Step 2: Including Stakeholders in the Decision-Making Process 
Identified stakeholders must be included in the decision-making process.4,5,22 This demands a 
pro-active attitude of health authorities, which starts with inviting stakeholders to attend meetings 
and ensuring meetings are accessible.22-24 Specifically, efforts should be made to ensure that 
known hard-to-reach stakeholders actually have reasonable opportunities to participate.24 
Alternatively, strategies for including stakeholders values, other than their direct participation, 
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should be explored pro-actively to ensure the uptake of arguments – in line with broader 
consultation and communication efforts as defined elsewhere.2,5 
Step 3: Ensuring Meaningful Participation 
Efforts must be made to ensure meaningful participation. This requires that stakeholders can 
actively interact in the deliberation, freely voice their perspectives and that they are treated with 
due respect – while being provided with sufficient time to do so.3,5,11,22,23,25 Also, it requires that 
further evidence is considered or commissioned when this is feasible. Furthermore, all evidence 
and argumentation put forward should be presented to stakeholders in time and carefully 
addressed in a way that is understandable to all stakeholders.5,22,25 Importantly, this requires 
that their input is considered, put to use, scrutinized and not ignored – and that its clear at the 
outset of a process, to all stakeholders involved, how divergent views and interests are to be 
resolved and this concern is to be satisfied.5 Overall, the deliberative process should provide 
opportunities for mutual learning.3,5,23,26,27
Step 4: Communicating Recommendations and/or Decisions in Understandable and 
Transparent Ways 
The final recommendations and/or decisions have to be determined by acceptable standards 
of voting or left to the discretion of legitimately appointed decision-makers. Decisions should 
be communicated shortly after being made, in transparent ways that help shape understanding 
among stakeholders of why the specific decision was made.4,5 In doing so, health authorities 
should provide clear argumentation for why those who become adversely affected by their 
decision are to carry the burden.5 
Step 5: Organizing Evaluation and Appeal Options 
User-friendly evaluation and appeal options should be organized.4,10 Any appeals made should 
be documented and made anonymous and publicly available. Moreover, mechanisms should be 
put in place that ensure all appeals are handled with care – providing justification of the appeals 
outcome by decision-makers in an understandable way.5
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Box 1. A Checklist for Stakeholder Participation 
A. Identification of potentially adversely affected stakeholders 
Who may experience a health loss as a result of a negative decision? 
Who may experience a health loss as a result of a positive decision? 
Who may be adversely affected because they are responsible for communicating the decision? 
Who may be adversely affected because they are responsible for implementing the decision? 
B. Comprehensive stakeholder inclusion 
1. Are all relevant stakeholders informed about the possibility and procedures of participation? 
2.  Is participation organized in a way that effectively and efficiently facilitates the inclusion of stakeholders? 
3. Are efforts made to include all relevant, especially difficult-to-reach, stakeholders? 
4.  Can stakeholders participate in the identification and topic selection of health services for evaluation? 
5. Can stakeholders participate in the scoping of relevant questions for evaluation? 
6. Can stakeholders participate in the development of recommendations? 
7. Can stakeholders participate in the evaluation of decisions? 
8. Are alternative non-participatory strategies used for inclusion of stakeholders’ values? 
C. Meaningful stakeholder participation 
1. Are stakeholders fully and in time informed about the available evidence? 
2.  Is argumentation and evidence presented in a way that is understandable to all relevant stakeholders? 
3.  Can stakeholders freely voice their perspectives (ie, no stakeholder is allowed to dominate a discussion 
or activity)? 
4. Are stakeholder perspectives addressed in respectful and courteous ways? 
5. Do stakeholders have sufficient time to provide input? 
6. Are stakeholder perspectives equally accounted for in the deliberation? 
7.  Is it clear to all stakeholders involved how their input is going to be considered, scrutinized and put to use? 
8. Can stakeholders actively interact in the deliberation? 
9. Is further evidence collection considered when judged relevant and feasible? 
D. Transparent communication of recommendations and/or decisions 
1.  Is information provided on the underlying argumentation and process to come to a recommendation and/
or decision? 
2. Is input from stakeholders documented and addressed explicitly? 
3. Are recommendations and/or decisions clearly communicated? 
4. Are stakeholders informed in time on the recommendation and/or decision? 
E. Appeal and evaluation 
1. Can stakeholders easily make an appeal on the underlying argumentation or process? 
2. Are appeals documented and publicly accessible? 
3. Are appeals handled consistently and is justification provided in an understandable way? 
4. Are mechanisms in place to revise decisions or the process based on appeals?
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HOW TO USE THE CHECKLIST?
 
Health authorities can use the checklist to revise for possible shortcomings of current processes 
and install mechanisms for improvement. As mentioned, the checklist is generic in nature and 
questions included in the checklist are relevant to reflect on throughout a decision-making 
process. In practice, processes may be split-up into specific steps (eg, assessment and 
appraisal) for which certain questions may be more (or less) relevant to consider. Also, if decision-
making is split-up into separate steps, it may well be that each step requires a different answer 
to the same question. Furthermore, answers to questions are context-specific and there is no 
decisive evidence on what would constitute ‘right answers’ to these individual questions. In some 
contexts it may eg, be reasonable to reimburse travel expenses for the sake of accessibility, while 
in other cases this may be judged irrelevant or inappropriate. Nevertheless, health authorities are 
advised to inform their specific choices by evidence if available – or to learn from other countries’ 
experiences. Finally, the checklist reflects an aspirational goal of ideal accountability of decision-
makers to adversely affected stakeholders. Authorities should take incremental steps towards 
meeting this goal by prioritizing specific efforts according to local needs and affordances.
CONCLUSION 
Accountable decision-makers are required to legitimize their priority setting decisions in health 
to members of society. Health authorities need to operationalize this requirement into real 
world action. In this perspective, we have argued for five key steps in doing so, in terms of 
proactively identifying potentially adversely affected stakeholders, comprehensively including 
them in the decision-making process, ensuring meaningful participation, communication of 
recommendations or decisions, and the organization of evaluation and appeal mechanisms. 
Health authorities are advised to use the provided checklist in the form of 29 reflective questions 
to assist them in the practical organization of legitimate priority setting in healthcare.
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Some studies in the Netherlands have gauged public views on principles for healthcare priority 
setting, but they fall short of comprehensively explaining the public disapproval of several recent 
reimbursement decisions. 
Objective
To obtain insight into citizens’ preferences and identify the criteria they would propose for 
decisions pertaining to the benefits package of basic health insurance. 
Methods
Twenty-four Dutch citizens were selected for participation in a Citizen Forum, which involved 3 
weekends. Deliberations took place in small groups and in plenary, guided by 2 moderators, 
on the basis of 8 preselected case studies, which participants later compared and prioritized 
under the premise that not all treatments can or need to be reimbursed. Participants received 
opportunities to inform themselves through written brochures and live interactions with 3 experts. 
Results
The Citizen Forum identified 16 criteria for inclusion or exclusion of treatments in the benefits 
package; they relate to the condition (2 criteria), treatment (11 criteria), and individual 
characteristics of those affected by the condition (3 criteria). In most case studies, it was a 
combination of criteria that determined whether or not participants favored inclusion of the 
treatment under consideration in the benefits package. Participants differed in their opinion 
about the relative importance of criteria, and they had difficulty in operationalizing and trading off 
criteria to provide a recommendation. 
Conclusions
Informed citizens are prepared to make and, to a certain extent, capable of making reasoned 
choices about the reimbursement of health services. They realize that choices are both necessary 
and possible. Broad public support and understanding for making tough choices regarding the 
benefits package of basic health insurance is not automatic: it requires an investment.





The government of The Netherlands, like its counterparts in most other countries that have some 
form of universal health insurance, faces challenges in obtaining public support for its choices 
regarding the composition of the benefits package. In the context of increasing pressure on a 
limited healthcare budget, decisions to not or no longer fund certain treatments regularly meet 
with opposition from healthcare providers, private-sector parties, politicians, patient interest 
groups, and the public in general. Cost increases that arise from innovations that enter the 
market (new diagnostic tests, drugs, technologies), changing disease patterns (more chronic 
conditions, multimorbidity), and aging all feed this pressure.1 Confronted with opposition to 
negative decisions, policy makers and scholars caution against budget increases that cannot 
be fiscally sustained.2 
Some studies in The Netherlands have gauged public views on principles for healthcare priority 
setting,3-5 but they fall short of comprehensively explaining the public disapproval of several 
reimbursement decisions, such as in the case of eculizimab used to treat atypical hemolytic 
uremic syndrome (aHUS); approval of reimbursement under strict conditions); lumacaftor/
ivacaftor (Orkambi), Vertex Pharmaceuticals Inc, Boston, MA, to treat cystic fibrosis (negative 
decision, later reversed); and fampyra for treatment of multiple sclerosis (negative decision). The 
opinion of informed citizens about services that should be covered under basic health insurance 
and the arguments they use are largely unknown. Citizens who are given the opportunity to 
reflect and interact with each other do appear to become more modest and more sympathetic 
to the complex tasks of healthcare decision makers.6 Thus, a better insight into the criteria that 
informed citizens consider relevant and acceptable for making tough choices in healthcare 
could inform the process of national-level decision making and improve public support for 
its outcomes. More specifically, it would assist The Netherlands’ Healthcare Institute (ZiNL) in 
strengthening the fulfilment of one of its mandates as the national health technology agency, 
which is to advise the Minister of Health on the composition of the benefits package of basic 
health insurance. 
During 3 weekends in the fall of 2017, the Citizen Forum “Choices in Health Care” was held, with 
24 participants discussing which kind of services they would like to see included in the benefits 
package or, in other words, which services they would be willing to pay for each other and for 
what reasons. The objective of this Citizen Forum was to obtain insight into citizens’ preferences 
and identify the criteria they would propose for decisions pertaining to the composition of the 
basic health insurance benefits package. The project’s overall aim was to inform decision 
making around public funding of health services based on societal values. Although surveys that 
do not allow respondents the time and opportunity for reflection and interaction with others may 
be of limited value, focus group discussions and citizen forums can offer a richer picture, with 
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participants expressing their views and opinions with more nuance.6,7 The guidance provided by 
O’Doherty et al8 for implementing a public deliberative forum informed the design of the “Choices 
in Health Care” Citizen Forum. One of the underlying premises of this Citizen Forum was “health 
technology assessment as learning.”9-11 As argued by Cohen and Sabel12 and Degeling et al,13 
deliberation is an essential democratic requirement for forming a reasoned opinion, enabling lay 
people to inform themselves and engage in priority setting. 
METHODS 
The participants in the Citizen Forum were selected from an existing panel compiled by 
Motivaction, a research and consultancy agency that specializes in values, motives, lifestyle, 
and behavior. Panel members were matched to 1 of 8 mentality groups (ie, attitudes to life) 
that represent shared aspirations regarding work, leisure, and politics and show similar lifestyle 
and consumption patterns. The segmentation into mentality groups was based on value 
orientation (eg, traditional, modern, postmodern) and status seeking (ie, low, middle, high).14 
For the Citizen Forum, 3 citizens were recruited from each of the 8 mentality groups, with equal 
overall distributions of sex, age, and residence (province). Rather than seeking a representative 
sample of Dutch society (which would not have been possible with only 24 participants), the 
attempt was to obtain a group as diverse as possible in terms of their value orientation vis-à-vis 
societal issues. Instead of overly pursuing the inclusion of ‘ordinary’ citizens, which Lehoux et al15 
considered misleading, the participants were seen as individuals who were given the opportunity 
to exercise their citizenship through a consultation process. The only characteristic participants 
had in common was that they had registered in the past with Motivaction to participate in surveys 
or market polls. Before the Citizen Forum, the participants were informed in general terms about 
the nature and purpose of the Citizen Forum, so as not to exert any influence beforehand. They 
received a financial incentive (a flat fee), as well as free accommodation (2 nights in each of the 
3 weekends) and free meals. All participants signed a letter of informed consent; none dropped 
out. 
A constitutional framework, conceived in the initial stages of the project, comprises criteria and 
considerations that are commonly used for healthcare reimbursement decisions (see Appendix 
A in Supplemental Materials found at https://doi.org/1 0.1016/j.jval.2019.07.015). It informed the 
selection of 8 case studies that were subjected to deliberation in the Citizen Forum (listed in 
Figure 1): dental (orthodontic) braces for youngsters, Alzheimer’s disease, heart burn (pyrosis), 
attention-deficit hyperactivity disorder (ADHD) among children, aHUS, total body scan, obesity, 
and hip prosthesis for elderly people. These case studies had been carefully preselected so as to 
obtain the broadest possible spectrum of viewpoints, dilemmas, inclusion/exclusion criteria, and 
societal values. For each case study, participants were asked to answer the following questions: 
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“Would you recommend that (all) medication/treatment for this particular condition be included 
in the basic health insurance benefits package?” and “What are your considerations?”
The program of the 3 weekends is listed in Appendix B (found at https://doi.org/10.1016/j.
jval.2019.07.015). At the start of the Citizen Forum, participants received a succinct brochure, 
compiled by the project group, with some background information about the Dutch healthcare 
system. At the end of the second weekend, they received a more detailed brochure for individual 
use.16 For each of the case studies, discussed during the first 2 weekends, the participants first 
received a description of the clinical manifestations and treatment options. This information, 
validated by ZiNL experts, was presented in a neutral manner to minimize the chance of bias. 
The deliberations around each case study typically lasted 2 to 3 hours, culminating in a listing of 
arguments in favor and against inclusion of treatment for that patient group in the basic health 
insurance benefits package. Two moderators guided the deliberations, which took place in 
small groups and in plenary sessions, most of which were tape recorded. Three researchers 
participated as observers-cum-rapporteurs. They compiled summaries of the deliberations and 
fed these back to the participants in the morning of the next day for validation. 
Participants further interacted in 3 separate sessions, each of which lasted 11 /2 to 2 hours, 
with the following experts: an ethicist, a health economist, and a specialist in health technology 
appraisal. The latter was also a former member of ZiNL’s appraisal committee that advises the 
Minister of Health about reimbursement decisions.17 These interactions, based on questions put 
forward by the participants themselves, served to share personal experiences and deepen their 
understanding of dilemmas. 
In the third weekend, participants worked in small groups to prioritize the 8 case studies, under 
the premise that not all treatments can or need to reimbursed, and to justify why the treatments 
involved should or should not qualify for reimbursement. By assigning rankings to indicate the 
order of priority, the participants were forced to discuss and agree on tradeoffs between 2 or 
more criteria. In a subsequent session, participants worked individually, rating each of the criteria 
identified on a scale of 1 to 5, to indicate their importance. In a third session, they indicated the 
extent to which they agreed or disagreed with a list of 146 statements compiled by the researchers, 
based on arguments that participants had put forward in earlier deliberations. Participants were 
asked to color code each statement: green meaning “I agree”; red, “I disagree”; and yellow, “I 
neither agree nor disagree.” For the latter category of answers, participants were requested to 
write narrative explanations. In the analysis afterward, the level of agreement among participants 
per statement was calculated, resulting in 4 categories: no agreement (less than 25% who agreed 
with the statement), some agreement (between 25% and 49%), much agreement (between 50% 
and 74%), and near full consensus (75% or more who agreed). If a statement had been colored 
yellow by more than a quarter of the participants with contradicting or inconsistent comments, it 
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was considered ambiguous (multi-interpretable) and therefore excluded from the analysis. This 
was the case for just 1 of the total of 146 statements. 
The Citizen Forum resulted in a manifesto (in Dutch), which contained a summary of the results 
and some of the most poignant quotes from participants.18 An ad hoc sounding board, composed 
of 12 scientists, practitioners, and organization/management experts in the healthcare sector, 
advised the Citizen Forum project group.
Figure 1. Eight case studies discussed in the Citizen Forum. 
RESULTS 
Identified Criteria 
The Citizen Forum resulted in 16 inclusion/exclusion criteria that participants considered 
important (see Figure 2). These criteria originate from underlying values, such as solidarity, 
equity, personal responsibility, and personal freedom. Here we highlight the 8 criteria that 
provoked the most discussion and best brought out opposing viewpoints as well as some of the 
principal arguments put forward by participants. 
Participants considered medical necessity an important criterion: the more serious a condition, the 
more important that its treatment be covered by basic health insurance. Life-saving interventions 
would always need to be covered, as a matter of principle. Participants were sceptical about 
paying for treatments that alleviate discomfort that “belongs to human life,” such as cosmetic 
surgery. They were also hesitant about conditions that have no clear medical cause.
Participants were of the opinion that treatments need to be effective, whereby effectiveness was 
interpreted broadly: improved health, better quality of life, and improved societal functioning 
were all considered relevant. There should preferably be scientific evidence of effectiveness.  
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Figure 2. Inclusion and exclusion criteria proposed by the Citizen Forum participants. 
The cost of treatment was considered an inevitable criterion for reimbursement decisions. 
Participants would prefer not to “attach a price tag on someone’s life” but argued that, ultimately, 
the cost of a treatment needs to be weighed against its benefits. 
If there is no alternative treatment for a particular condition, this could be a reason for participants 
to accept coverage of the cost of treatment, even if it is expensive. 
Participants did value prevention but were of the opinion that it should not be overemphasized: 
“life cannot be manufactured,” they explained. Preventive diagnostics should be reimbursed, 
but random investigations, such as total body scans, should not, because they give people a 
“false sense of security,” so the argument went. General prevention measures, such as health 
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education, were perceived to lead not only to better health but also to important cost savings. 
Participants were of the opinion that these may therefore be financed from public resources as 
long as there is evidence that they are effective. 
Participants almost unanimously rejected exclusion of patients for certain treatments above a 
certain age threshold. They considered it an unacceptable form of age discrimination. 
Most would not want to automatically reimburse interventions that address conditions related to 
lifestyle. Although they acknowledged that one cannot always be sure that a particular condition 
is caused by adverse behavior, they were of the opinion that certain patients need professional 
help, covered by health insurance, to change their lifestyle. They proposed to make it conditional: 
reimbursement should cease if the patient does not comply with the advice she or he receives. 
Participants considered it fair that people are asked to pay for themselves if a treatment is relatively 
cheap. Nevertheless, they warned against accumulation of costs, especially for patients with 
chronic conditions and/or multiple morbidity, and against potential avoidance of care seeking. 
Other criteria brought up by participants generated less controversy: the number of patients 
affected by the condition (the more patients are affected, the stronger the case for inclusion), 
the occurrence of societal side effects (positive side effects favor inclusion), the notion of people 
not wanting anything being taken away from them (a treatment once accepted should preferably 
not be removed from the package), feasibility of treatment (include only those that can actually 
be implemented), affordability (include only those that have a limited budget impact), and 
appropriate use (exclude treatments that may invoke inappropriate use). 
The arguments from which the 16 criteria were derived are listed in the summaries of the 
deliberations around the 8 case studies, appended as annex B to the final report (in Dutch); the 
ratings assigned by the participants to the statements are appended as annex C.19
Applying the Criteria 
Although many of the discussions focused on single criteria, in most case studies it was a 
combination of criteria that determined whether or not participants favored inclusion of the 
treatment under consideration in the basic insurance benefits package. 
Individual participants sometimes had difficulty in trading off criteria in order to provide a 
recommendation (inclusion or exclusion), especially in case studies that scored high on one 
criterion but low on another. An example is bariatric surgery (stomach reduction) in people with 
obesity. Effectiveness of this type of treatment was forwarded as a reason for reimbursement, 
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but several participants were uncertain whether that should outweigh the argument that it is 
someone’s personal responsibility to change his/her lifestyle and lose body weight. 
Participants differed in their opinion about the relative importance of criteria. This became 
particularly clear in the ADHD case study. Some argued that medication is potentially effective, 
despite uncertainty about the medical cause of ADHD, but they drew different conclusions: 
one let the effectiveness argument prevail, whereas another attached more importance to the 
medical necessity of treatment. Such differences precluded unanimous recommendations. 
In relation to the lifestyle criterion, participants had intense discussions about the role of one’s 
personal responsibility as a social value; whether personal responsibility should be taken into 
account in reimbursement decisions, for instance in the case of lung cancer, obesity, or sports 
injuries; and how to weigh it against the social value of solidarity. Although most participants 
considered it appropriate to reimburse (preventive) services that support people in changing 
unhealthy lifestyles, they were less unanimous about the reimbursement of medical treatments 
of lifestyle-related conditions. Those who favored reimbursement pointed at the role of addiction 
and the fact that children sometimes grow up in unhealthy environments (unhealthy diets, parents 
who smoke, limited opportunities for physical exercise), for which they should not be punished. 
In 2 case studies, participants generally agreed on the inclusion of particular health services 
in the benefits package: the provision of social support to people suffering from Alzheimer’s 
disease and the treatment of aHUS with eculizumab. In the latter case, the argument that 
treatment offers the possibility of a partial recovery from a life-threatening condition overturned 
the counterarguments, including the high cost of treatment and large budget impact. Three 
forms of treatment (among the 8 case studies) were almost unanimously considered less eligible 
for coverage under the basic health insurance: total body scan, treatment of heart burn with 
antacids, and bariatric surgery for people with obesity.
DISCUSSION 
The Citizen Forum has demonstrated that (1) citizens are capable of articulating their viewpoints 
and preferences, (2) engagement of a heterogeneous group of citizens leads to a broad 
spectrum of considerations and opinions, and (3) informed citizens who challenge each other 
in a structured deliberation process do learn and develop their opinions, without necessarily 
reaching consensus. 
The Citizen Forum has shown that informed citizens are prepared to make and, to a certain extent, 
capable of making reasoned choices about the reimbursement of health services. They come to 
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realize that such choices are necessary because there is a limit to how much society wishes to 
spend on healthcare, which causes budget limitations. Initially, several participants rejected high 
cost as an argument to deny someone who is sick a treatment that is available—sometimes they 
did so in rather strong words. As the deliberations unfolded, participants became more aware 
that there are limits to the available resources in healthcare and that choices about what to fund 
and what not to fund are therefore inevitable. But even if there was enough money to reimburse 
all available treatments and services, so was the argument of some participants, it would still be 
appropriate not to include certain services in the basic health insurance benefits package. 
Our study corroborates findings from a realist review performed by Kleinhout-Vliek et al20 in The 
Netherlands, who found that the general public, along with patients and the media, use a broader 
type of argumentation and different justification schemes for health insurance coverage decisions 
than policy makers and insurance companies. Citizens also seem to differ in the weights that 
they attach to these criteria and how they make trade-offs. The societal debate around choices 
in healthcare is inseparably connected to citizens’ preferences, norms, and values and the trade-
offs they would make if they were to choose. Nevertheless, it is the government that faces the 
challenge to actually make these choices. The legitimacy of such choices would be enhanced if 
the responsible government agencies managed to better align them with societal preferences. 
Two parallel studies evaluated whether and to what extent participants had changed their 
opinions by taking part in the Citizen Forum. The results of these studies—one based on in-
depth individual interviews before and after the Citizen Forum to unravel people’s interpretative 
frames and the other using Q-methodology to investigate participants’ views on priority setting, 
also using a before/after design—are reported separately (M. Jansen et al., unpublished data, 
2019; V. Reckers-Droog et al., unpublished data, 2019). These studies demonstrate that over 3 
weekends of deliberation, participants became more aware of the importance and complexity 
of making choices in healthcare, thereby transcending the views of the general public. They 
perceived the informed deliberation process as key to their newly acquired knowledge and 
insights. Many indicated it had also helped them to appreciate the reasonableness of other 
people’s viewpoints, even if they differed considerably from their own. 
In discussions around the prevention and treatment of lifestyle-related conditions, the Citizen 
Forum brought out the friction between personal responsibility and solidarity. Over time, 
participants appeared to look at such frictions with more nuance. Dolan et al6 in the United 
Kingdom reported on differences between people’s views at the start of a first series of focus 
group discussions involving randomly chosen patients who attended their general practitioner, 
and at the end of a second series, after they had had an opportunity to deliberate with others. 
Respondents varied in their willingness to accept co-payments for medical treatments by 
smokers, heavy drinkers, and illegal drug users; after discussion, several of them had changed 
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their opinion and looked differently at the issue of solidarity versus discrimination. Stronks et al21 
explored the arguments underlying the choices of patients, the public, general practitioners, 
specialists, and health insurers regarding healthcare priorities. The various panels emphasized 
personal responsibility for healthy behavior and chose for co-payments. This shows that informed 
citizens across different studies imagine a role for one’s personal responsibility in reimbursement 
decisions, especially in relation to the lifestyle criterion. 
The United Kingdom’s Citizens Council, which is a panel of 30 people who largely reflect the 
country’s demographic characteristics, regularly provides the National Institute for Health and 
Clinical Evidence with a public perspective on overarching moral and ethical issues that the 
National Institute for Health and Clinical Evidence needs to take account of when producing 
guidance.22 The Council’s recommendations include considerations such as patient safety, rule 
of rescue, and health inequalities, which are similar to the criteria identified by our Citizen Forum. 
Previous studies on citizen involvement in decisions around healthcare benefits packages have 
been reported in Belgium,23-25 Canada,26 Cyprus,27 Greece,28 and Switzerland.29 They have shown 
that citizen consultation offers a feasible approach to involving the public in setting healthcare 
priorities and that participants to a certain extent change their views on complex matters if given 
the opportunity to acquire new insights as part of the consultation and deliberation process. 
Although the underlying values are similar across countries, the specific criteria that participants 
identify as important for healthcare priority setting vary from one country to another, partly 
because of different healthcare systems and cultural contexts. 
The Citizen Forum had its limitations. Although we carefully selected participants, case studies, 
and experts—taking into account the findings from a systematic review of citizens’ juries in 
health policy decision making30—it is conceivable that different selections would have resulted 
in somewhat different lines of argumentation. Our Citizen Forum was a one-off event that would 
benefit from replication, so as to corroborate the findings. Clearly, because preferences and 
values are context specific, the results from this study cannot be transferred to other settings. 
Further studies are required to shed light on the extent to which the depth of deliberation and 
the eventual results of a citizen panel depend on prior knowledge and experience of the panel 
members and how participation in a citizen forum actually induces changes in a participant’s 
opinions and preferences. Relevant questions are, for example, how can such changes be 
achieved through other forms of informed deliberations? What are the essential ingredients of 
such processes? How can the above changes be achieved in the society at large?
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POLICY IMPLICATIONS: SCENARIOS FOR THE INVOLVEMENT OF CITIZENS 
This Citizen Forum has shown its potential for meaningful public accountability. Nevertheless, 
public support for choices in healthcare is not automatic. It requires an investment, which could 
take the form of 3 types of action. 
(1)  Take the 16 inclusion/exclusion criteria into account when taking health insurance benefits 
package decisions. 
The Citizen Forum supports the standard set of 4 criteria that ZiNL uses in its assessment 
framework (necessity, efficacy, costeffectiveness, and feasibility).17 The 12 additional criteria, 
most of which are mentioned in that framework, would need to be taken into consideration 
more explicitly. They include lifestyle, age, prevention, and whether a particular condition can 
be seen as a normal part of life and the aging process. ZiNL could take them into account more 
systematically in developing its recommendations to the Minister of Health. In its future advice, 
ZiNL could show how the results of this Citizen Forum have been taken on board. 
(2)  Ensure high-quality deliberation and transparency in reporting. 
The quality of deliberation is crucial for informed opinions and balanced decisions. Although the 
appraisal reports produced by ZiNL are available on the Internet and the advisory committee 
meetings are open to the public, ZiNL could further develop the quality of its consultations and 
deliberations as well as refine its reporting. Highlighting all the arguments considered and how 
they were weighed before arriving at final inclusion/exclusion advice would add nuance and may 
help increase the general public’s understanding. In addition, ZiNL might want to embark on a 
broad public debate about the composition of the benefits package of basic health insurance, 
or—more generally—on choices in the Dutch healthcare system. Parliamentarians could take 
advantage of an informed and more nuanced debate that allows space for the entire spectrum 
of criteria and arguments before endorsing or rejecting reimbursement decisions. 
(3)  Involve citizens in health insurance benefits package decisions as a matter of routine.
Although this study suggests that citizen participation is of limited value for informing specific 
coverage decisions, it may be more meaningful to use it for periodically assessing whether the 
current practice of developing recommendations for the Minister, including the criteria considered 
in the process, is still appropriate or for gauging citizen views around specific thematic issues, for 
example, on the use of proportional shortfall as a criterion for determining the cost-effectiveness 
threshold in reimbursement decisions (as in the current guidelines). 
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Overall, this study has demonstrated the potential value of organizing public deliberation on 
priority setting in healthcare for the legitimacy of the overall process and its outcomes. Continued 
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Appendix A: Constitutional framework: domain, criteria and considerations for inclusion/
exclusion of treatments in the basic health insurance benefits package 1
A. Domain Issue Eligible case studies
Does society consider the underlying 
problem as an illness? 
Which conditions are part of the 
health care domain (versus the 
wider domain of welfare)? E.g. 
infertility treatment, cosmetic surgery, 
bereavement.
Dental braces for youngster; 
IVF; Cosmetic surgery (nose, 
ear, breast); Viagra for erectile 
dysfunction
Does treatment belong to the medical or 
welfare domain?
Which treatments belong to the care 
domain?
COPD home treatment; 
Compensation of home-based 




a.  Severity of the condition (in physical, 
psychological, social terms)
Do treatments for conditions with 
a low burden of disease need to 
be reimbursed? Do we attach extra 
value to treatment of conditions with 
a high burden of disease?
Dental braces for youngsters ; 
Vitamin supplements; Orphan 
diseases (Pompe disease; aHUS); 
IVF; Cosmetic surgery; Viagra for 
erectile dysfunction; Heart burn 
(pyrosis)  
b. Financial capacity of the individual Do low-cost treatments (or those 
with predictable cost) need to be 
reimbursed, e.g. out of solidarity with 
those who will not use them unless 
they are reimbursed?
Vitamin supplements; Heart burn 
(pyrosis)
Effectiveness of treatment Are life-extending treatments and 
those that improve the quality of 
one’s life equally important? Can 
reimbursement be considered even if 
the efficacy of treatment has not (yet) 
been proven? 
Treatment of Alzheimer’s disease; 
psychotherapy
Cost-effectiveness Does medication for orphan 
conditions (rare conditions, very 
expensive treatment) that has an 
unfavourable cost-effectiveness ratio 
qualify for reimbursement?
Orphan diseases
Feasibility Should total budget impact be taken 
into account in reimbursement 
decisions? 
Vitamin supplements
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C. Additional considerations 
Alleviating the cost-effectiveness requirement
Condition/illness has negative societal 
side-effects 
Do we attach extra value to treatment 
of conditions that have undesirable 
societal side-effects?
Psychotherapy; Contraception
Condition impacts on the patient’s 
immediate environment 
Do we attach extra value to 
treatment of conditions that impact 
on the patient’s immediate social 
environment?
COPD home treatment; 
Compensation of home-based 
care volunteers for people with 
Alzheimer’s disease
No alternative treatment available Do we attach extra value to 
treatments of conditions for which 
no alternative treatment is available? 
What if the efficacy of treatment has 
not convincingly been proven?
Treatment of Alzheimer’s disease
Rarity of condition Do we want to be more lenient for 
rare (orphan) conditions for which it 
is more challenging to provide proof 
of treatment efficacy?
Orphan diseases (Pompe disease, 
aHUS)
Dignity Do we attach extra value to 
treatments that do not negatively 
affect patients’ dignity.
Treatment of Alzheimer’s disease
Equal access Do we attach extra value to 
treatments that enhance equal 
access? 
Acuteness of condition (rule of rescue) Do we attach extra value to treatment 
of patients with acute conditions?
Orphan diseases (Pompe disease, 
aHUS)
Functioning in society Do we attach extra value to 
treatments that enhance people’s 
functioning in society?
ADHD psychotherapy
Vulnerability Do we attach extra value to treatment 
of the prevention of conditions that 
are more frequent among vulnerable 
groups (e.g. low SES, children)?
Bariatric surgery and prevention of 
obesity; Smoking cessation
Prospect of more favourable cost-
effectiveness: 
a.   Stricter criteria for starting and 
ending treatment 
Do we attach extra value to 
treatments that have a chance to 
become more cost-effective than 
they are at present?
b.   Price negotiations with 
manufacturer




Aggravating the cost-effectiveness requirement 
Own responsibility Do we attach less value to treatments 
for conditions for which people 
carry responsibility themselves? 
Or for conditions caused by risky 
behaviour?
Bariatric surgery and prevention 
of obesity; Smoking cessation; 
Treatment of sports trauma; Liver 
cirrhosis; Pre-exposure prophylaxis 
(PrEP)
Risk of overconsumption (moral 
hazard)
Do we attach less value to treatments 
that could be used more than 
at present (and probably more 
than necessary) once they are 
reimbursed?
Dental braces; Vitamin supplements
Increase in consumption of other forms 
of treatment or care 
Do we attach less value to treatments 
that lead to more frequent use and 
higher costs of other forms of care?
Total body scan
Self-diagnosis Do we attach less value to treatment 
of conditions that are not medically 
confirmed by a qualified physician?
Vitamin supplements; Viagra for 
erectile dysfunction
Other possible arguments
Age, sex, ethnicity, sexual orientation, 
socio-economic status, residence 
Does age matter? Does sex or sexual 
orientation matter? Does SES or 
residence matter?
Treatment of Alzheimer’s disease
1 Sources: Kleinhout-Vliek et al. (2017); Zorginstituut Nederland (2017)
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Appendix B:  Programme of the Citizen Forum ‘Choices in health care’
First weekend
Day 1 Welcome, introductions, explanation of aim and working methods; announcement of house rules.
Brief presentation of the Dutch health care system and the basic health insurance benefits package.
Case study #1: Dental braces for children.
- 10 min introduction in plenary by moderator; viewing of a short explanatory film; 
- participants working individually, indicating their preference in favour of or against inclusion of 
treatment in the benefits package and listing their arguments on post-its; 
- opportunity to ask questions for clarification in plenary 
- breakout sessions (4 groups; 6 pp per group) for small group deliberations;
- plenary: sharing of viewpoints and arguments in favour and against inclusion of treatment in the basic 
health insurance benefits package.
Case study #2: Alzheimer’s disease.
Similar procedure: participants working individually after introduction & explanatory film; breakout sessions 
in 4 groups (different composition); followed by plenary session for sharing of viewpoints and arguments.
Day 2 Welcome, brief review of Day 1 proceedings.
Case study #3: Heart burn.
Similar procedure as for case studies #1 and #2.
Case study #4: Treatment of aHUS.
Similar procedure as for earlier case studies.
Second weekend
Day 3 Review of Proceedings of 1st weekend; feedback from participants; expectations.
Case study #5: Obesity.
Similar procedure. 
Participants questioning the expert in Ethics (plenary session; free interaction).
Case study #6: ADHD among children.
Different procedure: after individual period for reflection and listing of arguments, with participants chose to 
join one of two groups in the plenary session: proponents and opponents, facing each other and trying to 
convince each other. 
Day 4 Participants questioning the expert in Economics (plenary session; free interaction)
Case study #7: Hip prosthesis for elderly people.
Procedure as in earlier case studies.
Case study #8: Total body scan.
Procedure as in earlier case studies.
Third weekend
Day 5 Review of Proceedings of 2st weekend; feedback from participants; expectations.
Prioritising cases studies in breakout sessions: why include or exclude from basic health insurance?
Free interaction with third expert: expert in health technology appraisal, former member of the ZiNL advisory 
committee (plenary session).
Breakout session: appraising narrative text & quotes on identified inclusion/exclusion criteria .
Breakout session: selecting elements for inclusion in the Manifesto.
Breakout session: appraising narrative text & quotes on dilemmas.
Evening Rapporteurs reviewing, systematising and selecting statements and quotes on inclusion/exclusion criteria 
and dilemmas – in preparation for the final day.
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Day 6 Plenary session: final review of draft narrative text on inclusion/exclusion criteria and dilemmas.
Individual pitches, formulating viewpoints to build ‘argumentation clouds’ (in plenary).
Participants interviewing each other (in pairs; recorded by themselves on camera), addressing any of the 
following points:
- What was the most important insight that you have acquired?
- How serious have you taken your participation in the citizen forum?
- Did you feel free to express yourself?
What is your opinion about the general atmosphere during the citizen forum?
Repeat of the individual Q-sort exercise.
Oral process evaluation in plenary. 
Collective viewing of video recorded interviews. 
Next steps and Closure.
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A deliberative Citizen Forum ‘Choices in healthcare’ was held in the Netherlands to obtain insight 
into the criteria informed citizens would propose for the public reimbursement of healthcare. 
During 3 weekends, 24 citizens participated in evidence-informed deliberation on the basis 
of 8 case studies. The aim of this study was to assess how the opinions of 8 participants in 
the deliberative Citizens Forum changed and if so, why participants themselves believe their 
opinions have changed, whether participation influenced their perceived reasonableness of 
other participants in the forum and whether it influenced their opinions about involvement of 
citizens in decision-making. 
Methods
Semi-structured interviews were held with 8 participants before and after their participation in the 
Citizen Forum. Using the method of reconstructing interpretive frames opinions about the public 
reimbursement of healthcare were reconstructed. 
Results
Participants’ opinions changed over time; they became more aware of the complexity of 
decision-making and came to accept that there are limits to the available resources and accept 
cost as a criterion for reimbursement decision making. Participants report that exchanging 
arguments and personal experiences with other participants made them change their initial 
opinions. Participants ascribed increases in the perceived reasonableness of other participants’ 
opinions to feelings of group-bonding and becoming more familiar with each other’s personal 
circumstances. Participants further believe that citizens represent an additional opinion to that of 
other stakeholders and believe their opinions should be considered in relation to those of other 
stakeholders, given they are provided with opportunities for critical discussion. 
Conclusion
Organized deliberation should allow for the exchange of arguments and the sharing of personal 
experiences which is linked to learning. On the one hand this is reflected in the uptake of 
new arguments and on the other hand in the revision, specification or expansion of personal 
argumentation. Providing opportunities for critical deliberation is key to prevent citizens from 
adhering to initial emotional reactions that remain unchallenged and which may no longer be 
supported after deliberation.




Implications for policy makers 
 •  Policy-makers who wish to involve uninformed citizens in benefit package design 
should allow for deliberation – we show this influences participants’ opinions about the 
reimbursement of healthcare. 
 •  Such deliberation should allow the exchange of arguments and sharing of personal 
experiences – we show this is linked to learning. 
 •  Such deliberation should allow opportunities for critical discussion – we show this is key for 
involvement. 
Implications for the public 
The outcomes of this study demonstrate that uninformed citizens are both willing and able to 
participate in difficult discussions about the public reimbursement of healthcare. If uniformed 
citizens are provided opportunities to deliberate, they learn from each other and are prepared 
to revise their first reactions which may be mainly guided by emotions. This learning is reflected 
in both the uptake of new arguments and the revision, specification or expansion of personal 
argumentation. Organized deliberation should allow for the exchange of arguments and the 




In the Netherlands, the minister of Health, Welfare and Sport decides about the reimbursement 
of health services and their subsequent uptake into the Dutch national health insurance 
scheme. The Dutch National Health Care Institute (ZiNL) advises the minister by assessing 
health services on 4 criteria (effectiveness, cost-effectiveness, necessity, feasibility) and further 
appraises the health service on other identified criteria throughout their recommendation 
process.1 Stakeholders, including citizens, are provided opportunities to inform this process 
by sharing their views during public appraisal meetings1 although citizens are generally not 
present. Nevertheless, negative reimbursement recommendations by ZiNL, or final decisions 
by the minister, frequently attract public criticism. At the same time, the Dutch government is 
being confronted with policy-makers and scholars who caution them against budget increases 
in healthcare that cannot be sustained.2 
The potential value of organizing public deliberation to achieve a better alignment between 
health policy decisions and informed perspectives from the public is increasingly receiving 
attention.3-11 Providing the public with opportunities for deliberation to inform policy-making is 
considered more legitimate as this can make policies more responsive to public values and 
can increase its transparency.5,12 Moreover, previous studies show that providing opportunities 
for deliberation tends to influence opinions to some extent,4,13-28 suggesting participants’ initial 
opinions on complex topics like health care are open to change and may differ from participants’ 
informed opinions. 
It has long been argued that deliberative methods may improve the quality of uninformed 
opinions on political and social issues.29 Through practical reasoning participants deepen their 
understanding of their own preferences and those of others.26 They may replace uninformed 
opinions by views that are more rational, better supported by arguments and perhaps more 
consistent with their overall ‘belief system.’30 Opinions may become ‘enlightened’ as a result of 
deliberation, reflected by pre-deliberative opinions being ‘updated’ or revised based on ‘new 
information,’ which can be anything from facts to arguments.27 In the end, both the direction and 
the strength of individual opinions may change, albeit selectively depending on the quality and 
diversity of the information (or communication) as well as participants’ willingness to keep an open 
mind.25-27 Moreover, engaging in democratic deliberation may improve the mutual understanding 
among participants,26 or in other words the ‘political tolerance’ of other participants’ opinions or 
their ‘perceived reasonableness.’ 
This does not mean that opinion change necessarily results from reasoned processes of 
deliberation.25 Opinion change may result from harmful group dynamics, eg, if participants lack 
equal voice they may assimilate to the opinion of more effective participants.25 On the other 
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hand, knowledge and attitudes developed before taking part in deliberations may decrease 
people’s willingness to consider diverging information and arguments, resulting in reluctance to 
opinion change.25
Multiple deliberative methods have been developed that can be used to elicit informed public 
opinions while taking into account well-known aspects of group dynamics, such as group 
dominance, groupthink and addressing unequal power. These methods differ in their structure, 
the public involved and their link to actual policy processes.3,11 Minimal requirements for the 
robustness and reliability of deliberative processes have been proposed and include (i) the 
provision of balanced factual information to participants, (ii) the inclusion of a diverse range 
of potentially conflicting perspectives, including minority and marginal perspectives, and (iii) 
the creation of opportunities for open discussion among participants to challenge and test 
competing claims.31 
During 3 weekends in the fall of 2017 (October–November), the deliberative Citizen Forum 
‘Choices in healthcare’ was held in the Netherlands. The objective of the Citizen Forum was 
to obtain insight into citizens’ informed preferences and identify criteria they would propose for 
decisions pertaining to the composition of the benefits package.32,33 The aim of this qualitative 
study was to provide insight into how the opinions of individual participants in a deliberative 
citizens forum change and if so, why participants themselves believe their opinions have 
changed. In addition, this study aimed to provide insight into whether participation influenced 
their perceived reasonableness of other participants, and their opinions about the involvement of 
citizens in healthcare decision-making. With this study we further intend to contribute evidence 
to the existing literature on opinion change and the potential of applying deliberative methods to 
inform choices in healthcare.
METHODS 
Eligibility and Recruitment of Participants 
Participants in the Citizen Forum were selected from an existing panel compiled by Motivaction, 
a research and consultancy agency specialized in the relations between values, motives, lifestyle 
and behavior. Participants were recruited for diversity at 2 aspects, to ensure as much as possible 
the representation of diverse views held by Dutch citizens.34 The first aspect of diversity relates 
to participants’ mentality groups (ie, attitudes to life) that represent shared aspirations regarding 
work, leisure and politics, and show similar lifestyle and consumption patterns. The segmentation 
into 8 mentality groups is based on value orientation (eg, traditional, modern, postmodern) and 
status seeking (ie, low, middle, high).35 Three participants were selected from each mentality 
group (n=24). The second aspect of diversity relates to socio-demographic characteristics, 
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ensuring overall diverse recruitment according to age (18+), gender, geographical location and 
education level. Initial recruitment for participation in the Citizen Forum was done through an 
email invitation, which only indicated that the topic of deliberation would concern a social issue. 
Subsequently, for the interview study, one respondent from each mentality group was randomly 
selected to be interviewed (n=8), both before and after their participation in the forum. Each 
preselected participant for this study was subsequently invited face-to-face during an introductory 
meeting about the forum, 2 weeks prior to the first weekend of the forum, and all agreed – 
some afterwards by email having requested some time to decide. Participants in the forum 
received a financial incentive for their participation (a flat fee), as well as free accommodation (2 
nights during each of the 3 weekends) and free meals. Those who were interviewed received an 
additional financial incentive (also a flat fee).
The Citizen Forum – Topic and Structure of Deliberative Sessions 
Two moderators guided deliberations on 8 selected case studies, which included preventive, 
diagnostic and curative services for a range of conditions: dental (orthodontic) braces for 
youngsters, Alzheimer’s disease, heart burn (pyrosis), attention-deficit hyperactivity disorder 
among children, atypical hemolytic uremic syndrome (a rare disease), total body scan, obesity, 
and hip prosthesis for elderly people. Deliberations took place in both small groups and plenary 
sessions. Participants received descriptions of the clinical manifestations and treatment options 
for each of the case studies. This information was validated by experts and presented in a neutral 
manner to avoid any bias where possible. The deliberations around each case typically lasted 
2 to 3 hours, culminating in a listing of arguments in favor and against public reimbursement 
by participants. Participants further interacted in 3 separate sessions with experts: an ethicist, a 
health economist, and a specialist in health technology appraisal who was also a former member 
of ZiNL’s appraisal committee that advises the Minister of Health about reimbursement decisions. 
These interactions, solely based on questions put forward by the participants themselves, served 
to share personal experiences and deepen their understanding of dilemmas. A detailed agenda 
of the 3 weekends is listed in Supplementary file 1. More detailed descriptions of the methods, 
case studies and results of the Citizen Forum are presented elsewhere.32,33
Data Collection: Semi-structured Interviews 
The semi-structured in-depth interviews were guided by a predesigned topic guide (see 
Supplementary file 2). Interviews started with a short introduction by the interviewer explaining 
the context and goals of the interview. The interviewer then continued by inquiring about the 
overall meaning of the Dutch basic benefits package to the person interviewed, followed by 
questions identifying all arguments they believe should be used to decide whether specific 
healthcare should or should not be publicly reimbursed. Finally, respondents were asked what 
they think about the involvement of citizens in healthcare decision-making. For interviews after 
the Citizen Forum the same topic guide was used with the addition of questions asking them to 
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reflect on any moments throughout the forum during which they felt their own opinions somehow 
changed and in what way. Furthermore, they were asked whether their perceived reasonableness 
of other participants’ opinions changed during their participation in the forum. Interviews were 
pilot tested with a second researcher (MT). The first round of interviews was conducted between 
the introductory meeting of the forum and its first weekend. The second round of interviews 
took place in the weeks following the final weekend. Interviews took place at the interviewees’ 
homes and were conducted by one of the authors (MJ). Participants signed informed consent 
forms. Interviews were audio recorded and lasted between 45 and 120 minutes. In 4 out of 16 
interviews, one of the interviewee’s relatives was present in the same room during the interview, 
but none of them participated or intervened in the interview process. The interviewer made notes 
and wrote down important observations directly after the interviews.
Data Analysis: Reconstructing Interpretive Frames 
Interviews were transcribed verbatim after which interpretative frames were reconstructed for 
each theme addressed by the participants. The term ‘interpretive frame’ refers to a quadruple set 
of elements that together comprise a respondent’s view about a topic, in this case concerning the 
desirability of using certain criteria in healthcare decision making: (i) a person’s context-specific 
problem definition, (ii) perceived solutions, (iii) empirical and ethical background theories, and 
(iv) normative preferences.36 Transcripts were coded, making a distinction between these 4 layers 
of interpretive frames. For each transcript 2 researchers (MJ, MT) independently reconstructed 
the interpretive frames of that interviewee in Microsoft Word. The resulting frames for each 
of the interviewees were compared and any differences discussed until settled between the 
researchers, resulting in revision of frames if necessary. Finally, interpretive frames of interviewees 
were combined together for each of the themes, while still differentiating between views held 
before and after. Individual contributions to summarized theme narratives are numbered 1–8, 
each corresponding to a particular participant, which allows insight into individual-level opinion 
changes that would be concealed in the aggregated before/after comparisons that reflect 
net opinion changes only. See Table 1 for an overview of participant characteristics. Finally, 
summaries of change were constructed for each theme reflecting the overall observed changes 
in opinion. Replies to questions asking participants what they think about the involvement 
of citizens in decision-making and the additional questions asked only after the forum were 
extracted from interview transcripts, combined and summarized as narratives for each question 
in Microsoft Word. Illustrative quotes are added in italics.
Ethical issues 
The Committee on Research Involving Human Subjects of the Radboud University Medical 




Firstly, we present an overview of participants’ characteristics in Table 1. Secondly, based on the 
analysis we identified 6 themes: costs and medical necessity, evidence of effectiveness, personal 
responsibility, lifestyle and prevention, age, financial barriers and the number of patients in need. 
For each theme, we present a short summary of the observed changes in participants’ opinions, 
followed by a more detailed description of their opinions before and after deliberation. Thirdly, 
self-reported reasons for changes in opinions and changes in the perceived reasonableness of 
other participants’ opinions are presented. Finally, participants’ opinions about the involvement 
of citizens in decision-making are presented.
Table 1. Characteristics of interviewed participants (n=8).
Participant 
ID:







1 30 f West University Social climber
2 24 m Middle College Cosmopolitan
3 40 m North Vocational training Traditional
4 70 m South College Modern mainstream
5 30 f South Vocational training Convenience-oriented
6 50 f Middle College New conservative
7 32 f West College Post-materialist
8 28 f South University Post-modern hedonist
Narrative Summaries of 6 Identified Themes 
1. Costs and Medical Necessity 
Summary of change: Participants initially defined their problem as that the government does 
not reimburse all basic medical care. Afterwards, participants redefined the problem as that the 
government is not able to reimburse all basic medical care because of a limited health budget. 
It became acceptable to consider the financial feasibility of reimbursements. 
Before: Several participants find it problematic that not all basic medical care is reimbursed (ID 
1, 3, 4, 5, 7, 8). They define basic medical care as health services that are needed for ‘illnesses 
or conditions that simply happen to a person’ and help people to restore their functioning or 
contribute to the quality of their lives. Participants are of the opinion that the government bases 
its decisions disproportionately on costs and insufficiently on quality of life considerations (ID 
1, 4, 5, 7). Politicians prefer to reimburse luxury care, such as cosmetic treatments, instead of 
medically necessary care, (ID 3, 4, 5, 7) and appear unaware of the basic needs of the population 
(ID 3, 4). Some participants believe that the available healthcare budget is sufficient to fund all 
basic medical care and, if not, that the budget can be increased by lowering other government 
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budgets. They consider health as the number one priority (ID 1, 5, 7) and find it inappropriate to 
consider costs if a patient’s life is at risk (ID 5, 8). 
After: All 8 participants find it problematic that not all basic medical care can be reimbursed 
within the healthcare budget, even when healthcare budgets are increased in the future (ID 1, 
5, 8). One participant felt that the quality of care is at risk if not the right reimbursement choices 
are made under budget constraints (ID 7). Simple and clear limits should be set to which care 
is reimbursed and which care is not (ID 7). Most participants state that health services for life 
threatening conditions should always be reimbursed (ID 2, 3, 5, 6, 8) and costs should in principle 
not preclude health, though some believe that the best decisions are made by considering both 
medical necessity and financial feasibility (ID 1, 2, 5). In line with this reasoning, they consider 
calculating the cost per quality adjusted life year (cost/QALY [quality-adjusted life year]) an 
appropriate tool for making reimbursement decisions, with a higher medical necessity justifying 
a higher cost/QALY (ID 2, 5). They do not consider cosmetic treatments as medically necessary 
care (ID 1, 2, 3, 6, 7) and one participant believed costs can be significantly reduced if the 
government is more strict in reimbursing cosmetic treatments (ID 7). Some believe the minister 
should negotiate drug prices with pharmaceutical companies (ID 4, 6), preferably in cooperation 
with other European Union member states (ID 4) and reject reimbursement in case drugs are too 
expensive (ID 6). Ideally the prices of health services are strongly restricted (ID 5). 
  “Choices have to be made, unfortunately, otherwise you run short of funding for other forms of 
care. Before participating I always used to say “you should help everyone”, and I still believe 
we should, but sometimes you just can’t, because there is not enough money to do so” (ID 5).
2. Evidence of Effectiveness 
Summary of change: New arguments in favor of requiring evidence of effectiveness emerged, 
namely: the potential to save costs by not reimbursing ineffective care and protecting people 
from being provided with false hope. Claims of doctors and patients that a health service works 
were considered sufficient to meet this demand for evidence. 
Before: Some participants believe health services qualify for public reimbursement if there 
is evidence of effectiveness (ID 1, 5) or a visible and measurable effect (ID 3). If evidence of 
effectiveness is lacking and the condition is not life threatening the health service should not be 
reimbursed so that money can be spent on services that are proven to be effective or lifesaving 
(ID 3, 5). Health services for life threatening conditions should always be reimbursed regardless 
of evidence (ID 3, 5, 8). Reimbursing expensive health services with limited effects is considered 
a waste of public funding (ID 3, 4, 7). One participant claims scientific evidence of effectiveness 
is not necessary to justify reimbursement: it would be sufficient if patients report they benefit from 
a health service and if most citizens have positive attitudes towards its use (ID 7). 
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After: Four participants state that in addition to evidence of effectiveness, the claims of doctors or 
patients that a particular health service might work already justifies reimbursement (ID 1, 2, 5, 8), 
with one participant suggesting that one should do everything possible to improve someone’s 
health (ID 8). Treatments for life threatening conditions should always be reimbursed and if a 
condition is not life threatening then there should be at least ‘50% evidence of effectiveness’ (ID 
5). Another holds the opinion that at least a visible and measurable effect should be present (ID 
3). One participant explains that requiring evidence of effectiveness protects people from being 
provided with false hope in ineffective treatments (ID 6). One participant became explicit about 
the desirability of not reimbursing technologies that lack evidence of effectiveness to save costs 
(ID 7). 
  “If 2 treatments for the same condition can potentially be reimbursed, and a choice has to 
be made between them, scientific evidence should be decisive. However, due to personal 
stories from other participants in the forum, I now feel that whenever this is not the case it is 
also sufficient if doctors are of the opinion that it works” (ID 1).
3. Personal Responsibility, Lifestyle and Prevention 
Summary of change: Several participants proposed that lifestyle support programs should be 
reimbursed to provide patients a chance to show they can take responsibility for their own health, 
while explicitly adding that people should remain free to make their own choices in life and 
should not be belittled. 
Before: Participants claim health services should not be reimbursed if their need is the result of 
taking calculated risks (ID 1, 2, 3, 5) or immoral behavior (ID 4). Making people aware of their 
lifestyle should be promoted by means of reimbursing prevention programmes, which is believed 
to be cost saving (ID 4) and able to prevent worse longterm outcomes (ID 8). The continuation of 
reimbursement of certain health services should become dependent on the patients willingness 
to make lifestyle changes (ID 4). Certain participants were cautious in restricting reimbursement 
on the basis of personal responsibility, as there are usually underlying causes for specific 
lifestyles (ID 5, 7, 8). In addition, 2 participants believed some citizens are simply not capable of 
taking their responsibility, thereby justifying the reimbursement of programs that support them in 
taking responsibility (ID 6, 7). 
After: Some participants claimed health services should not be reimbursed if their need is a result 
of individuals taking calculated health-related risks (ID 1, 3, 4). Those taking calculated risks 
may seek other funding opportunities such as crowdfunding or payment in terms (ID 3). One 
participant believed prevention programs should be reimbursed if there is evidence that they are 
cost-saving (ID 4). Two participants claimed a patient must take his/her personal responsibility 
to improve their respective condition before the needed technology will be reimbursed (ID 2, 8) 
– although adding technologies should always be reimbursed in case of medical necessity (ID 
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2). Others instead claimed support programs to help patients change their lifestyle should be 
reimbursed to give people a chance to show they can actually take their responsibility (ID 4, 5, 
6, 7, 8). However, ideally patients pay for healthcare themselves if a technology is needed as a 
result of their own behavior (ID 6). Two participants believed there are always underlying causes, 
explaining someone’s behavior and stressed we should be cautious to judge these people (ID 
5, 8). Also, people should not be belittled and remain free to make their own choices (ID 5). One 
participant added that the use of personal responsibility in decision-making is only warranted as 
a last resort under budget constraints (ID 8).
4. Age 
Summary of change: The argumentation against using age as a decision criterium was further 
specified afterwards by explicitly linking it to questions of equal access, the appropriateness of 
using age as a prediction factor and questioning the discriminatory nature of cost-effectiveness. 
Arguments in favour of using age emerged too, claiming there is relatively less benefit gained at 
higher costs when treating older people compared to younger people. 
Before: Three participants consider the use of age in reimbursement decision-making as 
discrimination or a violation of equality (ID 1, 6, 8), even in the case of a limited budget (ID 1). 
One participant points out that treatment at old age should not automatically be reimbursed 
because the chance of success of treatment is dependent on age (ID 4). 
After: Participants believe personal characteristics should not be part of the decision criteria 
(ID 1, 2, 5, 8). Everyone should have equal access to care (ID 2) and as someone’s life may 
end anytime, age is not useful as a predictive factor (ID 5). One participant claimed the use of 
methods that discriminate against elderly people, like the cost-per-QALY method, is unjustified 
on this basis (ID 1). Another claimed only increased risks associated with the use of health 
services at an older age justify specifically not reimbursing health services at an older age (ID 
7). According to one participant, the more restrictive reimbursement of health services for older 
people can be justified by the need to reduce total healthcare costs because (i) care for elderly 
people is more expensive, (ii) elderly people in general enjoy a lower quality of life and (iii) they 
are less likely to benefit long-term from treatments (ID 3). If a choice must be made between 
younger and older people, younger people should have priority (ID 4).
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5. Financial Barriers 
Summary of change: Paying out-of-pocket for treatments became acceptable for treatments 
that are relatively cheap and at the same time used by many, provided that high costs at the 
individual level due to adding up of costs are prevented. Special concern for those with the 
lowest incomes shifted towards concern for those with incomes just above modal, for whom it 
was believed support is lacking the most. 
Before: Out-of-pocket costs for healthcare are perceived as extremely high (ID 6). Two participants 
argue it is unacceptable that costs prevent people from timely seeking care (ID 1, 5) – which in 
turn negatively affects the economy (ID 1). One participant stressed the need to remove financial 
barriers to visit the general practitioner, arguing it is important to discover diseases as early as 
possible (ID 3). Two participants stressed the need for solidarity and ensuring accessibility of 
care for those who are unable to pay out-of-pocket (ID 7, 8). Several participants believed it 
would be fair to make richer citizens pay relatively more compared to poorer citizens to abolish 
costs at the point of care (ID 5, 6, 8) with one claiming it would be preferable to have everyone 
pay a bit more (ID 1). On the other hand, one participant argued out-of-pocket contributions are 
sometimes preferable as this motivates people to carefully balance if they need the technology 
in the first place (ID 4).
After: Four participants believed that if a treatment is cheap, used by many patients and costs 
are acceptable to pay outof-pocket, the treatment should not be reimbursed (ID 5, 6, 7, 8), with 
the caveat that it should not result in high costs at the individual level due to adding up of costs 
of different treatments (ID 5, 6). Three participants stressed the benefits package should be 
based on solidarity and equality and that this implies that costs are reimbursed for those unable 
to pay out-of-pocket (ID 1, 3, 4). It is further believed that people with an income just above 
modal experience the largest consequences of out-of-pocket payments, while for those who are 
poor there is all sorts of support available (ID 4). Especially financial barriers to visiting a general 
practitioner and hospital care should be removed (ID 4).
6. Number of Patients in Need 
Summary of change: Before, participants argued that only frequently used healthcare should be 
reimbursed, or otherwise paid for via crowd-funding, but after the Citizen Forum it is considered 
inappropriateness to burden people with the task of raising funds themselves and crowd-funding 
being considered a too slow mechanism for doing so. 
Before: Participants believed that if the government has to make choices in healthcare only those 
health services should be reimbursed that are frequently used (ID 2, 7). Although not providing 
less frequently used health services is problematic in case citizens are not able to manage their 
health state by themselves (ID 7). For (other) technologies that only a few people use, including 
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expensive orphan-drugs, crowdfunding can be used to support financial access (ID 2, 7). If 
someone is unsuccessful in raising private funds it is argued one should learn to accept this (ID 
7). 
After: One participant now specifically considered it incorrect to only reimburse health services 
if they are frequently used on the basis of 2 arguments: (i) it is inappropriate to burden people 
with the responsibility of raising funds to improve their quality of life, and (ii) crowd-funding is to 
slow as a mechanism to raise funds (ID 2). Nevertheless, another participant mentioned that the 
basic benefits package is there in principle to reimburse care that is often used (ID 5). As we as 
a community pay for the reimbursement of care, we should all benefit from it (ID 5). Infrequently 
used care, such as expensive treatments for orphan diseases, would ideally be reimbursed but 
it is not preferable to reimburse all treatments in this category at the cost of more frequently used 
care (ID 5, 8). 
  “… should you then say, because only few people use a specific health service, that it 
should not be included in the benefits package and people should just take care of funding 
themselves?” (ID 2).
Self-reported Reasons for Changes in Opinions 
Participants claim their opinions changed after participating in the Citizen Forum, albeit in varying 
degrees. Afterwards, participants report that they have become more aware of the complexity 
of making reimbursement decisions; for every argument in favor of public reimbursement an 
argument against can be found. Public reimbursement has become less black or white. Three 
participants describe their overall change in opinions as achieving a better balance between 
more ‘intuitive emotional responses’ and more ‘rational responses’ (ID 5, 6, 8). 
  “Yes, you can’t help everyone unfortunately. That is my ratio speaking, but my feelings tell me 
‘you should help everyone.’ That is the biggest change. I still believe you should help everyone 
but that is not realistic” (ID 5). 
Several participants claim their opinions changed due to the continuous engagement in discussions 
about concrete cases and critically questioning each other’s arguments (ID 2, 3, 4, 5, 6, 7, 8), or 
being confronted with new arguments (ID 3, 4). One expressed the feeling that being provided with 
more time to deliberate would result in even further changes in opinions (ID 8). 
  “The detailed discussions during the citizen forum make that you become better able to weigh 
things and that you can better motivate your choices” (ID 8). 
  “The arguments of participants have contributed. […] Just like during one specific case when 
someone said ‘I’m not doing it’ which makes you think and become aware of the other side of 
the discussion (ID 4).” 
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For some participants the weight of certain arguments changed after being confronted with 
personal experiences of other participants (ID 1, 2, 7). 
Finally, some participants claim the interaction with experts has contributed to their change (ID 
1, 2, 5, 6, 8). Their contribution is linked most clearly to self-reported changes in reasoning about 
the role of costs and financial sustainability in relation to reimbursement decision-making (ID 1, 
2, 5, 6, 8). Expert knowledge is perceived as trustworthy.
Self-reported Changes in the Perceived Reasonableness of Other Participants’ 
Opinions
Participants unanimously report to perceive certain opinions held by other participants as 
relatively more reasonable after their participation in the Citizen Forum. 
  “…I also find myself thinking “OK, if you look at it from that perspective I can understand where 
you are coming from”. Even though I did not agree with everything, but you do get a better 
appreciation of each other’s arguments” (ID 7). 
Some participants explicitly mention this increase in perceived reasonableness does not apply 
to what participants describe as ‘extreme opinions’ (ID 2, 3, 5, 7, 8). 
  “… one person was always against reimbursement in a very stubborn way and then I thought 
to myself “Gosh, that person just doesn’t think any more than he has to” (ID 7). 
Finally, some participants ascribe part of this increase in perceived reasonableness of other 
participants’ opinions to becoming familiar with the personal life stories of other participants (ID 
2, 4, 6) and experienced group-bonding during the weekends (ID 2). 
  “In general I did come to perceive other people’s arguments as more reasonable […]. I 
believe this is the result of getting to know people better, and knowing their backgrounds. 
And, because you bond with people over time” (ID 2).
Changes in Opinions of Participants About the Involvement of Citizens in Decision-
Making
Before participation in the Citizen Forum participants claimed medical doctors should be the 
ones to decide on the reimbursement of health services (ID 1, 3, 4, 5, 6). They have medical 
knowledge (ID 1, 3, 4, 6) and know what patients can afford (ID 5), which is considered of more 
importance than the financial perspective used by the government (ID 1, 3, 4, 5, 6). Ideally, 
reimbursement decisions should result from cooperation between politicians, doctors, and other 
interest groups, such as patients and citizens (ID 2, 3, 4, 6, 7). Overall, the government should 
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listen more carefully to its citizens and better involve them in decisions (ID 2, 3, 5, 7), and that 
results of involvement should be used (ID 3, 4, 5, 8). On the other hand, 2 participants further 
felt that citizens in general do not necessarily represent the collective interest and put their 
own interests first (ID 1, 2), while adding medical doctors could best represent the collective 
perspective (ID 1). In addition, one participant raised concerns about whether medical doctors 
can also represent the perspective of healthy citizens (ID 6). Participants proposed to involve 
citizens as critical assessors of decisions (ID 2, 6), or to organize participation in the form of 
a representative Citizen Forum (ID 4, 6, 7). In addition, 2 participants considered a survey an 
inappropriate method to explore the opinions of citizens (ID 4, 8) as it is thought to have no impact 
on decision-making (ID 4). One participant claimed it is currently unclear how reimbursement 
decisions are made in the first place (ID 8). 
Afterwards, participants express the opinion that conscious decisions require the cooperation 
among politicians, as representatives of the public (ID 1, 2, 6), economists, who can decide 
on the financial feasibility (ID 1) and doctors, who have the knowledge to determine whether 
health services are basic medical care (ID 1, 2, 6). Others believe politicians (ID 4) or experts 
(ID 5, 7, 8) should take these decisions. With regard to involving citizens certain participants 
continued to express the opinion that citizens should be involved in decision-making (ID 3, 5, 7), 
while another participant now framed this as a democratic right (ID 8). On the other hand, one 
participant continued to believe medical doctors are best able to represent citizens’ interests 
from a medical perspective and better able to judge the medical necessity of treatments from a 
collective perspective, explicitly arguing against citizen participation in decision-making (ID 1). It 
was further considered necessary by participants to communicate in which way their arguments 
have been considered in decision making to improve the legitimacy of reimbursement decisions 
(ID 2, 3, 4, 6, 8). Translating decisions to citizens requires explanations about what is and what 
is not financially feasible (ID 1, 4). One participant afterwards believed one-sided reporting by 
the popular media should be addressed, as they fail to represent the argument that reimbursing 
one health service comes at the cost of no longer being able to reimburse other services (ID 4). 
Moreover, participants believe that the opinions of individual citizens should never be decisive in 
itself, rather, their arguments should be considered in relation to those of other stakeholders (ID 
2, 3, 5, 8). Afterwards, it was argued that online surveys are considered insufficient as they lack 
critical discussion (ID 2, 4, 5, 8).
DISCUSSION 
In this study we assessed how deliberation influenced participants’ opinions about choices 
regarding the composition of the benefits package by comparing their interpretive frames 
before and after the Citizen Forum. Overall, participants became more aware of the complexity 
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of decision-making and accordingly revised their opinions on how reimbursement choices 
should be made. Participants came to accept that there are limits to the available resources 
– in particular health budgets – and accept a role for costs despite several participants’ initial 
opinion that this is unacceptable. Participants report changes in their opinions are the result of 
exchanging arguments with other participants and sharing personal experiences. Increases in 
the perceived reasonableness of other participants’ opinions are ascribed to feelings of group-
bonding and becoming more familiar with each other’s personal circumstances. Participants 
further believed that citizens represent an additional opinion to that of other stakeholders and 
believe their opinions should be considered in relation to those of other stakeholders, given they 
are provided with opportunities for critical discussion. An opportunity to deliberate is considered 
a must for valuable contribution, guaranteeing that citizens not just represent their first emotional 
reaction.
 
The opinion change of individual participants was caused by new arguments that they had 
included (eg, new evidence of effectiveness), the revision of (strong) prior opinions (eg, on 
costs or medical necessity; or number of patients in need) and the specification or expansion 
of argumentation (eg, on financial barriers or personal responsibility; lifestyle and prevention). 
For certain topics opinion change went in opposite directions (eg, evidence of effectiveness) 
while for other topics the deliberation resulted in increased convergence of opinions (eg, cost 
and medical necessity). Overall, reframing of the problem for most topics came with a change 
in aggregated preferences for how these topics would need be taken into consideration in 
healthcare reimbursement decision-making. 
To our knowledge, this study is the first in the Netherlands to over time and qualitatively examine 
changes in citizens’ opinions towards the public reimbursement of health services when 
provided ample opportunity for deliberation. A second study, performed in parallel during the 
Citizen Forum, used Q-methodology to assess participants’ opinions in a quantitative way.37 
In this exercise participants were asked both before and after the citizens forum to rank-order 
a set of short written statements about the reallocation of healthcare, using a range from most 
agreeable to least agreeable. The study showed that: (i) participants’ support for prioritization in 
healthcare generally increased after participating; (ii) participants became more considerate of 
healthcare costs and (iii) cost-effectiveness emerged as a relevant criterion for setting priorities 
in healthcare. These results are in accordance with the results reported in this paper. 
Previous studies using deliberative methods to gather input from citizens on healthcare related 
issues have similarly shown that deliberation tends to influence people’s opinions.4,13-22 Due to 
much heterogeneity in context and the study methods used, a systematic comparison of the 
results of these studies is not feasible. Nevertheless, several previous studies do demonstrate 
that deliberation influences participants’ acceptance of choices in healthcare under budget 
constraints.19-21 In one specific study, aimed to test the assumption that the public will reject any 
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explicit consideration of costs in coverage policy, the authors conclude that participants who 
understood cost-effectiveness analysis, were largely open to its use, and changed their own 
funding priorities when given cost-effectiveness ratio information.22 Another study concludes that 
when working with a limited budget, participants supported the exclusion of high-cost, low-
value interventions, among others.38 Taken together with results from this study, this suggests 
that through deliberation participants may come to accept a role for costs and affordability 
considerations in decision-making. 
Although we did not explicitly test for factual knowledge gains by participants, which would be 
an indication that opinion changes are the result of individual learning and reflection (rather than 
merely of some social group dynamic), it does appear that participants have become more aware 
of the complexity of decision-making and the broader decision making context. Self-reported 
reasons for changes in opinions demonstrate that participants engage with and reflect on what 
is being said by others and how this information relates to their own opinions. This reflection is 
argued to be a critical dimension of what Himmelroos et al refer to as ‘deliberative reasoning.’25 
Other dimensions of deliberative reasoning include the referring by participants to the common 
good, and their refraining from being disrespectful towards other participants.25 Participants did 
not explicitly use the term ‘common good.’ They did refrain from being disrespectful towards 
other participants and, in fact, at least some participants expressed empathy with the personal 
life stories of other participants and hence understanding of the opinions they expressed. Both 
reflection and refraining from being disrespectful towards other participants are known to be 
strongly associated with the willingness of participants to change their opinions,25 which may 
have contributed to the opinion change observed in this study. 
Three participants of the Citizen Forum (ID 5, 6, 8) reflected on changes in their opinions as 
achieving a better balance between more ‘intuitive emotional responses’ and more ‘rational 
responses,’ with one participant feeling better able to motivate decisions not to reimburse a 
technology in spite of feeling intuitively guilty at first. This disjunction is recognized in Kahnemans 
‘theory of thinking fast, thinking slow’ which describes 2 modes of thought: “System 1” is fast, 
instinctive and emotional; “System 2” is slower, more deliberative, and more logical – with system 
1 thinking often being associated with biased views.39 It can be argued that deliberation caused 
participants to move away from their more frequently biased system 1 thinking towards more 
reasoned system 2 thinking. This raises concerns about the validity of citizens’ responses on 
health policy decision in case they are not provided with sufficient opportunities to deliberate. 
Further illustrating this point, participants came to believe surveys are not fit-forpurpose to inform 
decision-making. Surveys are believed to lack the necessary background information and 
critical discussion that is perceived as crucial by participants to prevent citizens from supporting 
positions they actually would no longer want to support after deliberation. Dolan et al mentioned 
that public’s views about setting priorities in healthcare are systematically different when they 
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have been given an opportunity to discuss the issues. Surveys that do not allow respondents 
time or opportunity for reflection may be of doubtful value.15 In a similar vein, Maxwell et al 
conclude that engagement of the public is more costly than polling but essential when opinions 
are unstable and difficult decisions must be made.14 Therefore, if health authorities seek to inform 
their decision-making process with citizens’ opinions as part of efforts to legitimize their decision-
making, it seems warranted they do so by providing citizens with deliberative opportunities. 
Our study has several strengths and limitations. The strength of this study is that it comprehensively 
captures how deliberation influences participants’ interpretive frames and thereby is able to 
illustrate the diverse changes that occur due to deliberation. This differs from more quantitative 
approaches that try to capture changes in opinions, eg, using Q-methodology. Another strength 
is the representation of diverse perspectives in this study by selecting participants from 8 different 
mentality groups. Although the interviewees were relatively young on average, this study shows 
that citizens with different backgrounds do reconsider their opinions about choices in healthcare 
reimbursement. At the same time, the sample size of 8 participants is a limitation in itself. 
Inclusion of more or other participants from the Citizen Forum might have resulted in different 
results, although the aim of this study was not to represent society at large but to provide insights 
into how opinions of participants in the Citizens Forum had changed and what had made them 
change their opinion. We believe the processes that took place are likely to be generalizable 
to larger groups of citizens if they participated in similar deliberative exercises. Furthermore, 
the preselection of participants in the Citizen Forum may have resulted in overrepresentation 
of participants who are highly motivated to engage in deliberations and more open to opinion 
change. This is in fact a limitation of any form of organized deliberation. One further limitation is 
that summaries of reconstructed interpretive frames were not sent to participants for feedback 
before and after the Citizen Forum. Although this type of respondent validation is valuable, 
we feared that participants would end up using these summaries as a personal reference 
point for staying consistent over time during the Citizen Forum. If used this way, summaries 
could become a barrier to the learning process the Citizen Forum was designed to facilitate. 
Another limitation is that participants were confronted with reallocation statements as part of 
the Q-methodology exercise before their first interview was conducted which may have already 
influenced their opinions on certain themes. Furthermore, the impact of experts on the quality 
of participants’ argumentation is influenced by and dependent on how much time participants 
were provided to ask questions to experts, who could challenge and potentially improve the 
quality of their argumentation. In addition, the selection of specific experts themselves may have 
influenced the views of participants, although experts were instructed to refrain from presenting 
their personal opinions in response to questions by participants and to present balanced views 
in their field of expertise to the best of their ability. Also, the observed learning curve may not 
just be the result of participation in the Citizen Forum. It is likely that participants learned, or 
were influenced, by factors outside the Citizen Forum that they were unable to recollect during 
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interviews, eg, exposure to news coverage, deliberations with their peers or their own private 
search for information about the subject. However, it could be argued this is part of daily life and 
therefore inherent to the application of deliberative methods that organize multiple meetings 
over time.
CONCLUSION 
The results of this study show that actively involving citizens in a deliberative Citizen Forum 
contributes to their revaluation of the complexity of decision-making and the need to make difficult 
choices, while becoming more receptive to costs as a criterion in healthcare decision-making. 
Participants believe that citizens represent an additional opinion to that of other stakeholders 
and should be involved in healthcare decision making. Organized deliberation should allow for 
the exchange of arguments and the sharing of personal experiences. On the one hand this is 
reflected in the uptake of new arguments and on the other hand in the revision, specification or 
expansion of personal argumentation. Providing opportunities for critical deliberation is key to 
prevent citizens from adhering to initial emotional reactions that remain unchallenged and which 
may no longer be supported after deliberation.
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Supplementary file 1. Programme of the Citizen Forum ‘Choices in health care’
First weekend
Day 1 Welcome, introductions, explanation of aim and working methods; announcement of house rules.
Brief presentation of the Dutch health care system and the basic health insurance benefits package.
Case study #1: Dental braces for children.
- 10 min introduction in plenary by moderator; viewing of a short explanatory film; 
- participants working individually, indicating their preference in favour of or against inclusion of 
treatment in the benefits package and listing their arguments on post-its; 
- opportunity to ask questions for clarification in plenary 
- breakout sessions (4 groups; 6 pp per group) for small group deliberations;
- plenary: sharing of viewpoints and arguments in favour and against inclusion of treatment in the basic 
health insurance benefits package.
Similar procedure is used during case studies 2-8 (with the exception of case study 6, described below): 
participants working individually after introduction & explanatory film; breakout sessions in 4 groups 
(different composition); followed by plenary session for sharing of viewpoints and arguments.
Case study #2: Alzheimer’s disease.
Day 2 Welcome, brief review of Day 1 proceedings.
Case study #3: Heart burn.
Case study #4: Treatment of atypical hemolytic uremic syndrome.
Second weekend
Day 3 Review of Proceedings of 1st weekend; feedback from participants; expectations.
Case study #5: Obesity.
Participants questioning the expert in Ethics (plenary session; free interaction).
Case study #6: Attention-deficit hyperactivity disorder among children.
Different procedure: after individual period for reflection and listing of arguments, with participants chose to 
join one of two groups in the plenary session: proponents and opponents, facing each other and trying to 
convince each other. 
Day 4 Participants questioning the expert in Economics (plenary session; free interaction)
Case study #7: Hip prosthesis for elderly people.
Case study #8: Total body scan.
Third weekend
Day 5 Review of Proceedings of 2nd weekend; feedback from participants; expectations.
Prioritising cases studies in breakout sessions: why include or exclude from basic health insurance?
Free interaction with third expert: expert in health technology appraisal, former member of the ZiNL advisory 
committee (plenary session).
Breakout session: appraising narrative text & quotes on identified inclusion/exclusion criteria.
Breakout session: selecting elements for inclusion in the Manifesto.
Breakout session: appraising narrative text & quotes on dilemmas.
Evening Rapporteurs reviewing, systematising and selecting statements and quotes on inclusion/exclusion criteria 
and dilemmas – in preparation for the final day.
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Day 6 Plenary session: final review of draft narrative text on inclusion/exclusion criteria and dilemmas.
Individual pitches, formulating viewpoints to build ‘argumentation clouds’ (in plenary).
Participants interviewing each other (in pairs; recorded by themselves on camera), addressing any of the 
following points:
- What was the most important insight that you have acquired?
- How serious have you taken your participation in the citizen forum?
- Did you feel free to express yourself?
What is your opinion about the general atmosphere during the citizen forum?
Repeat of the individual Q-sort exercise.
Oral process evaluation in plenary. 
Collective viewing of video recorded interviews. 
Next steps and Closure.
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Supplementary file 2. Interview guide:
Before the start of the interview:
 •  General introduction, explain the research goals, expected duration of the interview
 •  Informed consent, start the audio recording
Introduction:
 •  In the Netherlands, every citizen is obliged to have basic health insurance. This ensures 
citizens equal access to a so-called basic package of care. Not all the care that can 
potentially be delivered is in this basic package of care. Moreover, this package is not a 
single-time package, because new treatment options are constantly becoming available 
that can be added to the basic package, or for example, certain care included in the basic 
package may have become less relevant and the care may well be taken out of the basic 
package.
 •  Objective: We would like to ask you before the Citizens Forum about what you think are 
important considerations in determining whether or not care belongs in the basic package 
(or what you mean by valuable care) and would like to repeat this afterwards to see if your 
opinion on this has changed.
Questions:
 •  What does the basic package of care mean to you?
 •  What are your experiences with the basic package? What’s going well/not well?
 •  Perhaps you know examples of care decisions that are not (anymore) reimbursed from your 
environment or the news? What do you think about this? What do such decisions mean to 
you?
 •  What do you understand to be valuable care?
  •  What do you think are important considerations when determining whether or not care 
should be reimbursed through the basic package (whether care is valuable enough), or 
not?  
  •  What makes you think that these considerations should/should not play a role?
  •  What is important to you?
  •  Do you think the considerations you have mentioned will be well taken into account 
when the government decides? In your opinion, is there sufficient attention to such 
considerations?
 •  What do you think about making basic package decisions?
  •  Do you think choices should be made at all?
     1.  Should this choice lie with a practitioner, with policy makers or politicians?
  •  Do you have an idea of how decisions are made in practice?
  •  How do you think the management of the basic package could be improved?
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  •  Do you feel that you are involved/heard in decisions about the basic package?
     1.  How involved do you feel in decisions about the basic package?
     2.  Do you need to be better involved in decisions?
     3.  What would make you feel better involved in decisions or what could increase your 
support for decisions?  
Additional questions after the Citizen Forum:
 •  Could you reflect on whether you can recall any moments during which your opinion 
somehow changed and in what way?
 •  Could you reflect on whether your perceived reasonableness of other participants has 
changed over the course of your participation in the Citizen Forum?
End: Do you have anything else you would like to share?
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The Disease Control Priorities 3 (DCP3) project provides long-term support to Pakistan in the 
development and implementation of its UHC benefit package (UHC-BP). This paper reports 
on the priority setting process used in the project in the period 2019-2020, employing evidence 
informed deliberative processes (EDPs). The EDP framework is a tool for priority setting with 
the explicit aim to optimize the legitimacy of decision-making in the development of benefit 
packages.
Methods
We planned the six steps of the framework during two separate workshops at Radboudumc, 
the Netherlands with participants from all DCP3 Pakistan project partners (Oct 2019 and Feb 
2020), and implemented this at the country level in Pakistan in the remainder of 2020. Following 
implementation, we conducted a semi-structured online survey to collect the views of participants 
about the used process. 
Results
The implementation of EDPs concerned the installation of advisory committees (involving > 100 
members in technical working groups and a national advisory committee), definition of decision 
criteria (including effectiveness, health gain for money spent, avoidable burden of disease, 
equity, financial risk protection, budget impact, socio-economic impact and feasibility), selection 
of services for appraisal (169 in total), and assessment and appraisal (across all dimensions of 
the UHC cube) of these services. Survey respondents were generally positive on the employed 
process. 
Conclusions
The implementation of the priority setting process faced several challenges, was partly disrupted 
because of the Covid-19 endemic, but has overall contributed to the legitimacy of decision-
making by improving its quality, transparency and consistency. There were important lessons 
learned that can be beneficial for other countries designing their benefit package.  




Like many other countries around the world, Pakistan recognises health benefit package design 
as an important element in its strive for universal health coverage (UHC) and achievement 
of Sustainable Development Goal 3, Good health and well-being.1,2 The country’s long–term 
development strategy for health ‘Vision 2025’ reiterates the need for a revised service package 
that offers protection against financial hardship to individuals and communities when accessing 
health services.3 
The Disease Control Priorities 3 (DCP3) project provides long-term support to Pakistan in the 
development and implementation of its UHC benefit package (UHC-BP). DCP3 responds to the 
increasing need of low- and lower middle-income countries for technical guidance and support 
in benefit package design and in accelerating progress towards UHC.4-5 Pakistan is one of the 
first countries globally to implement the project.
The DCP3 project provides a review of evidence on cost-effective services, and a priority setting 
process is needed to translate this evidence into UHC-BP design in Pakistan. Such process deals 
with a range of requirements including the need to integrate benefit package decision-making 
with national policy and planning cycles; to take local values into account; to adapt the DCP3 
recommended services to the local reality; to contextualise DCP3 evidence on these services; 
and to develop mechanisms that carefully integrate this evidence, all within the available budget 
and prevailing health systems constraints.6  
This paper reports on the priority setting process used in the development of the UHC-BP in 
Pakistan in the period 2019-2020, employing evidence informed deliberative processes (EDPs). 
The EDP framework is a tool for priority setting with the explicit aim to optimize the legitimacy 
of benefit package decisions.6-8 Several other frameworks on priority setting are available,9-13 
and EDPs can be considered complementary because of its explicit focus on stakeholder 
participation including detailed practical guidance. 
  
The paper starts with the description of the institutional context, the operationalisation of the 
EDP framework for UHC-BP design in Pakistan, and the survey used to assess stakeholder 
satisfaction with the priority setting process (Methods section). We subsequently report on the 
EDP implementation and the survey results (Results section). We conclude by putting these 
results in a broader perspective (Discussion section). Separate papers report on the development 





The priority setting process was implemented by the Health Planning, System Strengthening 
and Information Analysis Unit (HPSIU) of the Ministry of National Health Services Regulations 
and Coordination (MNHSRC), referred to as the UHC-BP secretariat. Partners included the 
Community Health Sciences Department of Aga Khan University (AKU) and Health Services 
Academy (HSA), London School of Hygiene and Tropical Medicine (LSHTM), World Health 
Organisation (WHO) and Radboud university medical center (Radboudumc). 
Operationalisation of the framework
The EDP priority setting framework is a step-wise tool to guide policy makers in the organisation 
of their decision-making processes. We operationalised the six steps of the framework during 
two separate workshops at Radboudumc, the Netherlands with participants from all DCP3 
Pakistan project partners (Oct 2019 and Feb 2020). The resulting steps are provided in Figure 
1, in which steps A-D are realized in the present project and steps E-F are to be implemented 
in a next stage. All procedures, templates and instructions were pilot tested and trainings for 
facilitators were organised prior to implementation at the UHC-BP workshops in Islamabad, 
Pakistan (Nov 2019 and Feb 2020). 
Decision-making context
A  Installing an advisory committee
B Defining decision criteria
C Selecting services
D 1  Assessment
 2  Appraisal
E  Communication and appeal
F  Monitoring and evaluation
for every service
Figure 1. The six steps of the EDP framework*
*The EDP framework has been revised over the course of this PhD. For the most up-to-date version see Chapter 1, Figure 3.
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The rationale of using EDPs is to improve the decision process of the development of the UHC-
BP in Pakistan in terms of its quality (by taking into account all relevant stakeholder values, 
supported by evidence, and making appropriate trade-offs between them); its consistency (by 
repeatedly considering the same values); and its transparency (by being explicit on the selection 
of values and the performance of services on these values). Together, this may ultimately improve 
the legitimacy of decisions.6
Development of survey
We developed a semi-structured online survey to collect, ex-post, the views of participants about 
the used process, based on a broader Theory of Change framework produced for the project. 
The survey was structured around the topics of i) stakeholder involvement, ii) the (use of) decision 
criteria, iii) the (use of) evidence and iv) the appraisal process. For each topic, participants were 
asked to indicate to what extent they agreed with a set of statements related to that topic on a 
scale of 1 (strongly disagree) – 5 (strongly agree). The survey is provided in Annex I. 
RESULTS
Step A: The installation of advisory committees
Supported by DCP partners, the UHC-BP secretariat designed a governance structure for the 
UHC-BP, based around three connected stages of deliberation around priorities (Figure 2).
The first stage involved four Technical Working Groups (TWGs) for specific disease areas: 
Reproductive Maternal Neonatal Child and Adolescent Health, Non-Communicable Diseases, 
Communicable Diseases, and Health Services Access. These TWGs already existed to advise 
the Ministry on different areas representing relevant stakeholders. TWGs were tasked with 
reviewing the technical aspects of the services for potential inclusion, and broadly allocating 
services into priority categories, with each TWG covering between 28 – 51 services (for further 
details see below). The second stage involved the National Advisory Committee (NAC), whose 
mandate is to interpret the recommendations of the TWGs. The NAC had 90 members, including 
stakeholders representing societal interests, development partners and provincial representation, 
and one representative from each of the TWGs, so it was not dominated by any specific disease/
service area interest. The third stage involved a high-level Steering Committee (SC) responsible 
for reviewing the NAC recommendations and approving or revising them. Terms of reference 
were drafted and adopted for each entity in the structure, and conflict of interest forms were 
designed and used for TWG and NAC members. Please see Annex II for the composition of the 




















Figure 2. The UHC-BP governance structure  
Step B: Defining decision criteria
The Ministry conducted a survey on decision criteria in Oct-Nov 2019 to develop consensus 
on the importance and definition of criteria for the prioritization of services for use by TWG and 
NAC members. It was sent electronically to all TWG and NAC members invited for the Nov 
meeting, and 52 members responded (response rate 52%). The following criteria were selected: 
effectiveness, health gain for money spent, avoidable burden of disease, equity, financial risk 
protection, budget impact, socio-economic impact and feasibility. Full details on the development 
of the criteria definitions and their presentation are in Annex III.
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Step C: Selecting services 
The Ministry, jointly with the provincial department of health and key stakeholders, compared 
the current scope of Essential Health Services in Pakistan against the services covered by the 
DCP3 Essential UHC package (EUHC) (a model benefit package for UHC which lower middle 
income countries are recommended  to consider  for the development of their own health benefit 
packages). Participants concluded that 169 (77%) out of 219 recommended EUHC services 
should  be assessed for inclusion in the UHC-BP, while others may be included at a later stage. 
None of the services that were currently provided in Pakistan were omitted at this stage.14
Thereafter, the identified DCP3 services were further defined in terms of process and resource 
use by the UHC-BP secretariat, and reviewed by TWG members before and during the UHC-BP 
workshops (Nov 2019 and Feb 2020).
Step D1: Assessment 
The UHC-BP secretariat collected evidence on three criteria: cost-effectiveness, budget impact, 
and avoidable burden of disease. The process of developing this evidence base is reported 
elsewhere.(ref) No evidence was collected for other criteria selected by TWG members, and these 
were assessed during the appraisal stage using expert judgments only.
Step D2: Appraisal
The appraisal step involved the complex trade-off across the three UHC dimensions and was 
split into two substeps. These are described here as happening in a linear fashion. However, in 
reality these steps were taking place in a living process and their organisation was challenged 
by the Covid-19 endemic. 
Appraisal substep i – the division of health services into priority categories
The first substep involved the division of the 169 services in categories of ‘high priority’, ‘medium 
priority’ and ‘low priority’, reflecting the relative value of a service in the health system in Pakistan 
and its importance in implementation. To this end, the TWGs interpreted the results of the 
assessment stage and deliberated in two meetings in Nov 2019 (on community and primary 




Figure 3. An overview of the steps and templates used by the TWG and NAC during appraisal - substep i.
Each meeting started with an introduction of the process, followed by the actual TWG 
deliberations to prioritise health services. Each TWG was allocated a trained facilitator, who 
received instructions (Annex IV) to follow a step-wise deliberative process (Figure 4). A 
rapporteur recorded the arguments that participants put forward and their votes in a ‘rapporteur 
notebook’. TWG participants received an argumentation notebook to record their own votes 
and argumentation. The evidence collected for each of the health services in relation to three 
of seven criteria was summarized in ‘evidence sheets’ (Annex V) and a ‘criteria explanation 
sheet’ was produced with definitions of each of the criteria in lay-person language (Annex III). 
Immediately after the TWG stage, rapporteurs were asked to populate a ‘health service reporting 
sheet’ for each service and summary presentation slide.
The NAC subsequently reviewed TWG recommendations and amended these where necessary 
(its process is described in Annex IV).
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Figure 4. The step-wise deliberative process instructions for the evaluation of health services by TWGs. 
Proceedings for each health service evaluation round
i. Instruct each participant to read the service description themselves 
ii. Present the evidence summary of the service to participants
iii.  Check if there are any questions for clarification (don’t allow participants to already express their own 
preferences or priorities)
iv.  Instruct participants to write down their first vote (high/medium/low priority) and their argumentation in 
their argumentation notebooks
v. Check if everyone is ready to vote and proceed to voting
vi.  After the vote, systematically invite each participant to share their argumentation:
•  Start by asking participants who voted high priority to share their arguments
•  Second, ask participants who voted medium priority to share their arguments
•  Thirdly, ask participants who voted low priority to share their arguments
•  Fourthly, invite participants to deliberate amongst each other. Deliberations are finished when no more 
arguments are provided or time is up. 
•  Fifthly, ask participants to reflect on any criteria that have not yet been put forward
vii.  Call for a final round of votes on the priority class (high/medium/low) 
viii.  Ask the rapporteur to summarize the recommendation for validation by the group:
a. the final voting results 
b. the final argumentation provided for each priority class
ix.  The facilitator then closes the discussion and moves on to introduce the next service.
START: please follow for each service the proceedings as detailed in the box above.
Appraisal substep ii – making choices among high priority services 
Subsequently, the NAC had the complex task to further prioritize the list of high priority services 
within the available fiscal space, taking into account coverage and co-payment levels, and 
considering health complementary investments in health systems. See Figure 5 for an overview 
of steps and related templates. 
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Figure 5.  An overview of the steps and templates used by the NAC during appraisal - substep ii.
To inform these decisions, the UHC-BP secretariat prepared evidence on various packages with 
alternative assumptions on fiscal space, coverage levels, and co-payment levels; and taking into 
account the appropriate time horizon of NAC recommendations (0 –10 years). Some packages 
also represented specific trade-offs, e.g. explicitly prioritizing high priority community health 
services. The NAC developed recommendations on the preferred package (June 2020) and 
these were, upon consultation with the IAG presented to the SC for their approval. The contents 
of this package are reported in a companion paper.ref 
Survey results
Out of 139 invited TWG / NAC members, 35 members responded (25%).  Respondents were 
overall positive on the process used (Table 1). An analysis of the open-ended questions is 
provided in Annex VI.
Table 1. Views regarding the used evidence-informed deliberative process*, on a scale 1-5
Topic Average
Stakeholder involvement 4,0
The (use of) decision criteria 4,0
The (use of) evidence 3,8
The appraisal process 4,0
Satisfaction, acceptance and relevance of the process and outcomes 3,8
* Scores reflect average responses to neutral questions on the listed topics, with responses ranging from 1 
(‘fully disagree’) to 5 (‘fully agree’). 




This paper has described and evaluated the priority setting process to support health authorities 
in Pakistan in designing the UHC-BP.  The use of EDPs has likely improved the legitimacy of 
the UHC-BP decision process in Pakistan by improving the quality of decisions (by involving 
many TWG and NAC members and their values; evidence and expert-opinion where required, 
the exchange of argumentation in an explicit deliberative process, and an explicit link to fiscal 
and health system constraints); the transparency (because stakeholders’ argumentation was 
recorded and made publicly available) and consistency (as recommendations are based on 
the same set of decision criteria and standardised evidence). Our process evaluation survey 
indicates that stakeholders were generally and overall positive on these matters.
There were several practical challenges to the implementation of each of the six steps of EDPs 
in the context of DCP-Pakistan. Firstly, while TWG and NAC members were generally satisfied 
with stakeholder involvement in the advisory committees, they suggested participation could be 
improved in terms of its inclusive recruitment, specifically with regard to representation by the 
provinces. In future applications of EDPs, efforts should be made to pro-actively involve these 
stakeholders, plus members of the public and patient representatives, e.g. by further extending 
the membership sizes of advisory committees or through other non-participatory means e.g. 
eliciting input from the public/patients using surveys. 
Second, the UHC BP secretariat identified and selected a broad range of decision criteria through 
a stakeholder survey. Respondents were generally satisfied about the use of criteria, but also 
mentioned that these could be defined and operationalized more clearly. In future applications, 
more attention is needed to adequately pilot-test criteria terminology and definitions among a 
significant sample of its intended users. 
Third, the Pakistan DCP team was confronted with several challenges in compiling evidence 
for the assessment of health services. Evidence on cost-effectiveness was largely based on 
international registries. Due to both capacity and time constraints, the contextualisation of 
evidence using best practice translation methods was not feasible, requiring the development 
of novel rapid ways of translating evidence to the context of Pakistan.ref Although respondents 
generally agreed that the used methods to assess the evidence were acceptable, they do 
mention more local evidence would be an improvement to the process.  
In addition, evidence is ideally collected on all decision criteria. In the current approach, the 
assessment of health services in terms of their ‘feasibility’, ‘equity’, ‘financial risk protection’ 
and ‘social and economic impact’ was based entirely on expert judgements as part of the 
appraisal process. This raises the risk that certain difficult criteria, such as ‘equity’ or ‘social and 
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economic impact’ were considered less thoroughly. At the same time, ‘feasibility’ received much 
attention during group deliberations, potentially because it is intuitively easy to grasp given the 
backgrounds of certain TWG participants, e.g. clinicians. 
Fourth, even though the UHC DCP secretariat invested considerably in training facilitators 
and rapporteurs and explaining TWG members their tasks and materials at hand, there were 
differences in level of understanding and participation in the sessions. In addition, not all services 
may have been appraised equally because of the learning process (group members needed 
to familiarize themselves with the process in the appraisal of the first services) and cognitive 
overload (group members may have become tired at the end of the sessions). In addition, 
several TWG/NAC members observed a lack of adequate involvement of content experts in the 
composition of the TWG in some areas. This has led to a number of services being repeatedly 
re-visited and addressed. Nevertheless, TWG and NAC members were overall positive on the 
appraisal process.
Fifth, the overall decision-making process was heavily disrupted because of the Covid-19 
endemic. All TWG and NAC meetings were held onsite till February 2020, but largely online 
afterwards. This has likely compromised stakeholder participation, especially provincial 
engagement, and the quality of the decision-making process. 
An important contribution of this paper is how policy makers can integrate benefit package 
decisions across the three axes of the UHC cube.8 In the first step, the NAC, based on input 
by TWGs, decided on the priority categories of services. In the second step, the NAC decided 
whether it should expand the service package; improve population coverage for services; and/
or reduce co-payments for services. To our knowledge, this is the first paper that has explicitly 
articulated these trade-offs into a set of scenarios and translated the complex interplay between 
benefit package design, UHC dimensions and health system constraints into a series of practical 
steps This aspect and other features of the EDP process could serve as an example for other 
countries that wish to undertake benefit package design or revision. 
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Annex I: EDP process evaluation survey. 
Survey on the development of the universal health coverage benefit-package (HBP)
Welcome to the survey on the development of the universal health coverage benefit-package 
(HBP) to which you have contributed as either a TWG and/or NAC member. The purpose of this 
survey is to assess the process for HBP design, so this can be improved in the future.
The HBP process has largely been taking place through physical meetings but, because of 
Covid-19, the final NAC meeting was held online. In your responses in the survey, we like you to 
refer to the whole process, including physical and online meetings. At the end of the survey, you 
find a specific question on the online NAC meeting (June 2020).
Completing this survey will take approximately 10 - 15 minutes. All your answers will be treated 
confidentially: no attribution will be made to specific persons.
*Required
1.  Please select your choice below. Clicking on the “agree” button below indicates that you 
have read the above information and you voluntarily agree to participate. If you do not wish 
to participate in the research study, please decline participation by clicking on the “disagree” 
button. *
	 □ I agree
	 □ I disagree
Stakeholder involvement
2.  Please indicate to what extent you agree with the following statements on stakeholder 
involvement on a scale of 1 (Strongly disagree) – 5 (Strongly agree). *
Strongly 
disagree
Disagree Neutral Agree Strongly 
agree
It is clear to me how the stakeholders were 
selected to participate in the HBP design
All important stakeholders were involved in the 
HBP design
My involvement in the HBP design was valuable
Involved stakeholders had equal opportunities to 
contribute during meetings
Deliberation amongst stakeholders contributed to 
the development of my own opinions
Views of involved stakeholders have been 
adequately taken into account in the HBP design
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3.  How could involvement of stakeholders in HBP design be improved?
Decision criteria
4.  Please indicate to what extent you agree with the following statements on decision criteria on 
a scale of 1 (Strongly disagree) – 5 (Strongly agree). *
Strongly 
disagree
Disagree Neutral Agree Strongly 
agree
The criterion of “health gain for money spent” 
was clear to me
The criterion of “avoidable burden of disease by 
the intervention” was clear to me
The criterion of “budget impact” was clear to me
The criterion of “feasibility” was clear to me
The criterion of “equity” was clear to me
The criterion of “social and economic impact” 
was clear to me
The criterion of “financial risk protection” was 
clear to me
The decision criteria are an adequate reflection of 
the most important values for HBP design
The trade-offs between different criteria were 
clear to me
Each criterion was adequately taken into account 
in the HBP design
5.  Are any decision criteria for HBP design missing?




7.  Please indicate to what extent you agree with the following statements on the use of evidence 
on a scale of 1 (Strongly disagree) – 5 (Strongly agree). *
Strongly 
disagree
Disagree Neutral Agree Strongly 
agree
The evidence presented was clear to me
There was sufficient time to understand the 
evidence on each intervention 
The evidence presented was relevant to design 
the HBP
It is clear to me how the evidence was developed
I am generally satisfied with the methods used to 
assess the evidence
The evidence presented was sufficiently sensitive 
to the context of Pakistan
8.  How could the (use of) evidence for the development of the HBP be improved?
Appraisal process
9.  Please indicate to what extent you agree with the following statements on the decision-
process on a scale of 1 (Strongly disagree) – 5 (Strongly agree). *
Strongly 
disagree
Disagree Neutral Agree Strongly 
agree
There was sufficient time to deliberate on each 
intervention
Each intervention was evaluated according to the 
same standards
The process for taking decisions about the 
inclusion of interventions into the HBP was clear 
to me
I am satisfied with how decisions were taken 
about the inclusion of interventions in the HBP
The interventions under discussion were relevant 
to the context of Pakistan
10.  How could the decision-process in the development of the HBP be improved?




11.  Please indicate to what extent you agree with the following statements on a scale of 1 
(Strongly disagree) – 5 (Strongly agree). *
Strongly 
disagree
Disagree Neutral Agree Strongly 
agree
The NAC meeting in June 2020 was organized 
online and this limited my understanding of the 
process 
The NAC meeting in June 2020 was organized 
online and this limited my involvement in the 
process
The process and methods used have improved 
compared to previous approaches for HBP 
design in Pakistan
The final content of the HBP is acceptable for the 
context of Pakistan
I am satisfied with the outcomes of the HBP 
process
The outcomes of the HBP process are relevant to 
my setting/area
It is clear to me how the outcomes of the HBP 
process will be used moving forward
12.  If you wish to make any further comments about your experiences with the benefit package 
design in Pakistan and/or this survey, please use the space provided below
Personal	information
13.  Please indicate whether you participated in the TWG and/or the NAC * 
	 □   TWG only
	 □			NAC only
	 □			TWG and NAC
14.  What is your designation (position)? *
15.  What is the name of your organization/institution/department? *
16.  What province/federal area are you representing? *
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Annex II. Composition of the TWG and the NAC.
The use of evidence-informed deliberative processes for UHC benefit package design 
in Pakistan.
Federal Health Ministers
• Dr. Faisal Sultan, Special Assistant to Prime Minister / Federal Minister of State, Pakistan
• Dr. Nausheen Hamid, Parliamentary Secretary of Health, Pakistan
• Dr. Zafar Mirza, Ex-Special Assistant to Prime Minister / Federal Minister of State, Pakistan
National Advisory Committee (NAC)
• Dr. Malik Mohammad Safi, Director General (Health) NHSR&C (Chair)
• Dr. Sameen Siddiqui, Department of CHS, AKU (Co-Chair)
• Dr. Assad Hafeez, Vice Chancellor, HSA University
• Dr. Shabnam Sarfarz, Member Social Sector, M/o Planning, Development & Special Initiative 
• Allah Baksh Malik, Ex Secretary, NHSR&C
• Maj. Gen. Tahir Sardar, Secretary Health AJK
• Dr. Haroon Jahangir, DGHS Punjab
• Dr. Syed Irfan Abbas, Deputy Secretary Finance (External Finance-Policy), M/o Finance
• Dr. Irshad Memon, DGHS Sindh
• Dr. Niaz Ahmed, DGHS KP
• Dr. Aftab Hussain, DGHS AJK
• Dr. Saleem-ud-Din, DGHS GB
• Dr. Shakir Ali Baloch, DGHS Balochistan
• Dr. Asad Latif, AKU
• Saeed Ullah Khan Niazi, Join Secretary (Finance), M/o NHSR&C
NCD Technical Working Group
• Dr. Samra Mazhar, M/o NHSRC (Focal Point)
• Gillian Turner, DFID
• Dr. Sofia Saeed, Consultant
• Dr. S. Abbas Raza, Consultant Endocrinology, Shaukat Khanum Hospital (/ Peer Reviewer)
• Dr. A.H. Amir, Professor, Hayatabad Complex, Peshawar
• Dr. Shaheen Afridi, Director PH, Khyber Pakhtunkhwa
• Dr. Ahmed Tariq, DDP PH, Khyber Pakhtunkhwa
• Dr. Abdul Rasool Zehri, Chief Planning Officer, Balochistan
• Dr. M. Hayat, Director PH, Balochistan
• Dr. Adeel Khwaja, AKU
• Abdul Muqeet, Manager Digital Labs
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• Dr. Ch. M. Amjad, HSA (/ Peer Reviewer)
• Dr. Ramesh Kumar, HSA (/ Peer Reviewer)
• Dr. Siham Sikandar, HSA
• Shahzad Khan, WHO
• Sobia Khateeb, Clinical Psychologist
• Dr. S. Hussain Naqvi, Director DHS, Punjab (/ Peer Reviewer)
• Dr. Farooq Manzoor, Project Coordinator, Punjab (/ Peer Reviewer)
• Muhammad Javed, Project Manager, Tobacco Control Cell
• Dr. Waqar Memon, Addl. Director, DOH Sindh (/ Peer Reviewer)
• Dr. Muhammad Moosa, Assistant Director, DOH Sindh (/ Peer Reviewer)
• Dr. Asher Fawwad, Professor of Basic Medical Sciences, Baqai Medical University (/ Peer reviewer)
• Dr. Waqas Rabbani (/ Peer Reviewer)
• Dr. Jamal Zafar, Retd Professor, PIMS
• Dr. Ayesha Ahsani, Asst Professor, PIMS
• Dr. Aisha Isaani Majeed, Dy Project Director, Breast Screening, PIMS (/ Peer Reviewer)
• Arif Nadeem, SRO, PHRC
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Annex III: Decision criteria development and presentation sheet.
With support of the UHC BP secretariat and Radboudumc, the Ministry organized a survey 
on decision criteria in Oct-Nov 2019. The aim of the survey was to develop consensus on the 
importance and definition of criteria for the prioritization of services to guide TWG members as 
they categorize health services as high, medium or low priority. It was submitted electronically to 
all TWG and NAC members invited for the Nov meeting using Google Forms.
The survey asked respondents to indicate the importance they attached to eight pre-defined 
criteria for prioritizing services for inclusion into the UHC benefit package, whether they believed 
any criteria were missing, and to provide any additional comments or suggestions. 
The pre-selection of eight criteria included in the survey (effectiveness, health gain for money spent, 
avoidable burden of disease (BoD) by the service, budget impact, feasibility, equity, financial risk 
protection, and social and economic impact) was based on the Ministry’s initial scoping exercise 
(see below) and a subsequent document review of relevant UHC policy documents provided 
by the Ministry to identify the criteria they refer to in relevant policy documents. Subsequently, 
the identified criteria were matched to the criteria proposed in the literature, for which a recent 
extensive review of decision criteria was used.1 Finally, during the first workshop in Nijmegen 
(Oct 2019) a subgroup with representatives from the Ministry, LSHTM and Radboudumc further 
specified the criteria and their definitions for feedback and approval by TWG members. 
In total 52 invited TWG members responded to the decision criteria survey (response rate 52%). 
Based on the survey results, and feedback following the first appraisal workshop, several of 
the criteria were redefined (mainly phrased more in laymen’s language). Especially the cost-
effectiveness criterion proved difficult for participants to grasp and was rephrased as ‘health 
gain for money spent’. No additional criteria were suggested. While effectiveness was one of the 
eight original criteria it was not used during the prioritization exercise as the services subjected 
to deliberation and prioritization were all considered effective, being a requirement for their 
inclusion in the DCP3 list of recommended services. Table 1 presents the used decision criteria 
and their definitions. 
1  Rehfuess EA, Stratil JM, Scheel IB, et al. The WHO-INTEGRATE evidence to decision framework 




Table 1. Decision criteria and the 3-star system indicating the applicability of ‘the health gain for money 
spent’ evidence to Pakistan. 
Criteria: Definitions: Operationalization (indicating low 
(red), medium (amber) or high (green) 
performance):
1. Health gain for 
money spent 
The cost-effectiveness of the service; 
expressed as a ratio of the costs of 
the service to its health gains for the 
population. The rank-order among the 
total of 83 services is also provided 








gains for PKR 
2. Avoidable burden 
of disease (BoD) 
by the service
The health loss of a disease which can be 








3. Budget impact The overall financial implications of 
implementing the service for the national 
health budget. The budget impact is 
presented as share of the total budget.
The service 
uses more 
than 1% of 
budget
The service 
uses between  
0.5% - 1% of 
budget 
The service 
uses less than 
0.5% of budget 
4. Feasibility The extent to which a service can be 
delivered through the existing health 
system taking into account e.g. available 
human resources and infrastructure, and 
whether it is socio-culturally acceptable to 
the public.
N.A.
5. Equity The extent to which a service targets 
vulnerable groups, e.g. the severely ill, the 
poor, certain ethnic groups, children or 
women. This may be a reason to prioritize 
such a service for public funding.
N.A.
6. Financial risk 
protection
The extent to which inclusion into the 
package protects individuals against 
costs related to the disease or accessing 
the service. This may be a reason to 
prioritize such a service for public funding.
N.A. 
7. Social and 
economic impact
The extent to which a service results in 
societal consequences, e.g. in terms of 
stigma; as well as the broader economic 
consequences, such as national 
development. This may be a reason to 
prioritize such a service for public funding.
N.A.











* A partial evidence match could mean that the evidence had an i) exact service match and partial geographic 
match, or ii) a partial service match and partial geographic match.
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Annex IV: Appraisal substep i – the division of health services into high, medium and low priority 
categories. 
TWG facilitator and rapporteur instructions
As the facilitator you are charged with supporting the TWG in coming to a draft recommendation 
on UHC-BP interventions. For each intervention the group must prepare its recommendation 
within 30-45 mins.
The rapporteur is charged with filling in the TWG-reporting sheet and assisting the facilitator 
in memorizing the course of the deliberations. In case you are not sure how to record certain 
arguments brought forward by participants you need to check with the facilitator. After completion 
of the deliberation for each intervention you will summarize the results to the group for validation.
By way of introduction, the facilitator starts by providing the TWG participants with a general 
overview of what is expected of them and the procedure that will be followed. Please explain: 
•  The aim is to receive recommendations from TWG participants on whether the listed interventions 
should be considered high/medium/low priority and to obtain their argumentations
 •  High priority interventions should be recommended for inclusion in the package
 •  Medium priority interventions should only be recommended for inclusion in the package 
after the high priority interventions have been implemented and there is sufficient budget 
to do so. 
  •  Interventions can also be recommended as medium priority based on certain conditions 
that require further discussion by the NAC. They may be included but implementation 
deferred, because of:
     1.  insufficient evidence, further local research or piloting is required
     2.  there is evidence, but for other reasons the intervention should not be scaled-up 
immediately, e.g. very unfeasible
     3.  the platform of the intervention should be changed first
     4.  there is an issue with the name or content of the intervention
 •  Low priority interventions should be only be considered after all high and medium priorities 
are implemented or they should not be considered at all.
•  The number of interventions to be handled by your TWG varies between … and …
•  The available time per intervention: 30-45 mins
•  The proceedings for each discussion round are as outlined in the textbox below
•  Documents that will be provided are:
     1. Booklet with intervention descriptions and evidence summaries 
     2. Booklet to write down argumentation. 
     3. Explanations of criteria 
Chapter 10
204
Directions for the NAC Chair/ Co-Chair 
As the NAC Chair you are charged with supporting the NAC members in arriving at a draft 
recommendation on UHC/BP interventions.
Introduction
The Chair will firstly provide the NAC members with a general introduction of what is expected of 
them and how the NAC will achieve this. Points to emphasize: 
•  Over the past 2 days, the 4 TWGs (divided in a total of 8 groups) have prioritized interventions 
into low/medium/high priority ‘buckets’
•  A consolidated rank-ordering of interventions is being created for each of the low/medium/high 
priority buckets based on the voting results of the TWGs
•  The aim of the NAC meeting is to further review part of this consolidated rank-ordering and 
adjust it – where appropriate – by identifying interventions that should be ‘in’ or ‘out’ of the 
EPHS supported by the necessary argumentation
• The agenda for day 3 and 4 is as outlined below
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Proceedings for day 3 (first day of NAC meeting)
i.   During the morning of day 3 you will invite each of the TWG representatives on the NAC to briefly present 
their TWG recommendations (8 groups, 10-15 mins each). 
 a.    TWG representatives will present which of their respective interventions are in each priority bucket 
and the main argumentation 
  i.   For each of the TWGs the project team will provide 2-3 template PowerPoint slides specifying 
which of the interventions are given high/medium/low priority by TWG participants – based on 
majority votes
  ii.   Presentations on the high and low priority buckets will be short; the presentation of medium 
priority buckets can be a bit more elaborate.
Proceedings for day 4 (second day of NAC meeting)
i.   At the start of day 4 all NAC members will receive a printed version of the combined rank-ordering of 
interventions, created by combining all TWG recommendations obtained into one overall rank-ordering. 
The budget limit will have been added to this rank-ordering.
  Discussions will focus on inclusion or exclusion of medium-priority interventions, starting with the 
highest ranked intervention, followed by the second highest ranked intervention and so on, down to 
the lowest ranked intervention in the medium-priority class. 
ii.   As the NAC Chair you will work towards formulating recommendations on each of the interventions in 
the medium-priority bucket. For each intervention:
 a.    You first invite the TWG representative to summarize the argumentations used by TWG participants
 b.    Then you invite NAC members to provide additional argumentations to either:
  i.   Include the intervention in the EPHS
  ii.   Exclude the intervention from the EPHS
  iii.   Defer the decision on inclusion/exclusion to a later point in time in case the available evidence 
is insufficient to reach a justifiable decision 
 c.    When no (more) arguments are provided, or time is up, you will call for a vote on whether the 
intervention should be (i) Included, (ii) Excluded or (iii) Deferred. 
 d.    Depending on the voting results there will be four possible recommendations: 
  i.   Include the intervention if voting is (almost) unanimous in favor of inclusion
  ii   Exclude the intervention if voting is (almost) unanimous in favor of exclusion
  iii.   Defer the recommendation if the available evidence is insufficient
  iv.   Defer the recommendation if the available evidence appears sufficient but there is no clear 
majority for either inclusion or exclusion.
iii.   As a final step, the NAC recommendations will be used to further narrow down the list of interventions 
recommended for inclusion into the EPHS.  
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Annex V. Evidence sheets. 
Service # and name: 
Health gain for money spent
Medium health gains for PKR spent
44/86
Applicability of the evidence to Pakistan
   
Budget impact
Avoidable BoD by the service
 
<0.5% of budget
0.2 PKR per capita
Low avoidable BoD
Equity:  
Does it target vulnerable groups?
Financial risk protection:  
Does it protect against financial risk?
Social and economic impact: 
Does it have broader socio-economic consequences?
Feasibility: 
Can it be delivered and is it socio-culturally acceptable?
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Annex VI. Summary of open-ended questions in the EDP process evaluation survey.
In addition to asking survey respondents to indicate to what extent they agree with a set of 
statements on a scale of 1 (Strongly disagree) – 5 (Strongly agree), respondents were also 
asked how stakeholder involvement, the (use of) decision criteria, the (use of) evidence and the 
appraisal process could be improved using an open-ended question format. We here summarize 
the answers of respondents to these open-ended questions. 
Stakeholder involvement
Open Question: How could involvement of stakeholders in HBP design be improved?
Respondents mentioned stakeholder involvement in general could be improved by ensuring 
better inclusive recruitment of relevant stakeholders; involvement by the provinces; the private 
sector. More time for interaction between public health professionals and clinicians would also 
have been useful. In addition, stakeholder involvement could be improved by more timely 
sharing of documents for reviewing, providing more space and anonymity to stakeholders 
during meetings, stronger capacity building and improving continuing communication with 
stakeholders on steps taken in-between meetings. With regard to the final meeting hosted online 
due to Covid-19, it was suggested smaller groups working to prepare the meeting might have 
been useful.
The (use of) decision criteria
Open question: Are any decision criteria for HBP design missing?
Respondents mention the decision criteria could be improved by additionally reflecting the 
health system costs, to what extent the private sector caters for an intervention, to what extent 
an intervention is currently already being provided, how it relates to the social health insurance 
program currently being implemented in the country and the complementarity of interventions.
Open question: How could the (use of) decision criteria for HBP design be improved?
Furthermore, participants mention more clear definitions of criteria could be provided and possibly 
illustrated with examples, e.g. with regard to the ‘burden of disease avoided by the intervention’ 
and ‘budget impact’. The calculations used to score the performance of interventions on criteria 
could be explained more clearly. Ideally, criteria that lack evidence should be provided with some 
value(s) too. The use of evidence could also benefit from more timely sharing of background 
documents to allow familiarization with the decision criteria, better involvement of relevant 
departments and providing more information on the overall burden of disease and prevalence 
of conditions in Pakistan. Another participant mentioned ‘feasibility’ and ‘utilization of shared 
resources’ was not given due emphasis. 
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The (use of) evidence
Open question: How could the (use of) evidence for the development of the HBP be 
improved?
Respondents mention the (use of) evidence could be improved by the timely sharing of evidence 
sheets prior to meetings, the collection of local evidence, contacting of local public and private 
sector organizations to inquire about any ongoing work that they may be able to share, and 
updating some of the used definitions to better reflect clinical perspectives. Respondents also 
mention the use of evidence could be improved by providing more transparency regarding data 
sources and data collection methods.      
The appraisal process
Open question: How could the appraisal process in the development of the HBP be 
improved?
Respondents mention that the appraisal process could be improved by increasing contributions 
from the provincial level (or even starting the process at the provincial level rather than national 
level) and those working on the ground; involving the relevant departments; and more thoughtful 
selection of relevant stakeholders to represent each cluster. Others mention they would like 
to see stronger engagement of health care providers and clinicians during the assessment of 
interventions.  











This chapter responds to the main research question of this thesis: “How can legitimate health 
benefit package design be improved using evidence-informed deliberative processes 
in the context of UHC?” and is organized alongside the three sub-questions. Furthermore, this 
chapter presents the limitations of this thesis and further research needs.
Sub-question 1:
WHAT GUIDANCE DO HTA AGENCIES NEED TO IMPLEMENT EVIDENCE-
INFORMED DELIBERATIVE PROCESSES TO SUPPORT HEALTH BENEFIT 
PACKAGE DESIGN?
This thesis evaluated the need for practical guidance to support legitimate benefit package 
design in the context of universal health coverage (UHC) and argued for its further development. 
In Chapter 2 and 3 we call for the development of practical guidance to support health benefit 
package design. In Chapter 4 we explored to what extent health technology assessment (HTA) 
agencies applied the steps and elements stipulated in the evidence-informed deliverative 
processes (EDPs) framework and identified their needs for guidance, and learned about best 
practices. Results from a recent survey amongst HTA experts in low- and middle-income 
countries (LMICs)1, combined with results from our survey amongst members of the International 
Network of Agencies for Health Technology Assessment (INAHTA) clearly show the need for 
country support on EDPs and its various steps involved (Table 1).
Table 1. Need for guidance with respect to the steps of EDPs* as expressed by INAHTA members** (n=27) 
and HTA experts in LMICs (n=66)***
INAHTA members LMIC experts
A. Installing an advisory committee 46% 70%
B. Defining decision criteria n/a n/a
C. Selecting health technologies for hta 58% 85%
D1. Scoping 65% 81%
D2. Assessment 32% 82%
D3. Appraisal 64% 84%
E. Communication and appeal 52% 80%
F. Monitoring and evaluation 56% 86%
*  The steps of EDPs distinguished in the original survey among INAHTA members have since been subject 
to ongoing development and steps A-F presented in Table 1 reflect the latest differentiation of steps 
included in Version 2.0 of our practical guide for HTA bodies to enhance legitimate decision-making (to be 
published). Step B has not separately been addressed in the surveys due to the original organization of 
steps at the time the surveys were conducted.
** INAHTA is the International Network of Agencies for Health Technology Assessment. 




Based on these surveys we learn that guidance is especially felt necessary in terms of the 
practical organization of meaningful stakeholder participation and the methods to include 
deliberation during the appraisal step. This need is further recognized and reflected in HTAi’s 
2020 Global Policy Forum focus on ‘Deliberative Processes in Health Technology Assessment: 
Prospects, Problems, and Policy Proposals’2 and in the newly established ‘joint HTAi – ISPOR 
deliberative processes for HTA’ task force with the explicit goal to develop a consensus definition 
for a deliberative process from an HTA perspective and internationally recognized good practice 
recommendations on the use of deliberative processes in HTA.3
Moreover, the survey results are in line with recent findings of the ISPOR HTA Council that 
published a report on good practices in HTA.4 From this report it becomes clear that many good 
practices have been developed in the areas of assessment, and several with regard to priority 
setting and scoping, but only a few with regard to structure, governance, organizational aspects, 
deliberative processes, and measuring the impact. 
Sub-question 2:
HOW CAN HTA AGENCIES IMPLEMENT EVIDENCE-INFORMED DELIBERATIVE 
PROCESSES TO SUPPORT HEALTH BENEFIT PACKAGE DESIGN?
The design and implementation of EDPs can be informed by many different perspectives, as 
Culyer clearly states in his commentary of our survey amongst INAHTA members. He writes 
“…the understanding how best to make arrangements (that are cost-effective) immediately 
takes one to a highly complex academic and professional crossroads of behavioural science (to 
predict, for example, the likely behaviour of all the many stakeholder groups involved and affected 
by the decisions in question); governance (to predict, for example, the consequences of having, 
or not having, political accountability, advisory versus decisive powers, public participation 
in decision-making, a degree of independence from political and professional “authorities,” 
appeals mechanisms, security against conflicts of interest, and like mechanisms); political 
philosophy (to assess, for example, the desirability of independence, the delegation by ministers 
of important public decisions, the desirability for its own sake of transparency); political science 
(to anticipate, for example, political hazards, to engage with external agents like universities, 
medical colleges and regulatory authorities); the law (to ensure, for example, that all structures 
are consistent with the constitution and all processes are in line with statutory obligations and 
natural justice); administrative theory (to understand for example, committee structures that are 
best suited to the circumstances, committee decision rules like simple majority voting or powers 
of veto, skills required of committee chairs); industrial economics (to optimise relationships with 
pharmaceutical and other manufacturers and their national associations, investigate pricing 
strategies and their consequences for innovation and domestic industry); and communications 




professions, health service managers, patient advocacy groups and, of course, the general 
public).”5 
He continues by saying “This lattice of disciplines and professions militates against there being 
any single unifying “theory of deliberative processes” so one needs to add other requirement: 
imagination and descriptive evidence. The design and execution of deliberative processes 
requires imaginative work by people well-grounded in the practical realities of their own culture 
and politics and a systematic accretion of descriptive material from which, over time, one may 
be able to infer some general principles.”5
In Chapters 5 - 7 we provide guidance on how to incorporate elements of EDPs incrementally 
to support benefit package design, including important implications for HTA agencies that 
aim to use EDPs to make health benefit package recommendations. This ideal should not be 
interpreted as a blueprint for authorities but rather as an aspirational goal; countries are advised 
to take incremental steps towards this goal drawing on wide-ranging examples from across the 
globe and according to local needs and affordances. 
Developing a practical guide for HTA bodies to enhance legitimate decision-making
Since publishing our guidance on EDPs as reflected in Chapters 5 - 7 and as announced in 
Chapter 5, we developed a first version of a practical guide for HTA bodies to enhance legitimate 
decision-making using EDPs that concentrates on the practical organization of stakeholder 
participation through deliberation for benefit package design.6 That is, we provide step-by-step 
and detailed guidance on steps of EDPs, e.g. how to install an advisory committee, what are 
alternative ways of stakeholder participation, how to make argumentation explicit in deliberation 
and how to come to a joint conclusion. We are currently updating version 1.0, with Version 2.0 
going live in early 2021. This second version of our EDP guide includes more detailed practical 
instructions on the implementation of EDPs, based on our recent country work and further 
literature review. This guide also includes a chapter on ‘monitoring and evaluation’. Here we will 
highlight the main topics on which we expand further in our guide since publishing Chapters 5 - 7 
included in this thesis. 
Understanding the context
The implementation of EDPs depends on the policy environment in which the EDP is to be 
implemented, the institutional environment of the HTA agency implementing the EDP and the 
availability of HTA capacity to carry out the HTA required (Table 2).7-14 We advise HTA agencies 
to develop an implementation strategy for the use of EDPs in their own context, together with 
stakeholders. This will allow HTA agencies to identify potential barriers and enablers to the 
successful use of EDPs and to align their EDP design with local needs and affordances. 
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Table 2. Key contextual factors to consider when designing EDPs.
Policy environment
• Is there a policy statement on the willingness to use HTA in policy and/or practice?
• Is there a (formal) mechanism or process to link HTA to policy making (e.g. legislation)? 
• Is public funding allocated to HTA on an annual basis?
Institutional environment 
•  Is there an independent organisational structure and/or institutional set-up for a HTA agency (body) with 
a clear remit? 
HTA capacity
•  Is there sufficient capacity to carry out envisioned HTA activities (e.g. reviewing international literature), 
including medical disciplines, public health specialists, epidemiologists, statisticians, psychologists, 
biomedical engineers and/or economists? 
•  Are there any (domestic) HTA training opportunities (short courses, workshops, Master programmes and 
PhD training)? 
•  Is there an (inter)national networking strategy for collaboration between HTA agency(ies) and relevant 
stakeholders
 
Step A. Installing an advisory committee
We provide specific guidance and best practice examples on a wide range of topics regarding 
the installation of an advisory committee15-23:
 •  What are the tasks and mandate of an advisory committee and other stakeholders?
 •  What should be the size and composition of an advisory committee?
 •  How to identify and select the members of an advisory committee?
 •  What is the role of the chair/facilitator of the advisory committee?
 •  Should an advisory committee be supported by sub-committees?
 •  Should the advisory committee use a structured decision-making process?
 •  How should a decision be reached?
 •  How to avoid undue influences in the process?
 •  Should committee meetings be public?
 •  Should committee members and other stakeholders be trained? 




Step B. Defining decision criteria
The process of criteria selection involves the identification of broad health system goals and 
values and specifying these into decision criteria24, drawing on existing lists of potential decision-
criteria25,26, or examples of decision criteria used in policy making.27-30 This is a complex and 
abstract task, which should ideally be achieved through a broad consultation process with 
stakeholders, including members of the general population. We propose a stepwise process, on 
the basis of similar work we carried out in Iran, Kazakhstan and Pakistan. 
Step C. Selecting health technologies for hta
HTA bodies only have limited capacity, and they need to make important choices which health 
technologies to assess given their budget. We now provide step-by-step guidance on how to 
select technologies in need for hta31-37, differentiating between reimbursement and disinvestment 
decisions. Before selection of topics for HTA can be done, the topics need to be identified, for 
which we now describe the general methods used in practice (ad-hoc requests, nomination 
procedures and horizon scanning systems.38,39 
Step D1 and D2. Scoping and Assessment
Our guide extends guidance on scoping in terms of when and who to involve in scoping and how 
to conduct scoping.40-43 Although our guide does not provide detailed methodological guidance 
on the various assessment activities, as these already exist elsewhere, we do more explicitly 
refer to guidelines on data collection44-46 and assessing the quality of evidence47-52; guidance on 
reporting the evidence53-56; and how to transfer evidence reports from one setting to another.57,58
Step D3. Appraisal
We now provide more practical support to organise the appraisal step, especially on how to 
organise the deliberative process based on different options on how an advisory committee 
can trade-off criteria, i.e. quantitative analysis, qualitative analysis and analysis with decision 
rules59-63. In addition, our guidance explicitly addresses the following topics:
 •  How to best involve stakeholders in appraisal?
 •  How to best organise deliberation?
 •  How to best present evidence in the appraisal step?
 •  How can it be avoided that an advisory committee says ‘yes’ to all technologies? 
 •  How much time does the advisory committee need for appraisal?
 •  How should a decision be reached?
 •  How to deal with coverage and co-payment choices in the appraisal for UHC?
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Step E. Communication and appeal
We have included guidance on how to communicate the outcome and content of the deliberation 
of the advisory committee, how all argumentation surrounding a decision can best be registered, 
and how to organise a formal mechanism for reviewing decisions and addressing disagreements.
Step F. Monitoring and evaluation
We provide step-by-step guidance on how HTA agencies can organize their M&E, by defining 
the aims and developing a theory of change, based on which indicators can be selected and 
operationalised64-67 and now include examples of potential M&E questions and indicators.68-73
Sub-question 3:
WHAT IS THE ADDED VALUE OF USING EVIDENCE-INFORMED 
DELIBERATIVE PROCESSES TO SUPPORT HEALTH BENEFIT PACKAGE 
DESIGN?
Demonstrating added value is very important but also challenging with regard to EDPs. The 
evaluation efforts of our work are currently ongoing, yet we can already shed some light on 
the added value of the approach. In Chapter 9 we showed that the opinions of participants in 
an evidence-informed deliberative Citizen Forum changed over time; they became more aware 
of the complexity of decision-making and came to accept that there are limits to the available 
resources and accept cost as a criterion for reimbursement decision-making. Participants report 
that exchanging arguments and personal experiences with other participants made them change 
their initial opinions. Providing opportunities for critical deliberation is key to prevent citizens from 
adhering to initial emotional reactions that remain unchallenged and which may no longer be 
supported after deliberation.
In chapter 10 we evaluated the use of EDPs to support health authorities in Pakistan in the design 
of their health benefit package using a semi-structured online survey to collect the views of 
participants. Here we learned that using the step-wise EDPs approach faced several challenges 
with regard to organizing stakeholder participation, the use of decision criteria and evidence, and 
the appraisal process but that its use has likely contributed to the legitimacy of decision-making. 
In the end, what is needed to convincingly demonstrate the added value of EDPs is a more 
thorough monitoring and evaluation effort over longer periods of time, ideally informed by an 
elaborate theory of change, or impact pathway, to understand how it has or has not improved 
the legitimacy of health benefit package decisions. 
Motivated by the words of Culyer we will continue to support countries as they incorporate 




accretion of descriptive material by means of our academic work and its subsequent monitoring 
and evaluation.5 
LIMITATION OF THIS THESIS
We see two important limitations to this thesis. First, in developing our guidance on EDPs we 
have primarily relied on health(care) related literature. This means our guidance has not been 
informed by review(s) of the literature in other relevant areas of research, such as psychology, 
behavioural sciences, or other perspectives referred to by Culyer in his commentary of our 
work on EDPs.  Especially the EDP step ‘communication and appeal’ could benefit from being 
informed by broader literature. That said, more recently, we have begun to inform Version 2.0 
of our EDP guide with literature beyond our initial scope of attention. Second, we advise HTA 
bodies to organize stakeholder deliberation but have thus far provided limited evidence of its 
added value. It remains unclear whether the use of EDPs results in good quality deliberation and 
whether and how this contributes to the legitimacy of recommendations – especially in the long 
term. Moreover, the term ‘deliberation’ itself proves difficult to operationalise, lacking a uniform 
definition for use in the context of HTA, with deliberative approaches taking many different forms 
and shapes.
RECOMMENDATIONS FOR FURTHER RESEARCH
In summary, we present three main research areas to further support the use of EDPs to improve 
the legitimacy of health benefit package design.
Evidence-informed stakeholder deliberation
EDPs aim to facilitate good quality evidence-informed stakeholder deliberations. While the 
collection of evidence during the assessment and subsequent presentation of evidence during 
the appraisal step, in principle, hands participants the available evidence on decision-criteria, 
it is unclear how evidence is subsequently used by participants to inform their deliberations, or 
if not, why it is not used; and how evidence can best be presented to participants in ways that 
facilitate its uptake into deliberations. It furthermore remains unclear how deliberations can best 
be structured in order to facilitate good quality deliberation. 
Communication and appeal
Legitimate benefit package design requires the transparent communication of recommendations 
and/or decisions and the underlying rationales to affected stakeholders, including citizens, who 
should then be allowed opportunities to appeal where relevant. It will be important to inform our 
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guidance on communication and appeal based literature and approaches documented outside 
the health(care) area. 
Monitoring and evaluation 
This brings us to the final research area that deserves attention moving forward. Ultimately, 
EDPs promise to improve the legitimacy of benefit package design. This is not merely reflected 
in short-term outcomes but perhaps most importantly in long-term outcomes as countries gain 
experience with using EDPs to design and update their health benefit package and perhaps 
even institutionalize its use. Monitoring and evaluation of short and long-term outcomes is key to 
determine the added value of EDPs, as well as identify some general principles to the design of 
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Many citizens around the globe, including those in high-income countries, do not have access to 
high quality and affordable essential health services. This has led governments to put universal 
health coverage (UHC) high on the health agenda. Sustainable development goal (SDG) 3.8 
seeks to achieve UHC, including financial risk protection, access to quality essential healthcare 
services and access to safe, effective, quality and affordable essential medicines and vaccines 
for all. Progressive realisation is invoked as the guiding principle for countries on their own path 
to UHC and achievement of the SDG health targets. It refers to the governmental obligations 
to immediately and progressively move towards the full realisation of UHC, recognising the 
constraints imposed by limited available resources. Countries around the world are increasingly 
rethinking the design of their health benefit package as a means to support the progressive 
realisation of UHC. Health technology assessment (HTA) guides governments in their choices 
on the public funding of health technologies and is as an important policy tool on the path 
towards achieving UHC. 
HEALTH BENEFIT PACKAGE DESIGN
Health benefit package design is an intrinsically complex and value-laden political process 
that takes place in an environment of diverging social values and interests. However, value 
frameworks commonly employed by HTA bodies or units around the world to design benefit 
packages do not sufficiently account for this complex reality. There is broad recognition that 
such frameworks are ill fitted to take into account the wide range and diversity of stakeholder 
values and lead to insufficient sets of relevant information. This compromises the fairness of the 
decision-making process, and eventually the legitimacy of forthcoming decisions.
Increasingly, there is attention for organizing ‘fair, legitimate decision-making processes’ and 
facilitating ‘stakeholder deliberation.’ In line with this trend, health authorities often organize 
some form of stakeholder participation, embedded in their processes. However, in practice, 
health authorities lack easy-to-use tools that can support them in carefully organizing meaningful 
stakeholder participation. Important academic work on the conditions of fair processes is the 
accountability for reasonableness (A4R) framework. This framework identifies four key conditions 
for organizing fair processes: (i) all relevant values should be taking into account; (ii) ensuring 
transparency of the decisions; (iii) organization of appeal opportunities; and (iv) regulation of 
conditions i-iii. A4R has been criticized for being largely theoretical and not providing guidance 
on the identification and operationalization of values. Multicriteria decision analysis (MCDA) is a 
structured method that can be used to evaluate the overall value of interventions by reference to 
a set of multiple explicit criteria; although MCDA is generally praised for its rational pursuit, it is 
Chapter 12
230
criticized for being technocratic and lacking a deliberative component that involves stakeholders. 
“Evidence-informed deliberative processes” (EDPs) combine the virtues of both A4R and MCDA. 
They incorporate the element of structured decision-making from MCDA but not the mathematical 
elements, as we consider the latter to be only of limited relevance for priority setting. 
EVIDENCE-INFORMED DELIBERATIVE PROCESSES
EDPs provide an alternative framework to support HTA bodies in their aim to achieve this type 
of legitimate benefit package design, based on deliberation between stakeholders to identify, 
reflect and learn about the meaning and importance of values, informed by evidence on these 
values. EDPs are developed as a practical stepwise approach for HTA bodies to organize their 
processes to achieve legitimate benefit package design in the context of this thesis and guidance 
on their operationalization is subject to continued development and updating (Figure 1). 
An EDP integrates four core elements. First, the element of stakeholder deliberation which refers 
to the critical examination of an issue involving the weighing of reasons for and against a course 
of action. A deliberative process is generally defined as “a series of coordinated activities allowing 
a group of people (or relevant stakeholders) to receive and exchange information, to critically 
examine an issue, and to come to an overall group judgement. Second, the element of evidence-
informed evaluation which allows for the use of scientific evidence but also for contributions 
from stakeholders in terms of their experiences and judgments when (stronger) evidence is 
unavailable. Third, the element of transparency which ensures that the deliberative processes, 
including the objectives, modes of stakeholder involvement, the decision reached and its related 
argumentation is explicitly described and made publicly available. Fourth, the element of appeal 
which ensures that a decision can be challenged and revised if new information or insights become 
available. As such, EDPs provide the best way to combine evidence, information, perspectives, 






A  Installing an advisory committee
B Defining decision criteria
C Selecting health technologies for hta
D 1  Scoping
 2  Assessment
 3  Appraisal
E  Communication and appeal
F  Monitoring and evaluation
for every health
technology
Figure 1. The EDP framework.17
RATIONALE FOR THIS THESIS
Some HTA agencies already have several good practices on these steps in place (eg, the 
Canadian Agency for Drugs and Technologies in Health (CADTH), Scottish Medicines Consortium, 
National Institute for Health and Care Excellence (NICE) in the United Kingdom, and the National 
Committee for Health Technology Incorporation (CONITEC) in Brazil). These agencies rely on 
deliberative processes, for example regarding identifying topics for HTA and how to appraise 
health technologies. These agencies may serve as inspiration for others, especially those who 
have recently formally setup their HTA practice (eg, the Ministry of Public Health in Uruguay, and 
the Centre of Standardization of the Republican Centre for Health Development in Kazakhstan), 
but they can also improve regarding certain components.
At the time of writing the methodological development of EDPs is in an advanced state, and 
EDPs are being implemented in a range of countries such as Kazakhstan, Iran, Pakistan and 
Indonesia. Furthermore, deliberative processes and stakeholder involvement have become hot 
topics in the HTA community. This thesis reflects the methodological development of EDPs, their 
ongoing implementation and evaluation, as published in a series of papers in recent years.
1  Adjusted from: Oortwijn W, Jansen M, Baltussen R. Evidence-informed deliberative processes. A practical guide for HTA agencies to 





The main research question of this thesis is: 
How can legitimate health benefit package design be improved using evidence-informed 
deliberative processes in the context of UHC?  
The sub-questions of this thesis are:
1.   What guidance do HTA agencies need to implement evidence-informed deliberative 
processes to support health benefit package design?
2.   How can HTA agencies implement evidence-informed deliberative processes to support health 
benefit package design?
3.   What is the added value of using evidence-informed deliberative processes to support health 
benefit package design?
WHAT GUIDANCE DO HTA AGENCIES NEED TO IMPLEMENT EVIDENCE-
INFORMED DELIBERATIVE PROCESSES TO SUPPORT HEALTH BENEFIT 
PACKAGE DESIGN?
This thesis evaluated the need for practical guidance to support legitimate benefit package 
design in the context of UHC and argued for its further development. In Chapter 2 and 3 we call 
for the development of practical guidance to support health benefit package design. In Chapter 
4 we explored to what extent HTA agencies applied the steps and elements stipulated in the 
EDPs framework and identified their needs for guidance, and learned about best practices. 
Results from a recent survey amongst HTA experts in low- and middle-income countries 
(LMICs), combined with results from our survey amongst members of the International Network 
of Agencies for Health Technology Assessment (INAHTA) clearly show the need for country 
support on EDPs and its various steps involved. 
Based on these surveys we learn that guidance is especially felt necessary in terms of the 
practical organization of meaningful stakeholder participation and the methods to include 
deliberation during the appraisal step. This need is further recognized and reflected in HTAi’s 
2020 Global Policy Forum focus on ‘Deliberative Processes in Health Technology Assessment: 
Prospects, Problems, and Policy Proposals’ and in the newly established ‘joint HTAi – ISPOR 
deliberative processes for HTA’ task force with the explicit goal to develop a consensus definition 
for a deliberative process from an HTA perspective and internationally recognized good practice 
recommendations on the use of deliberative processes in HTA.
Moreover, the survey results are in line with recent findings of the ISPOR HTA Council that 




practices have been developed in the areas of assessment, and several with regard to priority 
setting and scoping, but only a few with regard to structure, governance, organizational aspects, 
deliberative processes, and measuring the impact. 
HOW CAN HTA AGENCIES IMPLEMENT EVIDENCE-INFORMED 
DELIBERATIVE PROCESSES TO SUPPORT HEALTH BENEFIT PACKAGE 
DESIGN?
The design and implementation of EDPs can be informed by many different perspectives, as 
Culyer clearly states in his commentary of our survey amongst INAHTA members. He states 
that “This lattice of disciplines and professions militates against there being any single unifying 
“theory of deliberative processes” so one needs to add other requirement: imagination and 
descriptive evidence. The design and execution of deliberative processes requires imaginative 
work by people well-grounded in the practical realities of their own culture and politics and a 
systematic accretion of descriptive material from which, over time, one may be able to infer some 
general principles.”
In Chapters 5 - 7 we provide guidance on how to incorporate elements of EDPs incrementally 
to support benefit package design, including important implications for HTA agencies that 
aim to use EDPs to make health benefit package recommendations. This ideal should not be 
interpreted as a blueprint for authorities but rather as an aspirational goal; countries are advised 
to take incremental steps towards this goal drawing on wide-ranging examples from across the 
globe and according to local needs and affordances. 
Developing a practical guide for HTA bodies to enhance legitimate decision-making
Since publishing our guidance on EDPs as reflected in Chapters 5 - 7 and as announced in 
Chapter 5, we developed a first version of a practical guide for HTA bodies to enhance legitimate 
decision-making using EDPs that concentrates on the practical organization of stakeholder 
participation through deliberation for benefit package design. That is, we provide step-by-step 
and detailed guidance on steps of EDPs e.g. how to install an advisory committee, what are 
alternative ways of stakeholder participation, how to make argumentation explicit in deliberation 
and how to come to a joint conclusion. We are currently updating version 1.0, with Version 2.0 
going live in early 2021. This second version of our EDP guide includes more detailed practical 
instructions on the implementation of EDPs, based on our recent country work and further 
literature review. This guide also includes a chapter on ‘monitoring and evaluation’. 
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WHAT IS THE ADDED VALUE OF USING EVIDENCE-INFORMED 
DELIBERATIVE PROCESSES TO SUPPORT HEALTH BENEFIT PACKAGE 
DESIGN?
Demonstrating added value is very important but also challenging with regard to EDPs. The 
evaluation efforts of our work are currently ongoing, yet we can already shed some light on 
the added value of the approach. In Chapter 9 we showed that the opinions of participants in 
an evidence-informed deliberative Citizen Forum changed over time; they became more aware 
of the complexity of decision-making and came to accept that there are limits to the available 
resources and accept cost as a criterion for reimbursement decision-making. Participants report 
that exchanging arguments and personal experiences with other participants made them change 
their initial opinions. Providing opportunities for critical deliberation is key to prevent citizens from 
adhering to initial emotional reactions that remain unchallenged and which may no longer be 
supported after deliberation.
In chapter 10 we evaluated the use of EDPs to support health authorities in Pakistan in the design 
of their health benefit package using a semi-structured online survey to collect the views of 
participants. Here we learned that using the step-wise EDPs approach faced several challenges 
with regard to organizing stakeholder participation, the use of decision criteria and evidence, and 
the appraisal process but that its use has likely contributed to the legitimacy of decision-making. 
In the end, what is needed to convincingly demonstrate the added value of EDPs is a more 
thorough monitoring and evaluation effort over longer periods of time, ideally informed by an 
elaborate theory of change, or impact pathway, to understand how it has or has not improved 
the legitimacy of health benefit package decisions. 
Motivated by the words of Culyer we will continue to support countries as they incorporate 
elements of EDPs incrementally and push forward with our efforts to contribute to the systematic 
accretion of descriptive material by means of our academic work and its subsequent monitoring 
and evaluation. 
LIMITATION OF THIS THESIS
We see two important limitations to this thesis. First, in developing our guidance on EDPs we 
have primarily relied on health(care) related literature. This means our guidance has not been 
informed by review(s) of the literature in other relevant areas of research, such as psychology, 
behavioural sciences, or other perspectives referred to by Culyer in his commentary of our 
work on EDPs.  Especially the EDP step ‘communication and appeal’ could benefit from being 




of our EDP guide with literature beyond our initial scope of attention. Second, we advise HTA 
bodies to organize stakeholder deliberation but have thus far provided limited evidence of its 
added value. It remains unclear whether the use of EDPs results in good quality deliberation and 
whether and how this contributes to the legitimacy of recommendations – especially in the long 
term. Moreover, the term ‘deliberation’ itself proves difficult to operationalise, lacking a uniform 
definition for use in the context of HTA, with deliberative approaches taking many different forms 
and shapes.
RECOMMENDATIONS FOR FURTHER RESEARCH
In summary, we present three main research areas to further support the use of EDPs to improve 
the legitimacy of health benefit package design.
Evidence-informed stakeholder deliberation
EDPs aim to facilitate good quality evidence-informed stakeholder deliberations. While the 
collection of evidence during the assessment and subsequent presentation of evidence during 
the appraisal step, in principle, hands participants the available evidence on decision-criteria, 
it is unclear how evidence is subsequently used by participants to inform their deliberations, or 
if not, why it is not used; and how evidence can best be presented to participants in ways that 
facilitate its uptake into deliberations. It furthermore remains unclear how deliberations can best 
be structured in order to facilitate good quality deliberation. 
Communication and appeal
Legitimate benefit package design requires the transparent communication of recommendations 
and/or decisions and the underlying rationales to affected stakeholders, including citizens, who 
should then be allowed opportunities to appeal where relevant. It will be important to inform our 
guidance on communication and appeal based literature and approaches documented outside 
the health(care) area. 
Monitoring and evaluation 
This brings us to the final research area that deserves attention moving forward. Ultimately, 
EDPs promise to improve the legitimacy of benefit package design. This is not merely reflected 
in short-term outcomes but perhaps most importantly in long-term outcomes as countries gain 
experience with using EDPs to design and update their health benefit package and perhaps 
even institutionalize its use. Monitoring and evaluation of short and long-term outcomes is key to 
determine the added value of EDPs, as well as identify some general principles to the design of 







Veel burgers over de hele wereld, ook in landen met een hoog inkomen, hebben geen toegang 
tot hoogwaardige en betaalbare essentiële gezondheidsdiensten. Dit heeft ertoe geleid dat 
regeringen universele gezondheidszorg (UHC) hoog op de gezondheidsagenda hebben 
geplaatst. Duurzame ontwikkelingsdoelstelling (SDG) 3.8 is gericht op het bereiken van 
UHC, met inbegrip van financiële risicobescherming, toegang tot hoogwaardige essentiële 
gezondheidsdiensten en toegang tot veilige, effectieve, hoogwaardige en betaalbare essentiële 
geneesmiddelen en vaccins voor iedereen. Progressieve realisatie wordt daarbij ingeroepen als 
leidraad voor landen op hun eigen weg naar UHC en het behalen van de SDG-gezondheidsdoelen. 
Progressieve realisatie verwijst naar de overheidsverplichtingen om onmiddellijk en progressief 
vooruitgang te boeken richting de volledige realisatie van UHC, waarbij de beperkingen worden 
erkend die worden opgelegd door de beperkte beschikbare middelen. Landen over de hele 
wereld heroverwegen het ontwerp van hun basispakket aan zorg als middel om de progressieve 
realisatie van UHC te bevorderen. Health Technology Assessment (HTA) ondersteunt regeringen 
bij hun keuzes over de publieke financiering van gezondheidstechnologieën en is een belangrijk 
beleidsinstrument op weg naar het bereiken van UHC.
ONTWERP VAN HET BASISPAKKET 
Het ontwerp van het basispakket aan zorg is een complex en met waarden beladen politiek 
proces dat plaatsvindt in een omgeving met uiteenlopende sociale waarden en belangen. 
Waardekaders die gewoonlijk door HTA-instanties of -units over de hele wereld worden gebruikt 
om basispakketten te ontwerpen, houden onvoldoende rekening met deze complexe realiteit. 
Er wordt algemeen erkend dat dergelijke kaders niet geschikt zijn om rekening te houden 
met het brede scala en de diversiteit aan waarden van belanghebbenden en dat dit leidt tot 
onvolledige informatie. Dit brengt de rechtvaardigheid van het besluitvormingsproces in gevaar, 
en uiteindelijk de legitimiteit van toekomstige beslissingen.
In toenemende mate is er aandacht voor het organiseren van ‘rechtvaardige, legitieme 
besluitvormingsprocessen’ en het faciliteren van ‘stakeholder deliberatie’. In lijn met deze trend 
organiseren gezondheidsautoriteiten vaak een vorm van stakeholderparticipatie, ingebed in hun 
processen. In de praktijk ontbreekt het de gezondheidsautoriteiten echter aan gebruiksvriendelijke 
tools die hen kunnen ondersteunen bij het zorgvuldig organiseren van zinvolle participatie van 
belanghebbenden. Belangrijk wetenschappelijk werk over de voorwaarden van rechtvaardige 
processen is het raamwerk voor ‘verantwoording voor de redelijkheid’ (A4R). Dit kader 
identificeert vier belangrijke voorwaarden voor het organiseren van rechtvaardige processen: (i) 
er moet rekening worden gehouden met alle relevante waarden; (ii) zorgen voor transparantie 
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van de besluiten; (iii) organisatie van beroepsmogelijkheden; en (iv) regulering van voorwaarden 
i-iii. A4R is bekritiseerd omdat het grotendeels theoretisch is en geen leidraad biedt voor de 
identificatie en operationalisering van waarden. Naast A4R wordt ook Multi Criteria Decision 
Analysis (MCDA) in toenemende mate toegepast. MCDA is een gestructureerde methode die 
kan worden gebruikt om de algehele waarde van interventies te evalueren aan de hand van 
meerdere expliciete criteria; hoewel MCDA over het algemeen wordt geprezen om zijn rationele 
streven, wordt het bekritiseerd omdat het technocratisch is en geen deliberatieve component 
heeft waarbij belanghebbenden worden betrokken. Evidence-informed deliberative processen 
(EDP’s) combineren de deugden van zowel A4R als MCDA. Ze bevatten het element van 
gestructureerde besluitvorming van MCDA, maar niet de wiskundige elementen, aangezien we 
van mening zijn dat deze slechts van beperkte relevantie zijn voor het stellen van prioriteiten.
EVIDENCE-INFORMED DELIBERATIVE PROCESSES
EDP’s bieden een kader om HTA-instanties te ondersteunen bij hun doel om legitieme 
besluitvorming over het basispakket te bevorderen. EDP’s zijn gebaseerd op deliberatie tussen 
belanghebbenden om de betekenis en het belang van waarden te identificeren, erover te 
reflecteren en te leren, op basis van bewijsmateriaal over deze waarden. EDP’s zijn ontwikkeld in 
de context van dit proefschrift als een praktische stapsgewijze benadering voor HTA-instanties 
voor legitieme besluitvorming en is onderhevig aan voortdurende ontwikkeling en actualisering 
(Figuur 1).
Een EDP integreert vier kernelementen. Het eerste element is stakeholder deliberatie dat 
verwijst naar het kritisch onderzoeken van een kwestie waarbij de redenen voor en tegen een 
besluit worden afgewogen. Een deliberatief proces wordt doorgaans gedefinieerd als “een 
reeks gecoördineerde activiteiten waardoor een groep mensen (of relevante belanghebbenden) 
informatie kan ontvangen en uitwisselen, een kwestie kritisch kan onderzoeken en tot een 
algemeen groepsoordeel kan komen”. Het tweede element is evidence-informed evaluatie 
dat het gebruik van wetenschappelijk bewijs verankert, maar ook ruimte laat voor bijdragen 
van belanghebbenden in termen van hun ervaringen en oordelen wanneer (sterker) bewijs 
niet beschikbaar is. Het derde element is transparantie dat ervoor zorgt dat de deliberatieve 
processen (doelstellingen, manieren waarop belanghebbenden worden betrokken en genomen 
beslissing en bijbehorende argumentatie) expliciet worden beschreven en openbaar worden 
gemaakt. Het vierde en laatste element is in beroep gaan dat waarborgt dat een beslissing 
kan worden aangevochten en herzien als er nieuwe informatie of inzichten beschikbaar komen. 
Als zodanig bieden EDP’s een goede manier om bewijs, informatie, perspectieven en waarden 







A  Installing an advisory committee
B Defining decision criteria
C Selecting health technologies for hta
D 1  Scoping
 2  Assessment
 3  Appraisal
E  Communication and appeal
F  Monitoring and evaluation
for every health
technology
Figuur 1. Het EDP kader.1 
RATIONALE VOOR DIT PROEFSCHRIFT
Sommige HTA-instanties kunnen reeds als een best-practice worden gezien met betrekking 
tot bepaalde EDP stappen (bijv. Het Canadian Agency for Drugs and Technologies in Health 
(CADTH), het Scottish Medicines Consortium, het National Institute for Health and Care 
Excellence (NICE) in het Verenigd Koninkrijk en de National Committee for Health Technology 
Incorporation (CONITEC) in Brazilië). Deze instanties maken gebruik van deliberatieve 
processen, bijvoorbeeld met betrekking tot het identificeren van onderwerpen voor HTA en het 
beoordelen van gezondheidstechnologieën. Deze agentschappen kunnen als inspiratie dienen 
voor anderen, vooral degenen die onlangs hun HTA-praktijk formeel hebben opgezet (bijv. Het 
Ministerie van Volksgezondheid in Uruguay, en het Centre of Standardization of the Republican 
Centre for Health Development in Kazachstan).
Op het moment van schrijven bevindt de methodologische ontwikkeling van EDP’s zich in een 
vergevorderd stadium en worden EDP’s geïmplementeerd in een reeks landen zoals Kazachstan, 
Iran, Pakistan en Indonesië. Bovendien zijn deliberatieve processen en betrokkenheid van 
belanghebbenden belangrijke onderwerpen geworden in de HTA-gemeenschap. Dit proefschrift 
weerspiegelt de methodologische ontwikkeling van EDP’s ende voortdurende implementatie en 
evaluatie van EDP’s, zoals gepubliceerd in een reeks artikelen in de afgelopen jaren.
1  Aangepast van: Oortwijn W, Jansen M, Baltussen R. Evidence-informed deliberative processes. A practical guide for HTA agencies 





De belangrijkste onderzoeksvraag van dit proefschrift is:
Hoe kan de legitimiteit van besluitvorming rondom basispakketten worden verbeterd met behulp 
van EDP’s in de context van UHC?
De deelvragen van dit proefschrift zijn:
1.   Welke ondersteuning hebben HTA-instanties nodig om EDP’s te gebruiken voor de 
ontwikkeling van hun basispakket.?
2.   Hoe kunnen HTA-instanties EDP’s implementeren om de ontwikkeling van basispakketten te 
ondersteunen?
3.   Wat is de toegevoegde waarde van het gebruik van EDP’s ter ondersteuning van de 
ontwikkeling van basispakketten?
WELKE ONDERSTEUNING HEBBEN HTA-INSTANTIES NODIG OM EDP’S TE 
GEBRUIKEN VOOR DE ONTWIKKELING VAN HUN BASISPAKKET?
Dit proefschrift evalueerde de behoefte aan praktische ondersteuning van legitieme 
besluitvorming over het basispakket in de context van UHC en pleitte voor de verdere ontwikkeling 
ervan. In hoofdstuk 2 en 3 roepen we op tot de ontwikkeling van praktische ondersteuning voor 
de ontwikkeling van basispakketten. In hoofdstuk 4 hebben we onderzocht in hoeverre HTA-
instanties de stappen en elementen uit het EDP kader reeds hebben toegepast en hun behoefte 
aan begeleiding, daarbij hebben we geleerd over best-practice voorbeelden. Resultaten van een 
recente enquête onder HTA-experts in lage- en middeninkomenslanden (LMIC’s), gecombineerd 
met resultaten van onze enquête onder leden van het International Network of Agencies for 
Health Technology Assessment (INAHTA), tonen duidelijk de behoefte aan landen ondersteuning 
bij het uitvoeren van EDP’s en de verschillende stappen.
Op basis van deze onderzoeken leren we dat ondersteuning vooral nodig wordt geacht in termen 
van de praktische organisatie van zinvolle participatie van belanghebbenden en de methoden 
om deliberatie tijdens de ‘appraisal’ (contextualisatie) stap vorm te geven. Deze behoefte 
wordt verder erkend en weerspiegeld in de focus van het HTAi 2020 Global Policy Forum op 
‘deliberatieve process in HTA: vooruitzichten, problemen, en beleidsvoorstellen’. Hetzelfde geldt 
voor de nieuw opgerichte ‘joint HTAi - ISPOR deliberative processen voor HTA’ task force met het 
expliciete doel om een  consensusdefinitie te ontwikkelen voor een deliberatief proces vanuit een 
HTA-perspectief en het ontwikkelen van internationaal erkende aanbevelingen voor het gebruik 




Bovendien zijn de onderzoeksresultaten in overeenstemming met recente bevindingen van 
de ISPOR HTA Council die een rapport publiceerde over goede praktijken in HTA. Dit rapport 
maakt duidelijk dat er veel best-practices zijn ontwikkeld op het gebied van assessment (het 
verzamelen van bewijs op systematische wijze), verscheidende met betrekking tot het stellen 
van prioriteiten en scoping, maar slechts enkele met betrekking tot structurering, governance, 
organisatorische aspecten, deliberatieve processen en het meten van de impact.
HOE KUNNEN HTA-INSTANTIES EDP’S IMPLEMENTEREN OM DE 
ONTWIKKELING VAN BASISPAKKETTEN TE ONDERSTEUNEN?
Het ontwerp en de implementatie van EDP’s kunnen vanuit veel verschillende perspectieven 
worden geïnformeerd, zoals Culyer duidelijk stelt in zijn commentaar op onze enquête onder 
INAHTA-leden. Hij stelt dat “De verscheidenheid aan disciplines en beroepen zich verzet tegen 
het bestaan  van een enkele verenigende ‘theorie van deliberatieve processen’, dus men moet 
nog een vereiste toevoegen: verbeeldingskracht en beschrijvend bewijs. Het ontwerp en de 
uitvoering van deliberatieve processen vereist fantasierijk werk van mensen die goed geworteld 
zijn in de praktische realiteit van hun eigen cultuur en politiek, en een systematische aanwas van 
beschrijvend materiaal waaruit men na verloop van tijd misschien enkele algemene principes 
kan afleiden.”
In de hoofdstukken 5 - 7 geven we richtlijnen over hoe elementen van EDP’s stapsgewijs kunnen 
worden geimplementeerd om de ontwikkeling van basispakketten te ondersteunen, inclusief 
belangrijke implicaties voor HTA-instanties die EDP’s willen gebruiken om aanbevelingen over 
basispakketten te doen. Dit ideaal moet niet worden geïnterpreteerd als een blauwdruk voor 
autoriteiten, maar eerder als een ambitieus doel; landen wordt geadviseerd om stapsgewijze 
stappen te ondernemen om dit doel te bereiken, op basis van voorbeelden vanuit de hele wereld 
en in overeenstemming met lokale behoeften en mogelijkheden.
Ontwikkeling van een praktische gids voor HTA-instanties om legitieme 
besluitvorming te verbeteren
Sinds we het EDP kader hebben gepubliceerd, zoals weergegeven in de hoofdstukken 5 – 
7, hebben we een eerste versie ontwikkeld van een praktische gids voor HTA-instanties om 
legitieme besluitvorming over het basispakket te verbeteren. De focus van de gids ligt op de 
praktische organisatie van stakeholderparticipatie door middel van deliberatie. Kortom, we 
bieden stapsgewijze en gedetailleerde begeleiding bij de stappen van EDP’s, bijv. hoe een 
adviescommissie in te stellen, hoe stakeholderparticipatie te organiseren, hoe argumentatie 
expliciet te maken in de beraadslaging en hoe tot een gezamenlijke conclusie te komen. We 
werken momenteel versie 1.0 bij, waarbij versie 2.0 begin 2021 live gaat. Deze tweede versie 
Chapter 12
242
van onze EDP-gids bevat meer gedetailleerde praktische instructies over de implementatie van 
EDP’s, gebaseerd op ons recente landenwerk en verder literatuuronderzoek. Deze gids bevat 
ook een nieuw hoofdstuk over ‘monitoring en evaluatie’.
WAT IS DE TOEGEVOEGDE WAARDE VAN HET GEBRUIK VAN EDP’S TER 
ONDERSTEUNING VAN DE ONTWIKKELING VAN BASISPAKKETTEN?
Het aantonen van meerwaarde is erg belangrijk, maar ook uitdagend met betrekking tot EDP’s. 
De evaluatie-inspanningen van ons werk zijn momenteel aan de gang, maar we kunnen al 
enig licht werpen op de meerwaarde van de aanpak. In Hoofdstuk 9 hebben we laten zien 
dat de meningen van deelnemers aan een Burgerforum gaandeweg veranderden. Deelnemers 
werden zich meer bewust van de complexiteit van besluitvorming en begonnen te accepteren 
dat er grenzen zijn aan de beschikbare middelen en accepteerden kosten als criterium voor 
de besluitvorming over vergoedingen. Deelnemers melden dat het uitwisselen van argumenten 
en persoonlijke ervaringen met andere deelnemers ertoe heeft geleid dat ze hun aanvankelijke 
mening hebben bijgesteld. Kansen bieden voor kritische deliberatie is essentieel om te 
voorkomen dat burgers vasthouden aan initiële emotionele reacties die onbetwist blijven en die 
na deliberatie mogelijk niet meer worden ondersteund.
In hoofdstuk 10 hebben we het gebruik van EDP’s geëvalueerd met behulp van een semi-
gestructureerde online enquête om de mening van deelnemers te verzamelen over de 
implementatie van een EDP door gezondheidsautoriteiten in Pakistan ter ondersteuning bij 
besluitvorming over het basispakket. Hier hebben we geleerd dat gezondheidsauthoriteiten 
bij het gebruik van de stapsgewijze EDP-benadering voor verschillende uitdagingen stonden 
met betrekking tot: het organiseren van participatie van belanghebbenden, het gebruik van 
besliscriteria en bewijs en het organiseren van de appraisal, maar dat het gebruik van de EDP-
benadering waarschijnlijk heeft bijgedragen aan de legitimiteit van de besluitvorming.
Wat er uiteindelijk nodig is om de toegevoegde waarde van EDP’s overtuigend aan te tonen, 
is een grondiger monitoring- en evaluatie-inspanning over langere perioden. Idealiter zijn 
deze inspanningen gebaseerd op een uitgebreide veranderingstheorie of impacttraject, om te 
begrijpen hoe EDP’s wel of niet de legitimiteit van besluitvorming over het basispakket verbeterd.
Gemotiveerd door de woorden van Culyer zullen we landen blijven steunen bij het stapsgewijs 
in de praktijk brengen van EDP’s. Daarnaast zullen wij onze inspanningen voortzetten om bij 
te dragen aan de systematische aanwas van beschrijvend materiaal door middel van ons 




BEPERKINGEN VAN DIT PROEFSCHRIFT
We zien twee belangrijke beperkingen aan dit proefschrift. Ten eerste hebben we ons bij het 
ontwikkelen van onze richtlijnen voor EDP’s voornamelijk gebaseerd op gezondheids (zorg) 
gerelateerde literatuur. Dit betekent dat het EDP kader niet gebaseerd is op literatuuroverzichten 
uit andere relevante onderzoeksgebieden, zoals psychologie, gedragswetenschappen of 
andere perspectieven waarnaar Culyer verwijst in zijn commentaar op ons werk over EDP’s. 
Vooral de EDP-stap ‘communicatie en beroep’ zou er baat bij hebben om geïnformeerd te 
worden door bredere literatuur. Dat gezegd hebbende, meer recentelijk zijn we begonnen met 
het updaten van onze EDP-gids aan de hand van literatuur die verder gaat dan de aanvankelijk 
gebruikte literatuur. Verder adviseren wij HTA-instanties om deliberatie i.c.m. het betrekken van 
belanghebbenden te organiseren, maar hebben tot dusverre beperkt bewijs geleverd van de 
toegevoegde waarde ervan. Het blijft onduidelijk of het gebruik van EDP’s leidt tot kwalitatief 
hoogstaande deliberatie en hoe dit bijdraagt  aan de legitimiteit van aanbevelingen - vooral op 
de lange termijn. Bovendien blijkt de term ‘deliberatie’ zelf moeilijk te operationaliseren omdat 
er geen uniforme definitie is voor het gebruik ervan in de context van HTA, waarbij deliberatieve 
benaderingen veel verschillende vormen aannemen.
AANBEVELINGEN VOOR VERDER ONDERZOEK
Samenvattend presenteren we drie belangrijke onderzoeksgebieden om het gebruik van 
EDP’s te bevorderen met als doel om de legitimiteit van besluitvorming over het basispakket te 
verbeteren.
Op bewijs gebaseerde deliberatie van belanghebbenden
EDP’s zijn bedoeld om op bewijs gebaseerde hoogstaande deliberatie met belanghebbenden 
mogelijk te maken. Hoewel de presentatie van bewijsmateriaal tijdens de appraisal stap de 
deelnemers in principe het beschikbare bewijsmateriaal over beslissingscriteria overhandigt, 
is het onduidelijk hoe bewijsmateriaal vervolgens door deelnemers wordt gebruikt om hun 
argumentatie te onderbouwen, of wanneer dit niet het geval is, waarom het niet wordt gebruikt; en 
hoe bewijsmateriaal het beste aan de deelnemers kan worden gepresenteerd op een manier die 
het gebruik ervan in deliberatie vergemakkelijkt. Bovendien blijft het onduidelijk hoe deliberatieve 
processen het beste kunnen worden gestructureerd om deliberatie van goede kwaliteit mogelijk 
te maken.
Communicatie en in beroep gaan
Het legitieme ontwerp van een basispakket vereist de transparante communicatie van 
aanbevelingen en / of besluiten en de onderliggende beweegredenen aan belanghebbenden, 
Chapter 12
244
waaronder burgers die vervolgens de mogelijkheid moeten krijgen om indien nodig in beroep te 
gaan. Het is belangrijk om ons EDP kader te verrijken op basis van literatuur op het gebied van 
communicatie en in beroep gaan en voorbeelden buiten het gezondheids- (zorg) gebied die zijn 
gedocumenteerd.
Monitoring en evaluatie
Dit brengt ons bij het laatste onderzoeksgebied dat aandacht verdient om door te ontwikkelen. 
Uiteindelijk beloven EDP’s de legitimiteit van besluitvorming over het basispakket te verbeteren. 
Dit komt niet alleen tot uiting in kortetermijnresultaten, maar ook en misschien wel het 
belangrijkst in langetermijnresultaten. Wanneer landen ervaring opdoen met het gebruik van 
EDP’s om hun basispakketten te ontwerpen en te reviseren en misschien zelfs het gebruik 
ervan institutionaliseren. Monitoring en evaluatie van korte- én langetermijnresultaten is van 
cruciaal belang om de toegevoegde waarde van EDP’s te bepalen, en om enkele algemene 
principes voor de implementatie van EDP’s te identificeren die bijdragen aan de legitimiteit van 
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Appropriate research data management is important for safeguarding scientific integrity, open 
science, safekeeping of valuable datasets and the reuse of data. Research data presented in 
this thesis and obtained during this PhD trajectory at the Department for Health Evidence, at the 
Radboud university medical center (Radboudumc) were archived according to the Findable, 
Accessible, Interoperable and Reusable (FAIR) principles.1 The primary data generated for 
Chapter 4 (survey responses), Chapter 9 (interview transcripts) and Chapter 10 (survey 
responses) is securely stored on Radboudumc servers at the departments’ H-drive. The 
Committee on Research Involving Human Subjects of the Radboud University Medical Center 
reviewed and waived ethical approval for the study reported in Chapter 9 (reference 2017-
3444). The London School of Hygiene and Tropical Medicine’s Observational / Interventions 
Research Ethics Committee approved the study reported in Chapter 10 (reference 21247). 
Informed consent was obtained for use of primary data in Chapters 4, 9 and 10. 
1. Wilkinson MD, Dumontier M, Aalbersberg IJ, et al. The FAIR Guiding Principles for scientific data 
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